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Oral delivery of therapeutic peptides has been a continuous target for the 
pharmaceutical industry, as most of these drugs are currently administered by 
parenteral routes. However, a major challenge limiting the success of oral 
delivery of these drugs is their poor permeability across the intestinal epithelial 
barrier. Extensive research efforts have investigated different strategies to 
overcome the epithelial barrier and enhance the oral bioavailability of 
therapeutic peptides. One of the most widely used strategies is the application 
of permeability enhancer (PE) agents that are co-administered with peptide 
drugs to facilitate their permeability across the intestinal epithelial barrier. The 
safety of most of the available PE agents, however, has always been 
questioned, because most PE agents act non-specifically in altering intestinal 
epithelial permeability which in many cases has been associated with epithelial 
damage. 
 
The work presented here investigates a novel strategy to overcome the 
intestinal epithelial barrier challenge and enhance the oral bioavailability of 
therapeutic peptides. This is by manipulating an endogenous mechanism that 
is used by the intestinal epithelial cells to dynamically regulate the permeability 
across the tight junction (TJ) structures by increasing myosin light chain 
phosphorylation at serine 19 (MLC-pS19), which is regulated by MLC kinase 
(MLCK) and MLC phosphatase (MLCP). A small membrane-permeant peptide 
inhibitor for MLCP, called PIP 640 peptide, was rationally designed to 
selectively alter MLCP activity in a manner that increases MLC-pS19 to 
transiently enhance TJ permeability for therapeutic peptides. The PIP 640 
peptide was designed to be relatively stable in the intestinal lumen, as it is 
intended to be co-administered orally with therapeutic peptides. It was initially 
examined for enhanced TJ permeability of fluorescent dextran and for toxicity 
induction in vitro. Accordingly, efforts were devoted to explore potential 
modifications of the peptide sequence that might optimize the PIP 640 peptide 
function. Moreover, studies were performed to examine the biochemical 
changes of TJ protein structures associated with the permeability 
XVIII 
	
enhancement function of the PIP 640 peptide. Finally, we investigated different 
aspects of the PIP 640 peptide permeability enhancement function in vivo. An 
overall outcome of these studies was that the PIP 640 peptide can enhance TJ 
permeability in vitro and in vivo without causing apparent damage to the 
epithelial barrier. This outcome suggest that the PIP 640 peptide has the 
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Chapter 1 : Introduction to oral 







1.1. Gastrointestinal (GI) tract of the digestive system anatomy 
and physiology   
 
The human digestive system is a multi-organ system that extends from the 
mouth to the anus (1). This system mainly consists of an alimentary tube, called 
the GI tract, and accessory organs. The alimentary tube includes the oral 
cavity, pharynx, esophagus, stomach, small intestine, large intestine, and 
rectum (1). The alimentary tube is functionally linked to several accessory 
organs, such as the salivary glands, the gallbladder, the liver, and the 
pancreas (Figure 1.1) (1). Food digestion, nutrient absorption, and waste 
elimination are the main functions of the GI tract (1). Food digestion occurs in 
different places within the GI tract in a functionally coordinated manner.  
Beginning in the mouth, food is mechanically broken down by chewing and 
exposure to salivary fluid containing digestive enzymes such as salivary 
amylase that function to break down sugars (1). Macerated food then reaches 
the stomach where digestion continues by the actions of digestive enzymes, 
such as pepsin, that is particularly well-suited to function in harsh acidic 
conditions (~ pH 1-2) that facilitates protein unfolding (1). Food processed by 
the stomach, now known as chyme, then passes through the pyloric sphincter 
to enter the duodenum where it is mixed with a bicarbonate-based, alkaline (~ 
pH 8), buffer containing enzymatic cocktail produced in the pancreas (1, 3). Via 
this mixing, the pH of the luminal contents of the duodenum is typically brought 
to ~ pH 5-6 (3). As chyme moves along the subsequent segments of the small 
intestine, the jejunum followed by the ileum where the pH of the luminal 
contents is brought to ~ 7.4, although the pH at the epithelial cell surface can 
be slightly acidic (3-5). Enzymes present at the beginning of the small intestine 
are focused on degrading large materials (such as proteins) while later in the 
GI tract appear to facilitate digestive events of smaller materials (such as 
peptidases) (1, 4). The ultimate goal of this digestive juggernaut is to breakdown 
complex food stuff, through a serious coordinated enzymatic actions, to 
release individual nutrient components (amino acids, nucleotides, lipids, etc.), 
that can be readily absorbed via selective uptake mechanisms for located at 




Figure 1.1: Diagram showing the recognized regions of the GI tract. Components that 
comprise the alimentary tube are in bold. This image was adopted from Scanlon et 
al.,2014  (1) with permission of F. A. Davis publications. 
are transported to the large intestine before being execrated from the body 













The small intestine is ~ 7 m in length with a mucosal surface that is 
increased dramatically by plica circulares folds (Figure 1.2 A) (1, 6). These folds 
in the mucosal layer establish projections in the luminal surface of the small 
intestine called villi; the base of these villi called crypts that the surface area 
for molecule diffusion (1). The small intestine consist of four major layers; 
mucosa, submucosa, external muscular layers that provide intestinal 
movement, and an outer layer of connective tissues called serosa (Figure 1.2 
B)  (1).  
 
 
The mucosa is composed of a single layer of columnar epithelial cells. 
Enterocytes are the most prominent of these cell types in terms of number (2). 




surface area generated by enterocytes is further increased by specialized 
apical membrane projections known as microvilli (1, 2). The specialized apical 
surface environment established by microvilli, called the epithelial brush 
border, contains a variety of digestive enzymes that function to complete the 
digestion of food into nutrients that can be readily absorbed by transporters 




Immediately beneath the monolayer of cells that comprise the intestinal 
epithelium is a non-cellular matrix of proteins and glycoproteins known as the 
basement membrane. And immediately beneath the basement membrane is a 
network of blood capillaries and lymphatic vessels that are themselves 
followed by thin layer of muscle (Figure 1.2 B) (1, 6). The submucosal layer 
contains more blood and lymphatic vessels in addition to nerve fibres (Figure 
1.2 B). Due to large luminal surface area of the small intestine and its high 
content of blood vessels in both mucosal and submucosal layers (1, 6), the 
small intestine is not only the main site of nutrient uptake, but has also been 
considered as a promising site for drug absorption, as most marketed drugs 
are formulated and administrated for absorption at this tissue (8).    
	
	
1.2. Small intestinal epithelium composition and maintenance   
 
There are a variety of cell types in the small intestine, many of which are 
regionally restricted to crypt and villus structures that characterize this region 
of the alimentary tract (Figure 1.3) (1, 2). These cells contribute in various ways 
to the many functions of the intestinal epithelia. Enterocytes are the most 
common cells, performing both digestive and absorptive functions (2). The 
remaining cells, representing only a fraction of the small intestinal epithelium 
are involved in functions that include secretion and protection (2, 9, 10). 
Enteroendocrine cells produce  a varierty of different hormones that have not 




Figure 1.2: Diagram illustrating the cellular organization of the small intestine. A) 
Cross-section of the intestine showing the gross appearance of the luminal surface. 
B) A magnified segment of the small intestine showing the four layers of the small 
intestine described in the text. This image was modified from Scanlon et al.,2014 (1) 
with permission of F. A. Davis publications. 
. 
example, enteroendocrine cells secrete glucagon-like peptides (GLP) that are 
essential for maintaining glucose homeostasis (11). Goblet cells produce and 
secrete mucus at the luminal intestinal surface to establish an important 
barrier to pathogen entry; Paneth cells have a protective role by the secretion 
of antimicrobial peptides (AMPs) (9, 10). The small intestinal epithelium also 
contains microfold cells (M cells) that mediate luminal antigens transport to 
subepithelial concentrations of immune cells (Peyer’s patch) for presentation 
























       The intestinal epithelial layer establishes a biological barrier against 
luminal toxins and microorganisms, which is important for health (2, 12). The 
integrity of the intestinal epithelial barrier is maintained by various 
mechanisms. Initially, the epithelial cells undergo a continuous renewal 
process that can compensate for damage resulting from the exposure to 
different substances from the external environment, such as alcohol and drugs 
(2, 13). This renewal process is regulated by both intestinal epithelial stem cells 
(IESCs) and stromal stem cells (Figure 1.3) (2). Another protective mechanism 
is provided by goblet cells that secrete mucin proteins.  In addition, other 
molecules such as trefoil factor 3 (TFF3) that can cross-link with mucins to 
further enhance its protective function (Figure 1.3) (2, 10). Paneth epithelial cells 
produce additional AMPs, such as defensin proteins, that can be secreted into 
the intestinal lumen in response to exposure to viable bacteria or their 
endotoxins (9). This function of Paneth cells beside the luminal secretory 
immunoglobulin A (sIgA), which secreted from the immune cells located 
beneath the epithelial cells, provide a further protective function against 













Figure 1.3: Components of the intestinal epithelium. It contains different epithelial 
cells; enterocytes, enteroendocrine cells, goblet cells and Paneth cells. Microfold cells 
(M cells) localized in the follicle-associated epithelium that cover the lymphatic follicles 
that contain immune cells. The intestinal epithelial stem cell (IESC) and stromal stem 
cells regulate the continuous renewal of the epithelial cell layer. Migration of 
differentiated epithelial cells occurs from crypt to villus, as indicated by the dashed 
arrows. Goblet cells and Paneth cells secrete mucus and antimicrobial peptides 
(AMPs), respectively, which provide protection to the intestinal epithelium. 
Subepithelial immune cell, such as dendritic cells (DCs) macrophages are responsible 
for sampling luminal antigens and presenting them to the immune system. This figure 











1.3. Small intestinal epithelial barrier function 
 
Intestinal epithelial cells are polarized, meaning that they are organized in 
a way where there are distinct apical and basolateral compartments (14). This 
polarized organization is stabilized by different cell-cell contacts on the lateral 
membranes between adjacent epithelial cells, called junctions (12, 14). These 
junctions include gap junctions, desmosomes and the apical junctional 
complex (AJC) (14, 15). Gap junctions function as cell-cell channels that allow 
communication between adjacent cells via the exchange of ions and signalling 
molecules (15). Desmosomes are transmembrane adhesive proteins that are 
linked to intermediate cytoskeletal filaments, which stabilize cell-cell contacts 
(14). The AJC is the most apical of these cell-cell contacts, consisting of tight 
junction (TJ) and adhesion junction structures, which work together to 
establish a close approximation of adjacent cell membranes at the apical neck 
of neighbouring epithelial cells (14). 
  
 
This organisation of intestinal epithelial cells establishes two possible 
pathways for molecules to pass across polarized small intestinal epithelial 
cells; transcellularly, through the cell membrane, or paracellularly, between 
adjacent cells (12) . The TJ is a protein complex that functions to seal and 
control transport of solutes and ions through the paracellular route (14). This 
controlled permeability across the intestinal epithelium that is mediated by the 











Figure 1.4: Permeability pathways across the intestinal epithelial barrier. 
Transcellular permeability is mediated by specific transporters. Paracellular 
permeability is controlled by TJ protein complex.  








1.4. Transcellular permeability across the small intestinal epithelial 
barrier  
  
 The transcellular route is primarily restricted by the hydrophobic properties 
of the lipids that make up the epithelial cell membrane, which allows the 
passive transport of small, lipophilic molecules (16), but not large hydrophilic 
molecules, such as therapeutic peptides (5). Various mechanisms can faciliate 
the transcellular transport of hydrophilic molecules across the intestinal 
epithelial barrier (16, 17). This can occur via transporters that are molecule-
specific, such as the Na+-dependent glucose transporter (SGLT1) that 
mediates glucose absorption across the small intestinal epithelium (16). The 
movement of hydrophilic molecules that are too large to engage transporters 
that function to absorb nutrients can traverse small intestinal enterocytes via 
mechanisms involving endocytosis and vesicular trafficking, termed 
transcytosis. The efficiency of transcytosis for the oral delivery of large 
hydrophilic molecules, such as therapeutic peptides, is typically very poor. 
While uptake from the luminal surface via receptor-mediated endocytosis 








1.5. TJ components and their role in intestinal epithelial barrier 
 
The way in which the molecular architecture of TJ elements is involved in 
the regulation of TJ function is still poorly understood. However, remarkable 
progress has been made towards understanding the ultrastructural 
arrangement of TJ components. In the early 1960’s, TJs were described as a 
fusion of cell membranes of neighbouring cells that reduces the distance 
between cells and regulates the diffusion of molecules (19). A few years later, 
electron microscopy studies revealed that TJ contains a network of 
transmembrane strands that were observed to be organized differently within 
various epithelial tissues (20). Subsequently, many integral and peripheral 
membrane proteins were discovered and found to be important in regulating 
TJ function.  
 
 




 Claudins are ~20 kDa transmembrane proteins that exist in approximately 
27 isoforms in the human body (21). Most claudins have a similar 
transmembrane tetra-spanning structure with a short N-terminal region, two 
extracellular loops (ECLs) and a C-terminal tail (Figure 1.5) (22). The 
cytoplasmic tail of claudins has a PDZ binding domain to facilitate interactions 
with TJ scaffolding proteins, primarily to the zonula occludens (ZO) protein 
family, to provide a connection to the actomyosin cytoskeleton (22, 23). Claudin 
proteins are able to associate with each other in the same cell membrane (cis-
interaction) or between adjacent cell membranes (trans-interaction) (22, 24). 




called homophilic interaction, or between different claudin isoforms, which is 
called heterophilic interaction (Figure 1.5) (22, 24).  
 
Claudin proteins have different functional properties. Several claudins, so 
called sealing claudins, have been found to tighten the paracellular barrier, 
e.g. claudin-1, claudin-3 (25, 26). Pore-forming claudins, e.g. claudin-2 and 
claudin-15, create paracellular channels that allow charge- and size-selective 
permeability to ions and small molecules (27, 28). This is supported by the 
observation that overexpression of pore-forming claudins, e.g. claudin-2, a 
cationic-selective claudin, enhanced the TJ permeability of cations but not 
macromolecules, such as 4 kDa dextran (27). Claudin pore charge selectivity is 
determined by an electrostatic force generated by the presence of charged 
amino acids on the first extracellular loop (ECL) (29, 30). The first ECL contains 
two conserved cysteine residues believed to stabilize the ECL folding by a 
disulfide bond to position specific amino acids that function in this perm-
selective function (Figure 1.5) (30, 31).  
 
 
Disrupting this disulfide bond has been associated with losing claudin 
function. This was observed when mutating either of the cysteines in claudin-
5, a sealing claudin, reduced the trans-epithelial electrical resistance (TEER) 
and induced mannitol flux in vitro (31). Moreover, Na+ flux was significantly 
reduced by mutating the two conserved cysteine residues in claudin-2, a 
cation-selective claudin (32). These studies demonstrate that the first ECL 
regulates the pore- and charge-selectivity properties of claudins. However, the 
second ECL was found to play a part in connecting claudins of adjacent cells, 
or trans-interaction. For example, the second ECL has been shown to 
contribute to the barrier function of claudin-5 (33, 34). Thus, it has been 




Figure 1.5: Diagram illustrating the structural components of claudin proteins and 
possible forms of interaction between claudin proteins. As shown, the tetra-span 
transmembrane structure has a short N-terminus, two extracellular loops (ECL-1, 
ECL-2) and a C-terminal tail. Homophilic trans-interaction and homophilic cis-
interaction, which are indicated with green and black arrows, respectively, occur 
between the same claudin isoform. Heterophilic trans-interaction and heterophilic cis-
interaction, which are indicated with red and violet arrows, respectively, occur 





























Accumulated data has suggested that claudins are critical elements for TJ 
protein assembly. Initially, expressing either claudin-1 or claudin-2 in mouse 
fibroblasts that lack of TJs was sufficient to produce TJ-like cell contacts (35). 
Furthermore, TJ-associated MARVEL proteins (TAMPs, which include 
occludin, tricellulin and MARVELD3) were only recruited into TJ in fibroblasts 
when co-expressed with claudin-1 (35, 36). This observation might be explained 
by the cis-interactions found between claudin-1 and TAMPs (37). These studies 
emphasise the fundamental role of claudin family members in TJ protein 
assembly but do not suggest an absolute role. Co-expression of TAMPs with 
claudin-1 in TJ-free human embryonic kidney cells, (HEK)-293, has been 
shown to modify the morphology of claudin-1 strands to a more physiological 
shape (37). Hence, collaboration between claudins and other TJ proteins seems 




Though the direct role of claudins in TJ macromolecule permeability is still 
being evaluated (38), many studies have provided strong evidence for the 
involvement of claudins in macromolecule permeability. An observation 
derived from intestinal biopsies from patients with early diagnosed Crohn’s 
disease, an intestinal disease characterized by an impairment in epithelial 
barrier function, has supported the idea that claudins might play an early 
regulatory role in inducing leaky gut (39), as changes in the expression and 
distribution of different claudin proteins was detected in patients’ samples at 
an early disease state and before the development of severe epithelial 
damage (39). In addition, claudin-1 knock-out mice present with severe defects 
in the epidermal barrier of the skin, which enhanced the flux of membrane 
impermeable tracers (26). Recent studies have shown that a peptide mimicking 
the ECL-1 of claudin-1 induced a TJ opening to large molecules preferentially 
by reorganisation of claudin-1 and claudin-5 (40). Together, this suggests that 






Figure 1.6: Structural similarities between TJ-associated MARVEL proteins (TAMPs); 
occludin, tricellulin and MARVELD3. All TAMPs contain the MARVEL domain, a four-
transmembrane helix structure, highlighted in black. The C-terminal tails of both 
occludin and tricellulin contain a coiled-coil ELL domain. 
 
1.5.1.2. TJ-associated MARVEL proteins (TAMPs) 
 
TAMPs contain a MARVEL domain (MAL and related proteins for vesicle 
trafficking and membrane link), a four-transmembrane helix structure that is 
essential for their cell membrane localization (Figure 1.6) (41). TAMPs comprise 
three proteins: occludin (MARVELD1), tricellulin (MARVELD2) and 
MARVELD3 (36, 41). The association of the tetra-spanning structure of the 
MARVEL domain of all TAMPs generates two ECLs and one cytoplasmic loop 
(36). This leaves both the N- and the C-terminal tails of TAMPs in the 
cytoplasm, where they play roles in both interacting with and recruiting other 
TJ proteins for TJ barrier function. The growing knowledge about TAMPs 
suggests that TAMP family members work as partners with overlapped 









Occludin was the first integral protein discovered at the bi-cellular 
interfaces of epithelial cells (42), and since then many studies have been 
conducted to define its structural basis that contributes to TJ function. The C-
terminal tail of occludin has a coiled-coil structure that shows a similar 
sequence to the ELL domain of RNA polymerase II elongation factor-ELL 
(Figure 1.6) (43, 44). This domain connects occludin to the GUK domain of the 
ZO-1 scaffolding protein to mediate occludin binding to actin microfilaments (23, 
44). The occludin C-terminus is susceptible to many phosphorylation events, 
many of which are linked with regulating occludin function (45). In Caco-2 
monolayers, the inhibition of casein kinase 2 (CK2), which mediates 
phosphorylation of serine 408 (S408) within the C-terminal tail of occludin, 
stabilized interactions of ZO-1 and claudin-2 with occludin at TJs (46). This 
resulted in an increase in the TEER of the monolayers and a reduction in the 
TJ permeability of ions, reflecting the essential role of occludin, particularly the 
C-terminal end, in regulating TJ protein function (46). It has been suggested that 
both ECLs of occludin are essential for its TJ localization, as the application of 
synthetic peptides mimicking the ECLs of occludin interferes with TJ 
localization of occludin (47, 48). However, the expression of truncated versions of 
occludin, with either or both ECL1 and ECL2 removed, in MDCK cells has 
shown that ECL2 alone was able to recruit occludin to TJs (49).  
 
 
 Early studies based on reduced occludin expression argued against the 
importance of occludin for TJ barrier function, as occludin knock-out mice 
showed normal TJ morphology and did not demonstrate enhanced intestinal 
permeability (50, 51). However, occludin knock-out mice do developed significant 
and a complex series of multi-organ pathologies (51). It has been suggested 
that the non-significant effect on barrier function of occludin knock-out was 
because other TAMP members compensated for the lack of occludin in the 
mouse (52). Supporting this idea is the observation that knockdown of occludin 
in MDCK cells showed redistribution of tricellulin protein to bi-cellular junctions, 
a member of the TAMPs family that is normally restricted to tricellular junctions 
(52). However, many studies have also suggested a direct role of occludin in 




suggested as a central cause in inflammatory bowel diseases (IBD)-
associated TJ barrier dysfunction (45, 53). Moreover, occludin knockdown 
induced leaky TJs with perm-selective profiles showing solutes with a diameter 
of up to 62 Å being transported (54). This enhanced transport was associated 
with increased claudin-4 and claudin-15 expression at the TJs and 
redistributed tricellulin to bi-cellular interfaces (54). Thus, claudins might have 
also contributed to compensating for occludin loss. All together, these findings 
indicate that the role of occludin is still unclear but it appears to play a critical 
role in normal events of TJ assembly and barrier function. 
 
Tricellulin was the first TJ-related protein normally restricted to tri-cellular 
junctions (55). Similar to occludin, tricellulin possesses the tetra-spanning 
MARVEL domain required for membrane association (41). A sequence 
comparison between occludin and tricellulin has shown strong similarities (36). 
The C-terminus of tricellulin has a ELL-domain similar to that of occludin, by 
which the latter uses to bind ZO-1 (Figure 1.6) (23, 56). Moreover, it was found 
that in vitro binding of tricellulin to ZO-1 was attenuated by an ELL-domain 
mutation of tricellulin (56). Therefore, it has been suggested that tricellulin binds 
to ZO-1 via the same C-terminal domain as occludin (56). However, binding to 
ZO-1 seems to be unnecessary for tricellulin cell membrane association, as 
tricellulin located at cell contacts in the absence of ZO-1 when co-expressed 
with claudin-3 in fibroblasts (52). This does not reflect the ability of tricellulin to 
self-associate at cell-cell contacts, as claudins can recruit TAMPs to cell 
contacts (36). In addition, claudin-3 has a cis-connection to tricellulin (37).  
 
 
Many studies have demonstrated that both tricellulin and occludin functions 
are closely related. Occludin knockdown in mouse EpH4 epithelial cells alter 
the distribution of tricellulin to bi-cellular junctions. Moreover, suppressing 
tricellulin expression in the same cell line increased occludin levels at 
tricellular contacts (55). Although the reduction of tricellulin levels was replaced 
by occludin at tri-cellular locations, this redistribution of occludin to tri-cellular 
locations failed to provide sealing outcomes at these locations. This was 




lower TEER compared to a wild-type cells. Moreover, the cells were 
permeable to large molecules, such as 4 kDa dextran (55). Consistent with the 
data obtained in EpH4, overexpression of tricellulin in the low-TEER cell line, 
MDCK II cells with low endogenous tricellulin expression, reduces the 
permeability to 4 and 10 kDa dextrans (57). These findings support the 
conclusion that tricellulin limits macromolecule permeability at tri-cellular 
junctions (57). Like occludin, tricellulin is known to be multiply phosphorylated. 
However, less is known about the role of phosphorylation in tricellulin function 
(58). In studies using a human pancreatic cancer cell line, HPAC, a 
phosphorylation event was detected in tricellulin in response to depletion of 
the cellular level of Ca2+ that was associated with the redistribution of tricellulin 
to the cytoplasm. This effect was reversed when the cellular Ca2+ was restored 
(58). This study suggests that phosphorylation events might play a role in 
tricellulin membrane integration.      
MARVELD3 was subsequently defined as a member of the TAMP family 
that contains the four transmembrane helixes of the MARVEL domain (36, 59). 
Unlike occludin and tricellulin, MARVELD3 has a shorter C-terminus that lacks 
the coiled-coil component of the C-terminus tail (Figure 1.6). This observation 
has suggested that MARVELD3 does not bind to ZO-1 (36, 59). Co-
immunoprecipitation studies using Caco-2 cell lysates revealed that 
MARVELD3 can associate with both occludin and tricellulin (36). Moreover, 
fluorescent imaging showed co-localization of MARVELD3 with other TAMP 
members and ZO-1 at the TJ both in vitro and in vivo (36). MARVELD3 
knockdown in Caco-2 cells increased the time required for the cells to develop 
normal TEER (36). However, no changes were detected in the overall 
distribution or expression of other TJ proteins (59). Taken together, MARVELD3 
seems to be less essential for TJ assembly, but still contributes to regulating 
TJ barrier function.  
      
 
1.5.1.3. Other membrane integral proteins 
 
Blood vessel epicardial substance (BVES) is a tri-spanning transmembrane 




experiments showed that the C-terminus of BVES interacts with ZO-1 (60). 
BVES knockdown in human corneal epithelial HCE cells has been associated 
with a decrease in the monolayer TEER values and disrupted barrier integrity 
(60). Accordingly, an essential role of BVES in TJ assembly has been 
suggested; however, less is known about the role of BVES in TJ permeability.  
 
 
Another type of TJ integral membrane protein are those with a single-span 
transmembrane domain, which include junctional adhesion molecules (JAMs), 
crumbs homologue 3 (CRB3), and the angulin protein family. A few years after 
the discovery of occludin as the first integral membrane protein, the JAM 
family was identified and shown to be concentrated at TJs of both endothelial 
and epithelial cells (62). JAMs are part of immunoglobulin superfamily (IgSF), as 
they contain two extracellular immunoglobulin (Ig)-like domains (62). The JAM 
family encompasses three homologous proteins: JAM-A, JAM-B and JAM-C, 
which are widely distributed in the human body (63). Additionally, proteins that 
are structurally related to the JAM family have been identified, such as the 
Coxsackie and adenovirus receptor (CAR), which has a lesser role in 
regulating barrier (63). Depletion of CAR in the mouse intestine does not 
interfere with epithelial integrity (63). While the length of the cytoplasmic C-
terminus of all JAMs and their related proteins varies, all bind to the PDZ 
domain of the ZO-1 scaffolding protein (64). It is been suggested that the JAM 
family has a role in regulating barrier function, since JAM-A -deficient mice 
have shown a deficiency in the intestinal barrier function that was permeable 
to 4 kDa dextran (65). JAM proteins are also expressed in the circulating 
leukocytes (66, 67). Therefore, they have been linked with the trans-epithelial 
and endothelial migration of leukocytes and the induction of various mucosal 
inflammations (63, 65). These data support the role of JAM in regulating 
paracellular permeability. However, JAM proteins do not seem to have an 
essential role in the assembly of TJ proteins, since overexpression of JAMs in 
fibroblasts failed to reconstitute TJ strand-like structures (68). This data 







The CRB3 protein is the mammalian homologue of the Drosophila  
transmembrane protein Crumbs, a protein that is expressed in the marginal 
zone of invertebrate epithelial cells and is essential for cell polarity (69). CRB3 
was found to be associated with the TJs in vitro in both Caco-2 and MDCK 
cells and in many organs in vivo (70, 71). It is been reported that the CRB3 
intracellular C-terminus forms complexes with different scaffolding proteins, 
e.g. protein associated to TJ (PATJ) and protein associated with Lin-7 
(PALS1), that play roles in TJ development (70, 71). Modulating the expression 
of these proteins has shown some disorganization of TJ proteins without 
disrupting overall TJ integrity (70, 71). Although less is known about the role of 
CRB3 in regulating TJ permeability, these findings suggest that CRB3 does 
not seem to be a critical player in determining TJ permeability compared to 
other TJ transmembrane proteins.   
 
         
The angulin protein family consists of three proteins: lipolysis-stimulated 
lipoprotein receptor (LSR/ angulin 1), immunoglobulin-like domain-containing 
receptor 1 (ILDR 1/ angulin 2) and ILDR 2 (angulin 3) (72, 73). All angulin 
proteins have closely related structures, and all possess an extracellular 
immunoglobulin-like domain (72, 73). The angulin family along with tricellulin 
have been known to be the protein components of the tricellular junctions (55, 
72, 73). Studies in mice showed that angulin protein expression varies within 
tissues; however, at least one protein of the angulin family was found in each 
epithelial tissue (73). Angulin-1 knockdown in EpH4 cells was associated with 
tricellulin redistribution (72). This observation led to the demonstration that the 
C-termini of angulin proteins bind to tricellulin (72, 73). Downregulation of 
angulin-1 in EpH4 reduced the monolayer TEER and increased permeability of 
40 kDa dextran (73). Despite the small surface of the tricellular junctions 
compared to that of the bi-cellular junctions, the function revealed for angulin 
proteins and tricellulin shows how essential tricellular proteins are to 





1.5.2. Cytosolic scaffolding proteins 
 
A network of cytoplasmic proteins is located peripherally to TJ proteins. 
These scaffolding proteins generally bind to each other and connect 
transcellular proteins to the cell’s cytoskeleton (74). ZO-1, was the first TJ 
protein to be discovered in both epithelial and endothelial cells (75). ZO-2 and 
ZO-3 are two proteins that are structurally related to ZO-1 that were found to 
bind to ZO-1 (76, 77). Among all TJ scaffolding proteins, the ZO protein family is 
believed to be a central component within the TJ scaffolding network, 
mediating TJ transmembrane proteins binding to the cytoskeleton (23). The N-
terminus of all members of the ZO protein family members contains three 
protein binding domains: three PDZ domains (postsynaptic density 95/discs 
large/zona occludens-1), Src homology 3 domain (SH3) and an apparently 
inactive guanylate kinase homology domain (GUK) where the TJ proteins 
associate with ZO proteins (Figure 1.7) (78). The C-terminal ends of ZO 
proteins vary in length; however, they are all associated with the F-actin 
cytoskeleton either directly through an actin-binding region (ABR), such as 
ZO-1 and ZO-2, or indirectly via other scaffolding proteins such as cortactin 
and cingulin, such as ZO-3 (79). Many other TJ scaffolding proteins have been 
identified, such as membrane-associated guanylated kinase inverted proteins 
(MAGI), the multi-PDZ domain proteins (MUPP1), and cingulin proteins; all 
have similarities in their protein binding domains to the ZO protein family (23). 
These proteins were found to play a supportive role to the ZO protein family in 
TJ assembly; but specific functions of these proteins have not been fully 
defined (23).  
 
 
Single knock-out or knockdown studies of scaffolding proteins have 
produced various outcomes. ZO-3 deficiency in mice and in the F9 
teratocarcinoma cell line have shown normal overall TJ structure and epithelial 
appearance (80). Similarly, mice lacking of cingulin show no significant effect on 
TJ assembly or barrier function (81). These findings might suggest that either 
some scaffolding proteins are not essential for TJ formation or that the 




Figure 1.7: Schematic representation of cytoplasmic zonula occludens (ZO) 
scaffolding proteins showing their binding domains to TJ membrane integral proteins, 
such as occludin and claudins. The N-terminus of ZO proteins contains three protein 
binding domains: three PDZ domains (postsynaptic density 95/discs large/zona 
occludens-1), Src homology 3 domain (SH3) and a guanylate kinase homology 
domain (GUK). The C-terminus of ZO proteins is connected to F-actin.  
loss. For example, ZO-3-deficient mice have increased ZO-2 localization in 
their TJs (80). On the other hand, ZO-1 and ZO-2 are known to have a vital role 
in TJ assembly and barrier function. In vivo, lethality was observed in mice 
embryos lacking either ZO-1 or ZO-2.(82, 83) Consistently, ZO-1 knockdown was 
shown to weaken the barrier function for macromolecule permeability in both 









Figure 1.8: Schematic representation of the endogenous mechanism that regulates TJ 
permeability through alteration of myosin light chain (MLC) phosphorylation status.  
MLC kinase (MLCK) increases MLC phosphorylation at serine 19 (MLC-pS19) that 
enhances TJ permeability. This process is reversed by MLC phosphatase (MLCP). 
1.5.3. Cytoskeletal elements 
 
A direct association between perijunctional actomyosin filaments and the 
junctional protein complexes has been revealed with the aid of electron 
microscopy (86). Since then, more efforts have been devoted to understanding 
the influence of the cytoskeleton on TJ structure and function. Disruption of 
actin filaments is associated with occludin internalization and loss of barrier 
function (87), an observation that has suggested the potential role of the 
perijunctional actin filaments in providing stability to TJ structures. In addition, 
a mechanism mediating actomyosin filaments contraction, triggered by 
increasing myosin light chain phosphorylation at serine 19 (MLC-pS19) via 
MLC kinase (MLCK) (Figure 1.8), was found to play a key role in inducing TJ 
permeability in response to various physiological and pathological stimuli (53, 
88). The MLCK-dependent alteration of TJ permeability was linked to changes 
in the distribution of selected TJ proteins that occurred secondarily to the 
induction of MLC-pS19 (53, 89). This function of MLCK is reversed by the action 
of MLC phosphatase (MLCP) (90, 91) (Figure 1.8). In addition, endogenous 
inhibition of MLCP by a specific protein inhibitor called C-kinase potentiated 
protein phosphatase-1 inhibitor-17 kDa (CPI-17) was found to increase MLC-
pS19 levels and enhance TJ permeability (92). Overall, these studies suggest 
that the perijunctional cytoskeleton is essential for regulation of TJ barrier 












1.6. Protein remodelling associated with intestinal TJ permeability  
 
As described above, many proteins have been discovered as components 
of endothelial and epithelial TJs. The expression of these proteins varies 
between different tissue barriers, helping to define their distinct profiles of 
paracellular permeability. In the intestinal epithelia, several intracellular 
mechanisms could trigger the dynamic modulation of TJ proteins that either 
promotes regulated permeability or induces barrier dysfunction, outcomes 
associated with physiological and pathological TJ permeability, respectively. 
This section will review the current knowledge of TJ protein modulation 
associated with paracellular permeability in the intestine.  
 
 
1.6.1. Nutrients regulating TJ permeability 
 
Over the years, studies have improved our understanding of how nutrients 
alter TJ permeability. Initially, it was reported that high luminal sugar content 
transiently enhanced the TJ permeability of small hydrophilic molecules (93). 
This phenomenon appears to function as a physiological strategy to alter TJ 
permeability, which could transiently increase nutrient uptake by providing a 
secondary uptake route through the paracellular space. Examination of this 
hypothesis led to the discovery that MLCK was activated as a consequence of 
increased Na+-glucose co-transport; events that led to increased glucose-
mediated TJ permeability (88). Freeze-fracture electron microscopy of TJ during 
glucose-mediated TJ permeability showed dilations in TJ structures lacking the 
ZO-1 protein without affecting the total ZO-1 cellular levels (94). As ZO-1 is a 
central scaffolding element holding transmembrane proteins at TJs, this 
finding suggested that the reduction of ZO-1 linked to the TJs might be 
responsible for inducing TJ permeability during the activation of Na+-glucose. 
An analysis of fluorescence recovery after photobleaching (FRAP) in Caco-2 
cells that stably express fluorescent TJ proteins has defined the kinetic 
behaviour of TJ proteins associated with active Na+-glucose cotransport (95). 
ZO-1 assembly at TJs reduced during Na+-glucose co-transport activity, an 




significant changes were observed on other TJ proteins, such as claudin-1, 
occludin and actin (95). This reorganization required the ZO-1 ABR domain that 
is involved in binding to actin cytoskeleton (95). Moreover, expression of the 
ABR domain in Caco-2 cells disrupted the function of ZO-1 and prevented 
MLCK-mediated barrier regulation (45, 95). 
 
 
Other diet-derived substances that are found in low concentrations in the 
diet, such as the medium chain fatty acid, capric acid, are well known to 
induce TJ permeability via intracellular pathways (96). Hence, sodium caprate, 
in millimolar concentrations, has been used as a permeability enhancer of 
poorly absorbed drugs. This will be discussed in great detail in another 
section. Dietary minerals such as Zn2+, a trace element, have been reported to 
be essential for maintaining TJ barrier integrity. Thereby, Zn2+ depletion was 
found to play a causative role in the development of IBD in vivo (97). This was 
investigated in detail in vitro using Caco-2 cell monolayers grown in medium 
lacking Zn2+; TEER was reduced and paracellular permeability was enhanced 
(98). This effect was shown to be due to downregulation of occludin and ZO-1 
levels at TJs that induced a leaky epithelium permeable to neutrophils, which 
induced inflammation and subsequently damaged the epithelium (98). In 
contrast to Zn2+ reduction in the outer environment, minimizing intracellular 
Zn2+ in both Caco-2 cells and mouse colon by using cell-permeable Zn2+ 
chelator resulted in TJ barrier deficiency but with different changes to TJ 
protein composition (99). Reducing the intracellular Zn2+ was associated with 
depletion in the cellular levels of occludin and claudin-3, a sealing claudin, with 
no effect on ZO-1. Although both extracellular and intracellular Zn2+ depletion 
was associated with a leaky epithelium, Zn2+ supplementation induced barrier 
function in in vitro models and reduced colitis-associated colon damage in 







1.6.2. Intestinal disorder-induced TJ barrier dysfunction  
 
The intestinal lumen contains a variety of microbial colonies that play an 
essential role in gut physiology, e.g., in improving digestion (100). Nevertheless, 
this microbial community also produces toxins that could cause serious 
problems when translocated into the blood circulation. Thus, gut epithelia with 
sealed TJs perform a critical task in preventing the passage of luminal 
pathogens into mucosal tissues while permitting selective permeability of other 
substances, such as nutrients (45). Under certain conditions, toxins and 
pathogens from the lumen could leak through the epithelial TJs leading to the 
induction of local tissue inflammation that subsequently could lead to systemic 
complications (101). This phenomenon is associated with intestinal inflammatory 
diseases such as Crohn’s disease and ulcerative colitis, which together are 
called IBD and characterized by leaky intestinal epithelia (45).  
 
 
1.6.2.1. TJ permeability associated with inflammatory mediators 
 
Accumulated evidence from both in vivo and in vitro studies have refined 
the role of the molecular remodelling of TJ proteins in determining TJ 
permeability behaviour in response to different cytokines during IBD. Similar to 
the physiological TJ opening mentioned above, MLCK activation was reported 
to be an essential process for the induction of IBD-associated TJ permeability 
(53, 102). This barrier defect was shown to be reversed by inhibiting MLCK (53, 
103). Intracellular signalling induced by TNF-α and INF-γ, defined as the main 
inflammatory mediators of TJ barrier defects in Crohn’s disease, can activate 
MLCK, which in turn induces occludin endocytosis leading to changes in the 
TJ protein complex sufficient to enhance macromolecule permeability (45, 53, 54). 
This so called leaky pathway has been detailed through a series of in vitro 
studies that have suggested that the time of exposure to pro-inflammatory 
cytokines is a critical factor defining the changes to TJ protein complexes. 
Short (~ 4 h) exposure to TNF-α and INF-γ was enough to induce only 
occludin endocytosis that resulted in enhanced TJ permeability to molecules 




Treating Caco-2 monolayers with TNF-α and INF-γ for ~ 48 h up-regulated 
claudin-2 and down-regulated claudin-4 at TJs, claudins demonstrated to 
enhance TJ permeability and sealing, respectively (104). Accordingly, it has 
been concluded that these changes to claudin proteins might play a role in 
disrupting the epithelial barrier function in IBD (104). However, less is known 
about whether these changes to claudin proteins in response to long exposure 
to TNF-α and INF-γ have an influence on TJ permeability profiles in terms of 
size and charge compared to a shorter exposure. 
 
 
 Unlike the type of barrier defect mediated by TNF-α and INF-γ, interleukin-
13 (IL-13), a cytokine associated with ulcerative colitis, reduces TEER with no 
effect on macromolecule permeability (102, 105). This was accompanied by 
increasing claudin-2 expression at TJs, resulting in increased charge-selective 
permeability to cations (102). Although the intracellular signalling pathway(s) 
responsible for reorganizing TJ protein complexes is presumed to be different 
in each of these cases, these studies have demonstrated that TJ protein 
remodelling is critical for determining TJ permeability behaviour. 
 
 
1.6.2.2. Life style factors mediate TJ reorganization 
 
Several studies in the literature have established a role of life style-related 
factors, such as alcohol consumption and stress, in inducing TJ protein 
reorganization and the enhancement of luminal endotoxin permeability. 
Chronic alcohol consumption was found to enhance the translocation of 
endotoxins into blood circulation, which was linked to alcoholic liver disease 
(106). Studies investigating the mechanism of action of ethanol and its 
metabolite, acetaldehyde, have shown that they induce TJ permeability 
through the reorganization of occludin and ZO1 (107). Treating Caco-2 cell 
monolayers with acetaldehyde reduced TEER and enhanced the TJ 
permeability to macromolecules, FITC-inulin (~11 Å) (107); both changes in TJ 
structures and altered interactions between occludin and ZO-1 were observed 




MLCK activation in generating TJ leakage associated with chronic alcohol 
consumption (109), a similar scenario to leaky TJs associated with IBD. 
However, changes in TJ protein complexes produced by alcohol are distinct 
from those occurring with IBD. These studies suggested that similar cellular 
signalling pathways could induce macromolecule permeability by developing 
TJ complexes with distinctive features.   
 
 
Psychological stress was reported to increase the level of endotoxin 
permeability to the blood stream that could result in disease initiation or 
progression (110). Both physiological and pathological stimuli were found to play 
a role in stress induced TJ permeability. Under acute stressful conditions, the 
body requires a higher level of energy. Therefore, a wide array of stress-
related signalling hormones, e.g. glucocorticoids, are released in different 
organs to provide and maintain energy supplies, nutrients and minerals, by 
reducing wastage and increasing absorption (110). In this case, the intestine 
responds by activating the epithelial Na+-glucose pathway, a physiological 
pathway, which enhances TJ permeability, a transient event that ends by 
removing the cause of stress (88, 110). Mechanistic studies using HT-29 cell 
monolayers and mice showed that chronic stress-induced TJ permeability is 
associated with up reglation of claudin-2, which was mediated by 
overexpression of the endotoxin-sensitive protein toll-like receptor-4 (TLR-4) 
(111). Furthermore, it was found that the TLR-4 activation resulted in the 
activation of the NF-κB pathway, which is involved in production of various 
cytokines, and is also correlated with stress-induced barrier dysfunction 
involving increased claudin-2 expression (111). Therefore, it is been suggested 










1.6.3. Studies clarifying the dynamic organization of TJ proteins 
 
The knowledge that is currently available about TJ dynamic remodelling 
was not fully realized by only studying TJ regulation induced by naturally 
existing mechanisms, e.g., physiological and pathological pathways. 
Monitoring the influence of artificial techniques on the regulation of TJ function 
has also contributed to a better understanding of TJ organization. These 
techniques can be categorized into two main groups: synthetic tools that can 
be used to target specific TJ proteins, such as synthetic peptidomimetics and 
RNA interference techniques, and the application of permeability enhancers 
primarily used to improve the permeability of drugs across the TJ barrier, 
which occurs through the reorganization of TJ proteins. This part will focus on 
summarizing studies involving peptidomimetics and permeability enhancers 
that induce transient modulation of TJ proteins. 
 
 
1.6.3.1. Peptides targeting TJ proteins. 
 
In polarized epithelial cells, TJ integral membrane proteins establish 
extracellular associations with neighbouring cells that regulate paracellular 
permeability. Amongst the known TJ integral membrane proteins, claudins and 
occludin have a fundamental role in generating these interacting complexes 
that regulate TJ barrier properties. Structural studies of claudins and occludin 
have revealed that both ECLs are important determinants of the function of 
these proteins at TJs. Peptides designed to emulate the ECLs of claudins and 
occludin have been used to define the role of these protein domains in 
modulating TJ protein assembly. Such a strategy has not only contributed 
valuable knowledge on the organization of TJ structure and function, but has 
also provided promising tools to enhance drug permeability. 
 
 
Several studies have concluded that the ECL2 of occludin is essential for 
its TJ recruitment (47, 49, 112). Application of 18-mer peptide mimicking residues 




monolayers, prevented TJ barrier re-establishment on T84 cells after Ca2+ 
repletion (112). This was suggested to occur by disrupting the organization of 
claudin-1, occludin and JAM-A in forming TJ structures (112). Consistent with 
this, a study investigating the role of claudin-1 ECLs in determining TJ function 
has shown that a 27-mer peptide related to residues 53-80 of claudin-1 ECL1 
reduced barrier function and increased macromolecule permeability in both 
T84 cell monolayers and in rats in vivo (113). This was accompanied by the 
rearrangement of claudin-1, occludin, JAM-A, and ZO-1 proteins. Although 
several studies performed on different epithelial barriers, have reported that 
disruption of claudin-1 or occludin can induce distinct changes to TJ protein 
complexes associated with TJ barrier dysfunction, both peptides, which target 
ECL-1 and ECL-2 of claudin-1 and occludin, respectively, have been shown to 
induce similar modulations to TJ proteins in intestinal epithelia (112, 113). This 
might suggest that in intestinal epithelia, claudin-1, a sealing claudin, and 
occludin have a communication by which they regulate TJ permeability when 
exposed to an external stimulus targeting their extracellular domains. 
Therefore, claudin-1 and occludin might be considered markers to monitor 
intestinal epithelial TJ permeability function.  
 
 
Another example of peptides modulating TJ barrier function is a peptide-
related to claudin-1 ECL-1 residues 53-81, similar to the previously mentioned 
peptide mimicking ECL-1 of claudin-1, but Cys54 and Cys64 mutated to serine 
residues, called C1C2 peptide (114). This peptide was designed to enhance the 
permeability of hydrophilic drugs across tissue barriers by modulating claudin-
1 sealing properties at the TJs (114). The C1C2 peptide was first tested for its 
capacity to enhance the permeability of nerve fibres towards analgesics within 
the peripheral nervous system that are surrounded by the perineurium barrier. 
Within 2 days of pre-treatment of C1C2, claudin-1 levels were reduced in the 
inner perineurium layer of rats sciatic nerve, and accordingly, an enhancement 
in the effect of membrane-impermeable analgesics was achieved, indicating 






A further study to confirm the mode of action of the C1C2 peptide was 
performed in different epithelial and endothelial cell monolayers, including the 
following: Caco-2, MDCK-II and primary mouse microvascular endothelial cells 
(pMBMECs). These cell lines have distinct barrier properties due to their 
different claudin expression patterns. This study has revealed consistent 
changes in TJ protein complexes that mediate a reversible reduction of TEER 
and the enhancement of macromolecule permeability 4- 6 h after treating 
these monolayers with the C1C2 peptide (40). Immunofluorescent staining has 
shown that the permeability enhancement induced by C1C2 peptide was 
associated with the redistribution of claudin-1, claudin-2, claudin-3, claudin-4, 
claudin-5 and occludin in both MDCK-II and Caco-2 monolayers and claudin-3, 
claudin-5 and occludin in pMBMECs monolayers (40). An observation 
suggested a direct disruption of TJ proteins by the C1C2 peptide (40, 114). 
However, investigating the direct interference of C1C2 peptide upon the 
distribution of different claudins using HEK-293 cells transfected with one 
claudin at a time revealed that the C1C2 peptide only disrupted claudin-1- and 
claudin-5-based TJs (40). This finding suggested that the C1C2-induced 
modulation of TJ proteins, apart from claudin-1 and claudin-5, might be 
mediated by a heterophilic trans- or cis-interaction with claudin-1 and claudin-5 
(40).  
 
Exposure to a peptide related to claudin-2 ECL1 called C2C2 for 24 h 
neither altered TJ protein distribution nor affected TJ barrier function in all cell 
culture models studies (40, 114). This was particularly surprising for the intestinal 
epithelial cell model, Caco-2, since many studies have shown that interference 
with claudin-2 changes the TJ barrier function in the intestine (28, 115). 
Moreover, TJ barrier dysfunction associated with some intestinal diseases has 
been linked with modifying claudin-2 expression (104). This might suggest that 
unlike claudin-1 and claudin-5, which have sealing functions, claudin-2-








1.6.3.2. Permeability enhancers inducing TJ permeability 
 
Oral delivery of protein and peptide therapeutics is limited by the intestinal 
epithelial barrier (5). Therefore, many delivery strategies, e.g., mucoadhesives 
and nanoparticles, have been examined for their ability to enable oral delivery 
of these biopharmaceuticals (116). Over ~ 250 permeability enhancers (PEs) 
have been used to improve drug permeability across intestinal epithelia either 
transcellularly via enhancing the drugs diffusion through the plasma 
membrane or paracellularly by modulating TJ proteins (5). In general, a number 
of these PEs for delivering biopharmaceutics have been shown to be safe, 
although their capacity to enhance their uptake has been less than efficacious 
or inconsistent (5, 96).  
 
 
Sodium caprate is an example of a well-studied PE that exists in dietary 
products, e.g., milk, and is one of the most promising PEs for enhancing oral 
drug delivery (5, 117). The mechanism of action by which sodium caprate 
modulates intestinal epithelial TJ proteins and enhances permeability has 
been investigated in different tissue barrier models. In each model, sodium 
caprate was shown to induce different modifications to TJ proteins that 
enhanced permeability (118). These changes in TJ modulation have been 
suggested to be due to differences in TJ protein composition between tissue 
barriers (119).  
 
 
Many reports have agreed on the role of cytoskeleton contraction mediated 
by MLCK as a primary cause of paracellular permeability induced by sodium 
caprate in Caco-2 cells (96, 120-122). Treating Caco-2 cells with 10 mM of sodium 
caprate induced a rapid, time-dependent reduction of TEER and induction of 
large molecule permeability, up to 10 kDa dextran (121, 122). A study reported 
that changes to TJ protein organization was only observed after extended 
exposure times to sodium caprate of > 60 min (121). Exposure to 10 mM of 
sodium caprate for 60 min reduced ZO-1 and occludin abundance at TJs in 




correlated with rapid changes to ZO-1 cell distribution (94, 95). Moreover, 
extended activation times for MLCK result in a constant effect on ZO-1 that 
could induce multiple changes to TJ proteins and TJ barrier function (54, 95). 
This might be the case with a long exposure to sodium caprate, as long-lasting 
activation of MLCK reorganized ZO-1 and occludin to form larger pores that 
were responsible for dramatic changes of permeability profile at the beginning 
and after a long exposure to sodium caprate.  
 
 
A brief sodium caprate exposure (~ 30 min) to enhance TJ permeability 
was associated with the activation of cytoskeleton contraction and claudin-1 
displacement from TJs (122). Monolayers of the human colon cell line, HT-
29/B6, have a higher TEER value than Caco-2 cells; exposure of HT-29/B6 
monolayers to ≥ 10 mM sodium caprate induced a similar time-dependent 
reduction profile of TEER reduction and TJ permeability (118). 
Immunofluorescent microscopy studies demonstrated tricellulin and claudin-5 
redistribution from tri-cellular and bi-cellular TJs after ~ 30 min, with no effect 
on other TJ proteins (118). None of these responses involved the activation of 
MLCK as observed in Caco-2 cell monolayers, suggesting a direct interference 
with tricellulin and claudin-5 (118). Comparison of findings obtained with HT-
29/B6 cells Caco-2 cells, regardless of variations between their barrier 
properties, suggest that the fast onset of TJ permeability induced by sodium 
caprate in intestinal epithelia involves regulation of claudins and tricellulin. This 
observation may reflect structure/function features of the TJ that enable their 
rapid dissociation from the plasma membrane. For example, claudins are 
palmitoylated proteins, a post-translational modification found to facilitate 
certain aspects of membrane trafficking (123). 
 
 
1.7. Therapeutic peptides and issues that hinder their oral delivery 
 
Since the discovery of human insulin as the first therapeutic peptide for the 
treatment of diabetes, production of therapeutic proteins and peptides has 




pharmaceutical products in the global market, a figure which is also expected 
to increase in the future (117, 124). This is because proteins, in general, can 
control specific functions in the human body mediated via discrete membrane 
receptors that generate selective cell signalling process (125). Among all the 
marketed peptides, which are mostly delivered by parenteral routes, only a few 
can be delivered by the oral route (Table.1)	 (5, 117). Developing oral peptide 
formulations has been an ongoing target for the pharmaceutical industry for 
many reasons (5, 117). Oral peptide formulations might enhance patient 
compliance to treatment, as patients prefer oral administration of drugs over 
injection (5, 117). Moreover, oral administration of peptides would reduce the 
cost associated with the production and application of injectable dosage forms, 
which include sterilization, needle disposal and staff/patient training in some 
instances (5). In addition, oral delivery for some therapeutic peptides can mimic 
their physiological release in the body. For example, insulin uptake from the 
intestine results in direct hepatic delivery via the portal vein, which mimics its 
natural release from the pancreas which also goes directly to the liver (5).    
 
 
Table 1.1: Commercially available oral therapeutic peptides (5, 117).  





Peptide drug MW (Da) Applications 
Cyclosporine 1202 Immunosuppressant 
Desmopressin 1069 Diabetes Insipidus 
Taltirelin 477 Spinocerebellar degeneration 
Glutathione 307 Acquired immune deficiency syndrome (AIDS)-
related cachexia/ cystic fibrosis 
Linaclotide 1526 Irritable bowel syndrome 
Vancomycin 1449 Pseudomembranous colitis 
Colistin 1155 Multi drug resistant bacterial infections 




There are many challenges to oral delivery of peptide therapeutics. First of 
all, these drugs are water soluble and too large to readily transport across the 
intestinal epithelial cells (5). Moreover, peptide therapeutics are typically 
susceptible to degradation by GI tract digestive enzymes including the gastric 
enzyme pepsin and intestinal enzymes secreted by the pancreas or 
enterocytes, such as trypsin and chymotrypsin (5, 126). In addition, drug 
absorption in the intestine, generally, requires its complete dissolution and 
solubility that can be pH-dependent (5). This could be an issue for some 
peptide drugs, such insulin, which has better solubility in mild acidic medium 
than the neutral medium of the intestine (5). However, most of these problems 
can be solved with the aid of existing pharmaceutical technologies. For 
example, the stability of peptide drugs in the GI tract can be improved by 
enteric coating or an oral dosage form and/or application of drug excipients, 
such as protease inhibitors, while solubility of insulin can be enhanced by 
acidifying agents (5, 117). This leaves poor permeability across the intestinal 
epithelial barrier as the main challenge for the oral delivery of peptide 








































1.8. Aims of this project 
 
This project represents an extension to previous work aimed at developing 
a novel strategy to enhance the oral permeability of therapeutic peptides 
across the TJ of intestinal epithelial cells by manipulating an endogenous 
pathway. This strategy involved examining the ability of rationally designed 
membrane permeant peptide inhibitors of MLCP, PIP peptides, to alter the 
activity of MLCP resulting in a transient induction of MLC-pS19 that could 
enhance the permeability of therapeutic peptides through TJ structures. 
Previous work on PIP peptides has suggested that these peptides can 
enhance TJ permeability by enhancing MLC-pS19, as anticipated (127). 
However, much less was known about how these peptides alter the activity of 
MLCP or how their effect was associated with TJ structure. The current project 
focused on improving our understanding of the mechanism of action (MoA) of 
one of the lead PIP peptides: PIP 640 peptide.  
 
Specific aims of the current project: 
• Validate and optimize the permeability enhancement function of PIP 
640 peptide and evaluate its safety in vitro. 
 
• Characterize the biochemical changes associated with TJ proteins 
induced by the actions of the PIP 640 peptide in vitro. 
 
• Investigate different aspects of the PIP 640 peptide-induced 





















































2.1. Reagents and materials 
	
Solvents and reagents for peptide synthesis and characterisation were 
purchased from Novabiochem, Sigma-Aldrich, and Rathburn Chemicals. 
Reagents and materials for cell biology studies were purchased from Sigma-
Aldrich, Fisher Scientific, Invitrogen, Phoenix Pharmaceuticals, Novabiochem, 
Tocris Bioscience, 2B Scientific, Sartorius, Promega, BIO-RAD, and Santa 
Cruz Biotech unless otherwise stated. All primary and secondary antibodies 
were obtained from Santa Cruz Biotech, Abcam, Invitrogen, Cell Signalling 
Technologies and LI-COR. All reagents, materials, and antibodies that were 
used to perform all experiments are listed in Table 2.4, Table 2.5, Table 2.6 
and Table 2.7. 
 
           
2.2. Solution preparation 
	
Solutions and media that were used for cell biology studies were 
commercially prepared and sterilised unless otherwise stated. Solutions which 
were prepared in the lab, were made by dissolving the required materials in 
Milli-Q water (18.2 MΩ.cm at 25 °C) followed by adjusting the pH as 
appropriate with HCl before making up to the final volume. The pH values of 
solutions were adjusted using a ceramic junction reference electrode that is 
connected to a Thermo Orion model 420 pH meter (Thermo Scientific, UK). 
The pH meter was calibrated by measuring different commercially obtained 
reference standard solutions (pH buffers) that have known pH values at room 
temperature (Thermo Scientific, UK). The calibration process was performed 
by placing the electrode in two pH buffers that bracket the desired sample pH; 
the first buffer usually has pH 7 and the second buffer should be near the 
expected sample pH, pH 10. All solutions that were prepared in the lab were 









 2.3. Peptide synthesis and characterization 
 
2.3.1. Peptide synthesis and biotinylation protocols   
 
All peptides were synthesized by 9-fluorenylmethyloxycarbonyl (Fmoc) 
solid phase peptide synthesis (SPPS) strategy using D-amino acids. Peptides 
were generally synthesised on 0.25 g of Rink amide methyl benzhydrylamine 
(MBHA) resin (0.6 mmol/g loading) to obtain peptides with an amidated C-
terminus (128, 129). For the synthesis of a C-terminally biotinylated peptide, 0.25 
g of biotin-PEG Nova TagTM resin (0.34 mmol/g loading) was used to produce 
a C-terminally biotinylated peptide with PEG spacer between the peptide and 
the biotin (130, 131). Removal of the Fmoc group was performed with 20 % (v/v) 
piperidine in dimethylformamide (DMF) (128, 132). The first coupling process was 
performed manually in a disposable plastic vessel with diisopropylcarbodiimide 
(DIC) and hydroxybenzotriazole (HOBt) as coupling agents in the presence of 
diisopropylethylamine (DIEA). Successful manual removal of Fmoc from the 
resin and coupling of the first amino acid were confirmed by Kaiser colour test 
(Kaiser reagents composed of 100 mM ninhydrin in ethanol (EtOH), 2.1 M 
phenol in EtOH, and 0.02 mM potassium cyanide in pyridine) (133). A few drops 
of each Kaiser reagents were added to a sample of the Fmoc de-protected 
resin prior to heating to ~100 °C for 1 minute. Appearance of a dark blue 
colour in the resin sample indicated the presence of free amino functions 
capable of reacting with ninhydrin. Upon completion of the first amino acid 
coupling, the remaining coupling processes were performed on an automated 
Symphony Quartet peptide synthesizer (Gyros Protein Technologies, USA) 
with (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate 
(PyBOP) as coupling reagent with DIEA. N-terminal biotinylation of peptides 
was performed during the automated process using a biotin-p-nitrophenyl 
ester (biotin-ONp) reagent (134). Quantities of all D-amino acids, biotin-ONp, 
and coupling reagents used were equal to 3 equivalents of the resin. The 
amount of DIEA used during all coupling steps was equal to 6 equivalents of 
the resin. All peptides were cleaved from the resin and side chain protection 






acid (TFA), 2.5% water, and 2.5% triisopropylsilane (TIPS) per 1g resin and 
incubating at room temperature for 3 h(132).  
 
2.3.2. Peptides purification and characterization by HPLC and mass 
spectrometry  
 
All cleaved peptides were purified by reversed-phase semi-preparative 
high performance liquid chromatography (RP-HPLC), and purified materials 
were characterized by analytical RP-HPLC with electrospray mass 
spectrometry being used to verify peptide identity. Semi-preparative RP-HPLC 
was performed on a Dionex HPLC system, using a Phenomenex Gemini 5µm 
C-18 (250 x 10 mm) column, and a flow rate of 2.5 mL/min. Analytical RP-
HPLC was performed using a Dionex UltiMate 3000 HPLC system (Dionex, 
UK), using a Phenomenex Gemini 5µm C-18 (150 x 4.6 mm, Phenomenex, 
UK) column, and a flow rate of 1 mL/min. Mobile phase for both analytical and 
semi-preparative HPLCs was: A)  0.1% (v/v) of TFA in water and B) 0.1% (v/v) 
TFA in acetonitrile. The semi-preparative RP-HPLC gradient used was T = 0 
min, B = 5%; T = 25 min, B = 95%; T = 35 min, B = 95%; T = 35.1 min, B = 
5%; T = 40 min, B = 5%. The analytical RP-HPLC gradient used was T = 0 
min, B = 5%; T = 10 min, B = 95%; T = 15 min, B = 95%; T = 15.1 min, B = 
5%; T = 18 min, B = 5%. Mass spectrometry analysis of all peptides was 
performed using a microTOF instrument from Bruker Daltonics run in positive 
ion mode (Bremen, Germany). 
 
 
2.4. Cell culture handling and maintenance  
 
2.4.1. General methodology 
 
The human colorectal adenocarcinoma (Caco-2) cell line (American Type 
Culture Collection, ATCC, USA) was used to perform all in vitro cell-based 
studies. All plastic-ware, which was used to culture and maintain cells, was 
purchased pre-sterilised. For general cell maintenance, cells were cultured in 






supplemented with 10% (v/v) of foetal bovine serum (FBS) and 1% (v/v) of an 
antibiotic mixture (P/S) containing penicillin (100 unit/mL) and streptomycin 
(100 µg/mL); known as complete DMEM. Cells were maintained in 5% CO2 at 
37 °C in a humidified incubator. All cell culture work was performed in a 
biosafety tissue culture hood applying the required aseptic techniques to keep 
cell cultures free from contamination by microorganisms. This included use of 
sterile cell culture tools and cleaning the working area using 70 % (v/v) EtOH 
in water and/or a UV lamp. For further sub-culturing or seeding onto semi-
permeable membrane supports, cells were split at a point of ~80 % confluence 
in T75 flasks. To split cells, spent media was removed and cells were washed 
once with pre-warmed phosphate buffered saline (PBS). Washed cells were 
then treated with 10 mL/flask of trypsin/ethylenediaminetetraacetic acid 
(EDTA) solution for ~ 5 min or until cell detachment was completed. An equal 
volume of pre-warmed complete DMEM was then added to the flask to 
inactivate the trypsin. Cells were then transferred to centrifuge tubes and 
pelleted at 125 x g for 10 min using AccuSpin™ 400 (Fisher scientific, UK). 
After removal of the media, pelleted cells were suspended with 1 mL of 
complete DMEM prior to further dilution with the same medium to achieve a 
split ratio of ~ 1:10. Cells were then either placed in fresh culture flasks or 
seeded on semi-permeable membrane supports to perform in vitro studies. 
 
 
Trypsin/EDTA solution was prepared as follows: 2% (w/v) of EDTA stock 
solution was prepared by dissolving 0.5 g in 25 mL PBS prior to passing 
through a 0.2 µm filter. Then, 100 mL of 10x trypsin (2.5%, v/v) was mixed with 
10 ml of 2% EDTA stock in 890 ml of sterile PBS to give a working 
concentration of 0.25% Trypsin/0.02% EDTA solution. The trypsinization 










2.4.2. Cells storing and reconstituting protocols 
 
Reconstitution of frozen cells was performed by placing a vial retrieved 
from the liquid nitrogen dewar in a pre-warmed water bath at 37 °C. Thawed 
cells were transferred to a 15 mL tube containing pre-warmed cell medium and 
centrifuged for 10 min at 125 x g. After discarding the supernatant, pelleted 
cells were suspended with fresh medium of sufficient volume to produce the 
desired cell concentration for growth as mentioned in Section 2.4.1.        
 
 
To store cells frozen in liquid nitrogen, cells that had reached ~80 % 
confluency on 75 cm2 flask were trypsinized and centrifuged as stated in 
Section 2.4.1.  After discarding the supernatant, pelleted cells were suspended 
with cryopreserving medium composed of 10 % (v/v) of dimethyl sulfoxide 
(DMSO) and 20 % (v/v) of FBS in DMEM. These cell suspensions were 
divided into cryotubes (1 mL/tube) and stored at -20 °C for 1 h prior to being 
placed in a -80 °C freezer overnight. On the next day, cell vials were 
transferred to liquid nitrogen for long-term storage.             
 
 
2.5. Analysis of barrier function 
	
2.5.1. Cell seeding 
 
Caco-2 cells were seeded into the apical chamber of a 1.2 cm2 (0.4 µm 
pore size) polyester membrane of 12-well Transwell® plates at a cell density 
of 7 x 104/well. Cells were left to grow for ~ three weeks to produce polarized 
monolayers. During this time cells were maintained in DMEM medium 
supplemented with 10 % (v/v) FBS and 1 % P/S with 400 µL in the apical 
chamber and 800 µL in the basolateral chamber. One well in each plate was 
left without cells for blank reading. Cell medium in each well was replaced with 








2.5.2. Transepithelial electrical resistance (TEER) measurement    
 
TEER measurements were used to monitor cell growth, formation, and 
changes in epithelial cell barrier function (88, 135). Caco-2 cell monolayer 
confluency is usually demonstrated by a TEER value of > ~ 300 Ω·cm2 (135). 
TEER measurement was performed using EVOM2TM epithelial voltmeter 
(World Precession Instruments, UK) using chopstick-like silver/silver-chloride 
electrodes that were 4 mm wide and 1 mm thick. Prior to each use, the 
electrodes were sterilized using 70 % (v/v) of ethanol in water then washed 
with and calibrated in Hanks' balanced salt buffer solution (HBSS). TEER 
values were obtained by placing one electrode in the apical chamber and the 
other in the basolateral chamber as per supplier’s instructions. Cell monolayer 
TEER values of each well were calculated by subtracting the blank well TEER 
value from the TEER value measured for each cell monolayer with that value 
then multiplied by the filter surface area.       
 
   
2.5.3. Fluorescent solutes used to study TJ permeability 
 
Evaluation of paracellular permeability of Caco-2 in vitro is commonly 
performed by measuring apical to basolateral transport of different poorly-
permeable solutes of different molecular weights, such as fluorescent dextrans 
(118, 135, 136). In our work, we assessed the extent of TJ opening by studying 
apical to basolateral transport of 4 kDa fluorescein isothiocyanate (FITC)-
dextran, 10 kDa FITC-dextran, and 70 kDa tetramethylrhodamine 
isothiocyanate (TRITC)-dextran across Caco-2 cell monolayers. In addition, 
the permeability of fluorescent dextran having different net charge across 
Caco-2 cell monolayers was also examined: positively-charged FITC-
diethylaminoethyl-dextran (FITC-DEAE-dextran) and negatively-charged FITC-
carboxymethyl-dextran (FITC-CM-dextran), both having a molecular weight of 
4 kDa. The listed molecular weights of all of these dextrans represent an 







2.5.4. Time-course assessments of TEER change of monolayers and 
fluorescent dextran transport induced by PIP peptides 
 
Studies were performed on polarized Caco-2 cell monolayers as defined 
by the measured TEER value as defined in Section 2.5.2. Transport 
experiments were initiated by discarding cell medium and washing apical and 
basal monolayer surfaces once with 400 µL and 800 µL of HBSS, respectively. 
Subsequently, this buffer was removed and replaced with fresh HBSS in both 
apical and basolateral chambers and monolayers were left at 37 °C for 30 min 
to equilibrate. Upon completion of the equilibration period, a study baseline 
TEER measurement was performed and a background sample that served as 
the initial time point for the transport study was collected.  
 
 
To start a study, apical buffer was removed and replaced with 400 µL of 
fresh HBSS buffer containing the required fluorescent dextran for each test 
(each prepared at a stock working concentration of 1 mg/mL) with or without a 
PIP peptide; fresh HBSS (800 µL) was exchanged in the basal compartment. 
For each time point of a study, a TEER measurement was performed followed 
by collection of the basal media, which was then replaced with fresh HBSS 
medium to the basal chamber. The extent of transported dextran was 
determined by measuring the fluorescence present in the HBSS samples 
collected from the basal compartment over time (FITC; Ex 490 nm/ Em 520. 
TRITC; Ex 540 nm/ Em 610 nm) using FLUOstar® Omega Microplate Readers 
(BMG Labtech, Germany). 
 
 
2.5.5. Induction of TJ barrier loss by proinflammatory cytokines 
 
This was performed as described in the literature (54, 137, 138) to compare TJ 
barrier loss induced by proinflammatory cytokines with changes in TJ barrier 
properties induced by PIP peptides. A mixture of the human proinflammatory 
cytokines tumour necrosis factor alpha and interferon gamma (TNFα/INFγ) 






containing DMEM medium without P/S antibiotic to induce TJ barrier loss. 
Specifically, Caco-2 cell monolayers were treated with 10 ng/mL INFγ 
overnight prior to addition of 5 ng/mL TNFα for 4 h. After induction of TJ barrier 
dysfunction, media containing proinflammatory cytokines was discarded and 
cell monolayers were washed once with HBSS, 400 µL in the apical chamber 
and 800 µL in the basal chamber. Subsequently, transport of different-sized 
fluorescent dextran molecules across Caco-2 cell monolayers was as 
described in Section 2.5.4. 
 
 
2.6. Protein characterization 
 
2.6.1. Protein extraction for immunoblotting (western blotting) 
 
Upon completion of an experiment, cell media in the apical and basal 
compartments was discarded prior to washing monolayers thrice with ice cold 
PBS. Cells were then lysed by adding 100 µL radioimmunoprecipitation assay 
buffer (RIPA) that contained a cocktail of protease and phosphatase inhibitors 
(25 µL/mL each), added to the apical surface of each Transwell® filter. Lysed 
cells were scraped into Eppendorf tubes and placed on ice for 10 min prior to 
centrifugation at 10,000 x g for 10 min at 4 °C using Heraeus™ Fresco™ 17 
Microcentrifuge (Fisher scientific, UK). Supernatants obtained from this 
centrifugation step were then diluted with electrophoresis sample buffer 
(composed of 500 µL/mL 4x NuPAGER® lithium dodecyl sulfate (LDS), 200 
µL/mL NuPAGER® reducing agent, and 300 µL/mL Milli-Q water) in a 1:1 ratio 
prior to separation by sodium dodecyl sulfate polyacrylamide gel 









2.6.2. Protein extraction for immunoprecipitation, native-
immunoblotting and pull-down assay with biotinylated PIP peptides 
 
Proteins were extracted using the same method as in Section 2.6.1. 
However, cells were harvested from 75 cm2 flasks and lysed using a 1 mL of 
lysis buffer composed of 50 mM Tris at pH 7.4, 200 mM NaCl, 10 mM EDTA, 
20% (v/v) of glycerol, and 1% (v/v) Nonidet P40. 
 
 
2.7. Determination of extracted protein  
 
2.7.1. Detergent-compatible Bradford assay 
 
The Bradford colorimetric assay is commonly used to determine the 
protein concentration of a solution (139). This assay uses the protein-binding 
capacity of Coomassie blue dye that results in an absorption maximum shift 
from 465 nm (un bound dye, green colour) to 595 nm (dye bound to protein, 
blue colour) (139). Unfortunately, the traditional Bradford reagent is incompatible 
with cell lysis buffers containing detergents (139). Thus, the Pierce™ detergent 
compatible Bradford reagent was used that is compatible with commonly used 
detergents. For these protein determinations, bovine serum albumin (BSA) 
was used as a standard protein.  
 
 
2.7.2. General methodology 
 
Protein determinations were performed in a 96-well plate using 10 µL of 
cell lysates and 300 µL of Pierce™ detergent-compatible Bradford reagent. 
Plates were incubated for 10 min at room temperature on a plate shaker. The 
intensity of Bradford dye converted to 595 nm emission was determined using 
a FLUOstar® Omega Microplate Reader. Protein concentrations were 
determined using a plotted BSA standard curve with the following 







2.8. Immunoprecipitation protocol 
 
Immunoprecipitation of proteins was performed on confluent Caco-2 cells 
grown in 75 cm2 flasks. Separate flasks of cells were treated with the PIP 640 
peptide for set times. Untreated cells were used as controls. Treated cells 
were then washed with HBSS once and lysed as described in Section 2.6.2. 
Cell lysates containing ~ 500 µg of total protein were quantified as described 
in Section 2.7.2 and mixed with a primary antibody recognizing the protein of 
interest (Section 2.16, Table 2.6); this solution was incubated with rotation for 
1 h at 4 °C. Subsequently, 20 µL of agarose beads was added to each sample 
and the suspension was mixed by gentle rotation overnight at 4 °C. Agarose 
beads were then collected by centrifugation at 1,000 x g for 5 mins at 4 °C and 
washed thrice by centrifugation with 500 µL of the same lysis buffer for each 
wash. After the final wash, agarose beads were re-suspended with 50 µL of 
electrophoresis sample buffer (described in Section 2.6.1) and the agarose 
bead-associated proteins separated by SDS-PAGE prior to Western 
immunoblotting analysis (Section 2.11).  
 
 
2.9. Pull-down assay with biotinylated peptides  
 
Confluent Caco-2 cells grown in 75 cm2 flask were lysed as described in 
Section 2.6.2. Lysates were divided equally, with each being prepared from 
cells treated with a different concentration of biotinylated PIP 640 peptide and 
rotated slowly for 3 h at 4 °C, each then being combined with 50 µL of 
streptavidin magnetic beads that had been pre-equilibrated with 500 µL of lysis 
buffer. Samples were incubated with gentle rotation for 1 h at 4 °C. 
Biotinylated PIP 640 peptide-bound beads were pulled-down using a magnet 
and washed thrice with 500 µL lysis buffer, being captured each time using the 
magnet pull-down step as above. After the final wash, the streptavidin 
magnetic beads were suspended in 50 µL of electrophoresis sample buffer 
and proteins associated with these beads being separated by SDS-PAGE 







2.10. Detection of myosin light chain phosphatase protein 
components interacting with PIP 640 peptide 
 
A 75 cm2 flask of Caco-2 cells was lysed as described in Section 2.6.2. An 
aliquot of the lysate was combined with each PIP peptide to be tested and 
then incubated by gentle rotation for 3 h at 4 °C. Subsequently, 10 µL of each 
lysate-PIP peptide sample was mixed with 40 µL of a non-denaturing sample 
buffer (Native sample gel buffer, Table 4). Proteins present in these 
preparations were separated by native gel electrophoresis (Section 2.11.1) 
prior to western immunoblotting analysis as described in Section 2.11.4. 
 
 
2.11. SDS-PAGE and native-PAGE immunoblotting  
 
2.11.1. Gel preparation for SDS-PAGE and native-PAGE 
immunoblotting 
 
The resolving element of the gels used in these studies was prepared by 
mixing the ingredients described in Table 2.1; the solution being poured into 8 
cassettes of 1 mm thickness each and allowed to polymerize at room 
temperature for 60 min. Ingredients of the stacking gel described in Table 2.2 
were mixed and immediately poured into the cassettes over the resolving gel 
prior to inserting a comb to form the desired number of wells where protein 
samples are loaded. 
 
 
2.11.2. Buffers for electrophoresis and immunoblotting  
	
Electrophoresis running buffer for both SDS-PAGE and native PAGE was 
prepared by combining 3 g of Tris and 14 g of glycine in 1 L of Milli-Q water; 
the SDS-PAGE running buffer also contained 1 g of SDS. Protein transfer onto 
polyvinylidene fluoride (PVDF) membranes was performed using a buffer that 
was composed of 1.5 g of Tris, 7 g glycine, and 200 mL methanol (MeOH) in 






Tris-HCl (pH 7.5) and 37 mL of 4 M NaCl in 957.5 mL Milli-Q water. TBS 
containing 0.1 % (v/v) of Tween®20 (TBS-T) was used for washing, BSA 
blocking, and antibody incubation of PVDF membranes.   
 
 
Table 2.1: Reagents used to prepare the resolving gel used for both SDS-PAGE and 
native-PAGE 
Reagent (resolving gel) SDS-PAGE Native-PAGE 
Milli-Q water 24 mL 24 mL 
40 % acrylamide/bis-acrylamide (29:1) 16.8 mL 16.8 mL 
Tris-HCl buffer (1.5 M, pH=8.8) 14 mL 14 mL 
10 % (w/v) of SDS in Milli-Q water 560 µL ---- 
10 % (w/v) of Ammonium Persulfate (APS) in 
Milli-Q water  
560 µL 560 µL 
Tetramethylethylenediamine (TEMED) 56 µL 56 µL 
 
 
Table 2.2: Reagents used to prepare the stacking gels used for both SDS-PAGE and 
native-PAGE 
Reagent (stacking gel) SDS-PAGE Native-PAGE 
Milli-Q water  11.6 mL 11.6 mL 
40 % acrylamide/bis-acrylamide (29:1) 3 mL 3 mL 
Tris-HCl buffer (0.5 M, pH=6.8) 5 mL 5 mL 
10 % (w/v) of SDS in Milli-Q water 200 µL ----- 
10 % (w/v) of APS in Milli-Q water 200 µL 200 µL 






2.11.3. SDS-PAGE and electrophoretic transfer  
 
SDS-polyacrylamide gels were placed in an XCell™ Sure Lock Mini-cell 
electrophoresis box (Invitrogen, UK) with SDS-PAGE running buffer (Section 
2.11.2). Cell lysates were mixed with sample buffer, heated for 5 min at 95°C, 
and then loaded into wells generated by the removal of the comb (20 µL/well). 
Samples were electrophoresed at 160 V for ~ 2 h to separate proteins. Upon 
completion of proteins separated by gel electrophoresis were electro-
transferred onto PDVF membranes using an XCell™ Blot module (Invitrogen, 
UK) at 30 V for 90 min. Membranes were then blocked by 2% BSA (w/v) in 
TBS-T for 1h at room temperature prior to an overnight incubation at 4 °C with 
an appropriate primary antibody diluted in TBS-T (Section 2.16 Table 2.6). On 
the next day, membranes were washed with TBS-T thrice, for 5 min each, then 
incubated with infrared (IR) dye-labelled secondary antibody diluted in TBS-T 
(Section 2.16 Table 2.7). Afterwards, membranes were washed thrice with 
TBS-T and imaged using the Odyssey CLX imaging system (LI-COR, UK). 
Images were analyzed using the Image Studio Lite software, version 5.2.    
 
 
2.11.4. Native-PAGE immunoblotting protocol   
 
Native-PAGE immunoblotting was performed using a running buffer that 
does not include SDS, as mentioned in Section 2.11.2, following a similar 
method to that described in Section 2.11.3, except that protein electro-transfer 









2.12. Confocal microscopy and immunofluorescent staining  
 
2.12.1. Confocal microscopy and image analysis 
 
All images were collected at 63x magnification using a Zeiss LSM 510 
META confocal microscope equipped with 3 laser lines: diode (Ex 405 nm), 
argon (Ex 488 nm) and helium-neon (Ex 543 nm). Filters with different ranges 
were used to collect the emitted fluorescence including: (Em 550-625 nm, 
red), (Em 420-480 nm, blue) and (Em 505-530 nm, green). Z-stacks were 
collected at 1 µm intervals to generate xz plan images. Collected images were 
analyzed using Zeiss LSM Image Browser software, version 4.2.0.121. 
Maximum excitation/emission wavelengths of fluorophores used in confocal 
images are described in Table 2.3. 
 
 
Table 2.3: Maximum excitation/emission wavelengths of fluorophores used in 
confocal microscopy. 
Fluorophores Ex (nm) Em (nm) 
Alexa 488 (Green) 495 519 
Alexa 546 (Red) 556 573 




2.12.2. Immunofluorescent staining  
 
 2.12.2.1. Intracellular localization of biotinylated PIP peptides 
 
Caco-2 cell monolayers, incubated at 37 °C, 5% CO2, were treated 
apically with different analogues of biotinylated PIP peptides dissolved in 
HBSS buffer; HBSS was used as a control. Upon completion of the incubation 
period, cell monolayers were washed thrice with HBSS to remove extracellular 
peptides prior to fixing with 4 % (w/v) paraformaldehyde (PFA) in PBS for 20 
min. Fixed cell monolayers were washed thrice with 500 µL of PBS, each for 2 






as a quenching reagent to reduce background fluorescence resulting from 
residual aldehyde groups generated by PFA fixation. Fixed cell monolayers 
were then permeabilized with 0.1 % (v/v) of Triton X-100 in PBS for 20 min 
and then washed thrice with PBS prior to blocking with 10 % of FBS (v/v) in 
PBS for 1 h with gentle rocking.  
 
Fixed, permeabilized cell monolayers were then treated with a primary 
antibody recognizing occludin (Section 2.16, Table 2.6) followed by a species-
specific secondary antibody-conjugated to Alexa 546 to highlight TJ structures 
(Section 2.16 Table 2.7). Subsequently, cell monolayers were washed, as 
described above, and biotinylated peptides were detected with 1µL/mL of Alex 
488-conjugated streptavidin in PBS for 40 min. Nuclei were stained with 1 
µL/mL of DAPI in PBS for 20 min. Finally, stained cell monolayer membranes 
were cut off the Transwell® inserts and placed on glass slides with cells facing 
up. After a one drop application of Vectashield® mounting medium a glass 
coverslip was positioned to allow examination by confocal microscopy, as 
described in Section 2.12.1. 
  
 
2.12.2.2. Assessment of TJ protein distribution 
 
Caco-2 cell monolayers were treated with the PIP 640 peptide in HBSS, or 
HBSS only (control), for set times at 37 °C. Subsequently, cell monolayers 
were washed thrice with 500 µL of HBSS to remove unincorporated peptide, 
then washed once with the same volume of ice-cold MeOH prior to placing in 
pre-cooled MeOH at -20 °C for 1 h. Cell monolayers were re-hydrated by 
incubation in PBS for 15 min before being blocked with 10 % (v/v) FBS in PBS 
for 1 h. Monolayers were then incubated with primary antibodies against 
different TJ proteins (Section 2.16, Table 2.6). This was followed by 3 washes 
with PBS before incubation with the appropriate fluorophore-conjugated 
secondary antibodies against the primary antibody being used (Section 2.16 
Table 2.7). Cell monolayers were then washed thrice with PBS and mounted, 






2.13. In vivo studies 
 
All in vivo experiments were performed using male adult (7-8 weeks old) 
Wistar rats with an average weight ~250 g. All experiments were conducted 
using non-recovery protocol. Rats were anesthetized using inhaled isoflurane 




2.13.1. Insulin subcutaneous administration or co-administration with 
PIP 640 peptide by intraluminal injection (ILI) and tissue collection 
protocols  
 
Rats were anesthetized with 5% inhaled isoflurane in combination with O2 
(induction rate) using a rodent anaesthesia system equipped with isoflurane 
vaporizer. A 4–5 cm midline abdominal incision was made to access the small 
intestine (mid-jejunum to proximal ileum regions). After performing the incision, 
isoflurane concentration was lowered to 2% (maintenance rate). A stock 
solution of human insulin (30 IU/kg) and (20 mM) PIP 640 peptide was 
prepared in PBS containing 10 mM citric acid. Using a 1 mL syringe connected 
to a 27-gauge needle, 50 µL of a prepared stock solution was injected into the 
rat intestinal lumen. Changes in blood glucose levels over time were 
measured using a glucometer (AccuChek,UK) in blood samples collected from 
the tail vein. Negative control treatment was performed by injecting insulin in 
PBS containing citric acid into the rat intestine. After the desired exposure 
times, rats were euthanized by CO2 asphyxiation. At that time, a ~ 1 cm 
section of rat intestine at the injection site was collected for biochemical 
studies. A subcutaneous (SC) insulin injection (3 IU/kg) as a positive control 
was performed in the mid-scapular region followed by assessment of blood 










2.13.2. Tissue preparation for immunoblotting  
	 
Collected rat tissues, as described in Section 2.13.1, were washed with 
ice-cold PBS and then maintained in ice-cold PBS for 10 min. Intestinal 
segments were then sliced into smaller pieces and placed into 5 mL 
Eppendorf tubes containing 2 mL of RIPA lysis buffer containing a cocktail of 
protease and phosphatase inhibitors (25 µL/mL, each) followed by a 10 min 
incubation on ice. Lysates were clarified by centrifugation at 10,000 x g at 4 
°C. Supernatants were aliquoted and stored at – 80 °C prior to their analysis in 




2.13.3. Rat intestinal tissue processing for immunofluorescence 
staining  
 
Rat intestine sections were collected and washed with ice-cold PBS as 
described (Section 2.13.1). Tissues were then fixed overnight at 4 °C in ice-
cold PBS containing 4 % (w/v) PFA. On the next day, fixed intestinal sections 
were opened longitudinally, placed in marked tissue cassettes, and 
dehydrated using an automated Leica TP 1020 tissue processor (Leica 
Biosystems, UK) that used sequential immersions into 70 %, 80 %, 90 % and 
100 % (v/v) EtOH/water solutions for 2 h each. Dehydrated tissues were 
embedded in paraffin using a Leica EG 1160 tissue embedding device (Leica 
Biosystems, UK) and allowed to set at 4 °C overnight. Paraffin-embedded 
tissues were sectioned using a Leica RM 2155 microtome (Leica Biosynthesis, 
UK) to obtain 5 µm slices that were placed onto glass slides.   
 
 
The procedure of immunofluorescent staining of sectioned intestinal tissue 
on glass slides was initiated by rehydration that involved immersing slides first 
in Histo-clear™ solution for 10 min followed by 100%, 90 %, 80 %, and 70 % 






thrice for 5 min before being subjected to an to antigen retrieval step that was 
performed by placing slides into a beaker containing boiling 10 mM sodium 
citrate buffer (pH=6) for 10 min. Subsequently, tissue slices were washed 
thrice with PBS for 5 min, permeabilized with 0.2 % (v/v) Triton X-100 in PBS 
for 30 min and blocked with 2% (w/v) BSA in PBS for 1 h. Tissues were then 
incubated with primary antibodies diluted in PBS containing 1% (w/v) BSA 
overnight at 4 °C (Section 2.16; Table 2.6). On the next day, slides were 
washed thrice with PBS then incubated with the required dilution of species-
specific secondary antibody in PBS (Section 2.16 Table 2.7) for 2 h at room 
temperature. Slides were then washed thrice with PBS and once with Milli-Q 
water for 5 min each. Finally, slides were dehydrated by sequential immersion 
into 70 %, 80 %, 90 % and 100 % (v/v) EtOH/water solutions for 5 min each 
followed by immersion into Histo-clear™ solution for 10 min prior to cover slip-
mounting the tissue with Vectashield® medium, as described in Section 




2.13.4. Assessment of enhanced calcitonin and exenatide 
permeability in rats in vivo  
 
Rats were anesthetized and their abdominal cavity accessed via surgical 
incision as described in Section 2.13.1, to allow ILI and blood sample 
collection from the portal vein. ILI (50 µL) injections were performed for 
solutions containing either calcitonin or exenatide (0.5 mg), 20 mM PIP 640 
and 1.5/mL soybean trypsin inhibitor (SBTI). Control injections were performed 
with either calcitonin or exenatide and SBTI, but no PIP 640 peptide. Blood 
samples (100 µL) were collected at set time points from the portal vein and 
placed into Eppendorf tubes containing 50 mM of EDTA and 0.6 IU/mL 
aprotinin to prevent blood coagulation and protein degradation, respectively. 
Blood samples were then centrifuged at 1,600 x g for 15 min at 4 °C and the 






content in plasma samples were measured by enzyme linked immunosorbent 




2.13.5. Assessment of blood endotoxin levels in vivo 
 
Plasma samples that were used to evaluate therapeutic peptide 
permeability enhancement (Section 2.13.4), were also examined for 
determining if PIP 640 also enhanced the trans-epithelial uptake of luminal 
endotoxin. This was performed using a commercial, semi-quantitative assay 
kit: E-Toxate™ Limulus amebocyte lysate (LAL). This kit uses as readout the 
formation of a gel-like clot with the reagent when reacted with endotoxin (140). 
Analysis using the LAL kit was performed on 50 µL of a plasma sample and 
endotoxin standards in separate sterile 10 x 75 mm glass test tubes. This was 
followed by adding 150 µL of LAL reagent into each tube and incubation for 1 
h at 37 °C in a water bath. Afterwards, tubes were inverted 180° to evaluate 
gel formation; generation of a hard gel, which was not disrupted by tube 




















2.13.6. Hydrodynamic radius calculation 
 
Hydrodynamic radius was approximated using the relationship established 
between the molecular weight (MW) and the hydrodynamic radius (RH) of a 
protein that assumes the protein have the simple shape of a sphere. (141):   
 
RH= ! !"! !"! !! 
 
Where  RH in (cm) 
MW in (g/mol)  
ρ is the average density of a hydrated 
protein (0.99 g/cm3)(141) 





2.14. Cell viability assay in vitro    
 
The extent of viable cells with active mitochondrial metabolism can be 
correlated with the amount of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) that can be 
converted to formazan (142). This conversion is presumably accomplished by 
NADPH- or NADH-dependent oxidoreductase and dehydrogenase enzymes in 
metabolically active cells (142). The colour intensity of formazan formed by this 









Caco-2 cells were seeded in 96-well plates at a density of 2 x 104 in 100 
µL DMEM cell medium supplemented with 10% FBS and 1% P/S and 
incubated overnight at 37 °C under 5% CO2. On the next day, cells were 
treated with different PIP peptides dissolved in 100 µL of cell medium, as 
described above, for 12 h. Control cells were incubated with 100 µL of cell 
media that did not contain a PIP peptide. Upon completion of this 12 h 
incubation period, cells were treated with 20 µL of MTS reagent (at the 
concentration provided by the supplier) and incubated at 37 °C and 5% CO2 
for 3 h. Finally, absorbance was recorded at 490 nm using the plate reader 
described in Section 2.5.4.     
 
 
2.15. Statistical analysis  
 
All data are represented as values ± SEM of three independent 
experiments, unless otherwise specified. A two-tailed unpaired t test was used 
for comparison between two groups.  Potential differences between treatment 
groups were examined using one-way ANOVA; Tukey’s multiple comparison 
was used to test for experiments involving three or more treatments. All 



















2.16. Reagents and materials 
 
Table 2.4: Chemical reagents for peptide synthesis 
Reagent Catalogue number Supplier 
Biotin-ONp 851027 Novabiochem, UK 
biotin-PEG Nova TagTM 
resin 
855055 Novabiochem, UK 
DIC D125407 Sigma-Aldrich, UK 
DIEA D125806 Sigma-Aldrich, UK 
DMF RG2014 Rathburn chemicals, UK  
Fmoc-D-Ala-OH 852142 Novabiochem, UK 
Fmoc-D-Arg(Pbf)-OH 852165 Novabiochem, UK 
Fmoc-D-Asp(OtBu)-OH 852154 Novabiochem, UK 
Fmoc-D-Glu(OtBu)-OH 852155 Novabiochem, UK 
Fmoc-D-Lys(Boc)-OH 852146 Novabiochem, UK 
Fmoc-D-Tyr(tBu)-OH 852151 Novabiochem, UK 
Fmoc-D-Val-OH 852152 Novabiochem, UK 
HOBt 157260 Sigma-Aldrich, UK 
piperidine 411027 Sigma-Aldrich, UK 
PyBOP 851009 Novabiochem, UK 
Rink amide MBHA resin 855003 Novabiochem, UK 
TFA T62200 Sigma-Aldrich, UK 
TIPS 841359 Sigma-Aldrich, UK 
 
 






A7802 Sigma-Aldrich, UK 
Aprotinin 10820 Sigma-Aldrich, UK 
APS 10744171 Fisher Scientific, UK 
Bolt™ empty mini gel cassette 
combs, 10-well 






BSA A7906 Sigma-Aldrich, UK 
Calcitonin (Salmon) - ELISA Kit EK-014-09 Phoenix Pharmaceuticals, 
US 
Calcitonin, salmon 05-23-2401 Novabiochem, UK 
Cell culture flask, 75 cm2 156499 Fisher Scientific, UK 
Citric acid C1909 Sigma-Aldrich, UK 
DAPI D3571 Invitrogen, UK 
DMEM medium 41965039 Fisher Scientific, UK 
DMSO D8418 Sigma-Aldrich, UK 
EDTA BP118 Fisher Scientific, UK 
Empty mini 1.0 mm gel cassettes NC2010 Invitrogen, UK 
Ethanol 32221 Sigma-Aldrich, UK 
E-Toxate™ kit E8779 Sigma-Aldrich, UK 
Exenatide (Exendin-4) 1933 Tocris Bioscience, UK 
Exenatide (Exendin-4) ELISA Kit MBS031942 2B Scientific Ltd, UK 
FBS 10500064 Fisher Scientific, UK 
FITC-CM-dextran, 4 kDa 68059 Sigma-Aldrich, UK 
FITC-DEAE-dextran, 4 kDa 53557 Sigma-Aldrich, UK 
FITC–dextran, 10 kDa FD10S Sigma-Aldrich, UK 
FITC–dextran, 4 kDa FD4 Sigma-Aldrich, UK 
Gibco™ IFN-γ 10474733 Fisher Scientific, UK 
Gibco™ TNFα 10699920 Fisher Scientific, UK 
Glass square coverslip 12363138 Fisher Scientific, UK 
Glycerol BP229 Fisher Scientific, UK 
Glycine 10061073 Fisher Scientific, UK 
HBSS buffer 12352207 Fisher Scientific, UK 
Histo-clear™ 12358637 Fisher Scientific, UK 
Immobilon®-FL PVDF transfer 
membrane, 0.45 µm, 
IPFL00010 Novabiochem, UK 
Insulin, recombinant human 91077C Sigma-Aldrich, UK 
Methanol 34860 Sigma-Aldrich, UK 
Minisart® syringe filter, 0.2µm 16532 Sartorius, UK 
MTS reagent, CellTiter 96® one 
solution cell proliferation assay 






Nalgene™ cryogenic tubes 11375644 Fisher Scientific, UK 
Native sample gel buffer 1610738 BIO-RAD, UK 
NH4Cl 09718 Sigma-Aldrich, UK 
NP-40 detergent 85124 Invitrogen, UK 
Nunc™ 96-well microplates 10212811 Fisher Scientific, UK 
4X NuPAGE™ LDS sample buffer NP0007 Invitrogen, UK 
10 X NuPAGE™ sample reducing 
agent material 
NP0009 Invitrogen, UK 
P/S antibiotics P0781 Sigma-Aldrich, UK 
Paraffin wax SA4523 Science Services, 
Germany 
PBS tablets BR0014G Fisher Scientific, UK 
PFA P6148 Sigma-Aldrich, UK 
Phosphatase inhibitor cocktail IV 12851650 Fisher Scientific, UK 
Pierce™ detergent compatible 
Bradford assay kit 
23246 Invitrogen, UK 
Polysine adhesion slides 10219280 Fisher Scientific, UK 
Protease inhibitor cocktail III 12841640 Fisher Scientific, UK 
Protein A/G plus agarose beads sc-2003 Santa Cruz Biotech, UK 
RIPA buffer R0278 Sigma-Aldrich, UK 
SBTI T9128 Sigma-Aldrich, UK 
SDS 10090490 Fisher Scientific, UK 
Sodium chloride S9625 Sigma-Aldrich, UK 
Sodium citrate dihydrate W302600 Sigma-Aldrich, UK 
Streptavidin Sepharose™ 
magnetic bead 
11791456 Fisher Scientific, UK 
Streptavidin, Alexa Fluor™ 488 
conjugate 
S11223 Invitrogen, UK 
TEMED 10549960 Fisher Scientific, UK 
Tissue cassette 12026839 Fisher Scientific, UK 
Tissue cassette lid 12096829 Fisher Scientific, UK 
Transwell® polyester membrane, 
0.4 µm, cell culture inserts 
3460 Sigma-Aldrich, UK 
TRITC-dextran, 4 kDa T1037 Sigma-Aldrich, UK 






Triton™ X-100 X100 Sigma-Aldrich, UK 
Trizma® (Tris) base T6066 Sigma-Aldrich, UK 
Trypsin 10x SV30037.01 Fisher Scientific, UK 
Tween®-20 P1379 Sigma-Aldrich, UK 




Table 2.6: List of primary antibodies used for western blotting (WB), 











WB: 1 µg/mL 
 




WB: 1 µg/mL 
IF: 1 µg/mL 
Ab15098 Abcam, UK 
Claudin-15 Rabbit 
(polyclonal) 
WB: 1 µg/mL 
 




WB: 1 µg/mL 
IF: 5 µg/mL 
Ab125293 Abcam, UK 
Claudin-2 Rabbit 
(polyclonal) 
IP: 2 µg/mL 
 




WB: 1 µg/mL Ab15102 Abcam, UK 
Claudin-4 Rabbit 
(polyclonal) 
WB: 1 µg/mL 
IF: 1 µg/mL 
Ab15104 Abcam, UK 
Claudin-5 Rabbit 
(polyclonal) 
WB: 1 µg/mL 
 




WB: 5 µg/mL 
IF: 5 µg/mL 
Ab27487 Abcam, UK 
Claudin-8 Rabbit 
(polyclonal) 
WB: 2 µg/mL 
 








WB: 1 µg/mL 
IF: 2 µg/mL 




WB: 1 µg/mL 
 




WB: 1 µg/mL 
IF: 5 µg/mL 
Ab31721 Abcam, UK 
Occludin Mouse 
(monoclonal) 











WB: 1 µg/mL 
 
sc-365678 Santa Cruz 
Biotech, UK 
Total MLC Rabbit 
(polyclonal) 
WB: 1 µg/mL Ab79935 Abcam, UK 
Tricellulin Rabbit 
(polyclonal) 
WB: 1 µg/mL 
IF: 2 µg/mL 
48-8400 Invitrogen, UK 
ZO-1 Rabbit 
(polyclonal) 
WB: 1 µg/mL 
IF: 2 µg/mL 
40-2200 Invitrogen, UK 
	
	






















IF: 4 µg/mL A-10036 Invitrogen, UK 
IRDye® 
800CW anti-
goat  IgG 
Donkey 
(polyclonal) 









anti-rabbit  IgG 
Donkey 
(polyclonal) 
WB: 1 µg/mL 926-68073 LI-COR, UK 
IRDye® 680CW 
anti-mouse  IgG 
Donkey 
(polyclonal) 
WB: 1 µg/mL 
 





























Chapter 3 : Validation of PIP 







































Peptide therapeutics have become an increasingly popular type of 
medication because of their efficient target selectivity and potency (143). 
Therefore, the development of peptide-based medications has increased in 
the global drug market over the last decade (143, 144). Currently, most of the 
available peptide therapeutics are only administered parentally by injection 
(143). This route of administration usually requires frequent and high dosing with 
expensive materials and is considered inconvenient for patients (145). Hence, 
enabling other routes of administrating therapeutic peptides, such as oral, 
pulmonary and intranasal, would provide more options to improve the 
medication’s targeting efficiency and patient acceptability. The pharmaceutical 
industry considers the oral route of administration the desired method for 
peptide therapeutics (116, 145). This is probably because of the remarkable 
acceptance and preference for oral dosage forms. Methods to improve 
outcomes of such oral dosage forms have benefited from enteric coatings that 
would provide protection of therapeutic peptides during transit through the 
harsh environment of the stomach to allow biologically active materials to 
reach the intestinal lumen where they might be absorbed (13, 116). However, 
such oral dosage form-related strategies do not address the ultimate barrier to 
oral delivery of a peptide therapeutic: restriction of these materials to cross the 
single layer of epithelial cells that line the intestinal lumen (146).  
 
 
Most previous efforts to overcome this epithelial barrier were focused on 
developing or modifying the functional properties of the intestinal epithelium. 
For example, agents known to enhance drug permeability, such as sodium 
caprate that function by altering the intestinal epithelial cell-cell contacts, have 
been co-administered with peptide drugs. The main challenge with this 
approach is that, in such cases, there is a great deal of uncertainty as to the 
mechanism of action (MoA) for such permeation enhancing agents (5). 
Moreover, the application of some technologies, for example, nanoparticles, 






intestinal degradation and improving the ability to cross the intestinal epithelial 
cells (116). However, the safety of this delivery technology is still controversial 
and appears to again lack a clear MoA (116). Therefore, it seems essential to 
focus on approaches to improve the absorption of peptide therapeutics that 
might be facilitated by known MoA for alteration of epithelial barrier properties. 
By taking such an approach where a specific MoA is used, a clear strategy or 
safety assessment can be planned to optimize a rapid and logical strategy to 
clinical studies.   
 
 
Under certain physiological and pathological conditions, TJ structure and 
thus barrier properties can be modulated to increase paracellular permeability 
(147). This is primarily mediated by the reversible phosphorylation of myosin 
light chain (MLC) protein at the serine 19 of the protein (MLC-pS19); a 
phosphorylation state controlled by the interplay of a specific kinase (MLCK) 
and a specific phosphatase (MLCP) (147, 148). MLCK enzyme contains a 
pseudosubstrate region that acts as an auto-inhibitory domain, with activation 
of kinase in epithelial cells being induced by the action of the Ca2+ binding 
protein calmodulin (CaM) (149). Increased cytosolic Ca2+ levels lead to the 
formation of Ca2+/CaM complexes, which in turn bind to MLCK and interrupt 
the auto-inhibition caused by its pseudosubstrate domain. As a result, 
Ca2+/CaM binding causes MLCK activation, allows it to selectively induce 
MLC-pS19 and trigger contraction of TJ-associated actomyosin filaments and 
enhance TJ permeability (147, 149). This process is reversed by MLCP, a trimeric 
protein complex composed of protein phosphatase 1-δ (PP1-δ), a myosin -
targeting subunit-1 (MYPT-1) and a 20 kDa accessory subunit (91, 150). 
Dephosphorylation of MLC-pS19 by MLCP is strictly dependent on the binding 
of PP1-δ to the MYPT1 subunit, because PP1 is a ubiquitous enzyme that has 
various functions determined by its binding to different regulatory proteins (151-
153). In addition to MLCP components, a protein kinase-C (PKC) dependent 
protein inhibitor called C-kinase potentiated protein phosphatase-1 inhibitor- 







Previous data have shown that reducing the level of MLC-pS19 with a 
membrane-permeant peptide, called PIK peptide that was designed to mimic 
the inhibitory domain of MLCK, repaired TJ barrier dysfunction associated with 
some intestinal inflammatory diseases by closing TJs opened by the action of 
pro-inflammatory cytokines (53, 103, 129). By adopting a similar principle to PIK 
peptide design, membrane permeant peptide inhibitors of MLCP (PIP) were 
designed to selectively inhibit MLCP to transiently increase MLC-pS19 levels to 
enhance paracellular permeability so that the transient permeability of 
therapeutic peptide could be briefly increased across intestinal epithelial cells 
(127). This was done by synthesizing small peptides targeting interfacial 
surfaces where PP1 interacts with the MLCP regulatory subunits MYPT-1 or 
CPI-17 (91, 155, 156).  
 
 
Two candidates for PIP peptides were identified; PIP 250 (rrfkvktkkrk-NH2) 
and PIP 640 (rrdykvevrrkkr-NH2), which were designed to emulate binding 
events between PP1 to MYPT1 and interactions between CPI-17 and the 
MLCP holoenzyme, respectively (127). Both PIP peptides were able to increase 
4 kDa dextran flux across Caco-2 monolayers in vitro and also enhance insulin 
permeability into blood circulation in vivo (with bioavailability of 3-4%), as 
detected in a rat portal vein after direct intestinal loop injection (127). The PIP 
640 peptide induced a more dynamic response (rapid onset and fast recovery 
of TJ permeability) on Caco-2 cell monolayers in vitro compared to the PIP 
250 peptide (127). These results of PIP peptide-mediated enhancement of 
solute permeability were consistent with the time course observed for 
increased MLC-pS19 levels (127).  
 
 
Manipulation of MLC-pS19 levels is a mechanism used in intestinal 
epithelial cells to transiently enhance TJ permeability. Work performed in this 






peptide with regard to this endogenous pathway. Moreover, the work in this 
chapter aimed to characterize the functional properties of the PIP 640 peptide 
and examine the impact of amino acid changes to the peptide on its action in 
vitro. Finally, toxicity associated with the PIP 640 peptide was examined in 
vitro to estimate the safe application of PIP peptides as a permeability 


































3.2.1. Rationale for PIP 640 peptide design 
 
Abundant data support the role of PKC-mediated phosphorylation of a 
threonine residue at amino acid position 38 (pT38) of CPI-17 in converting this 
protein into a potent inhibitor selective for MLCP (90, 148). Both in-silico 
simulation and in-vitro binding assessments indicate that pT38-CPI-17 binds to 
both MLCP elements PP1:MYPT1 (156, 157). This binding of pT38-CPI-17 to 
MLCP, which is responsible for the inhibitory function of CPI-17, is mediated 
by the sequence R36V(pT)VKYDRR44 of CPI-17 (148, 155). Therefore, a peptide 
mimicking this CPI-17 sequence was designed to inhibit MLCP and, in turn, 
increase MLC-pS19 levels to enhance TJ permeability, since MLCP inhibition 
by CPI-17 enhances MLC-pS19 (92). Because the ultimate application of this 
peptide will involve delivery to the intestinal lumen, some strategies to limit its 
rapid digestion are required to provide a reasonable chance of it working in an 
in vivo setting. This was achieved by using the D-retro inverso strategy (158). 
The carboxylic acid at the peptide C-terminus was replaced with a primary 
amide for two reasons: to stabilize the peptide against carboxypeptidase (129), 
and to mask the negative charge on the C-terminus carboxylic acid for better 
permeability enhancement. Moreover, an additional basic amino acid, arginine 
(R), was added at the N-terminus of the PIP 640 peptide to enhance its 
potential cell-penetrating peptide (CPP)-like properties (159). The pT38 was 
substituted with glutamic acid (E) as a stable phosphomimetic analogue of 
pT38 (148). Accordingly, a lead candidate, PIP 640 peptide = H2N-rrdykvevrr-NH2, 
was identified (a summary of modifications on the PIP 640 peptide design are 










Table 3.1:  A summary of the cumulative modifications on the emulated pT38-CPI-17 
sequence, R36V(pT)VKYDRR44, are highlighted in red. Lower case letters indicate the 








































3.2.2. Experimental design to explore the PIP 640 peptide MoA in vitro   
 
The PIP 640 peptide was designed to selectively emulate the protein-
protein interactions between CPI-17, and the MLCP protein complex, PP1-δ: 
MYPT-1, with the ultimate aim of inhibiting MLCP to transiently enhance TJ 
permeability. Because our previous work involved an in vivo investigation of 
PIP 640 peptide-induced permeability enhancement across rat intestinal 
epithelia, a longer version of PIP 640 peptide with three additional basic 
resides on the C-terminus, sequence: rrdykvevrrkkr-NH2, was used to ensure 
faster cell permeability because the peptide residence time in the intestinal 
lumen is variable (127). Therefore, in the current work several lines of effort 
were made to further refine our understanding of the MoA of the parent PIP 







First, an optimal PIP 640 peptide concentration for modulation of epithelial 
barrier function was determined using the human colorectal adenocarcinoma 
cell line, Caco-2, grown as confluent monolayers on a semi-permeable support 
in vitro. The PIP 640 peptide was applied to the apical surface, and the 
change in trans-epithelial electrical resistance (TEER) was monitored over 
time. As a measure of the change in solute permeability, the apical to basal 
movement of 4 kDa and 70 kDa fluorescent dextrans was also followed over 
the same 60 min time course. Caco-2 monolayer recovery from the actions of 
the PIP 640 peptide was determined by replacement of the apical media with 
fresh DMEM medium, then measurement of TEER values once again after an 
overnight incubation.  
 
These studies showed that exposure of Caco-2 monolayers to 10 mM of 
PIP 640 peptide caused a rapid, significant decrease in TEER values to 
approximately 20 % of their original value (Figure 3.1 A). This response was 
dose-dependent, with 5 mM peptide showing a lesser effect on Caco-2 
monolayer TEER values compared to 10 mM (Figure 3.1 A). With both 5 mM 
and 10 mM concentrations, PIP 640 peptide significantly enhanced the flux of 
both 4 and 70 kDa fluorescent dextrans, the extent of 70 kDa fluorescent 
dextran transport enhancement by 5 mM peptide being less that that observed 
for 10 mM treatment (Figure 3.1 B). PIP 640 peptide at a 1 mM apical 
concentration induced about a 30% reduction in TEER of Caco-2 monolayers 
upon 60 min exposure (Figure 3.1 A). This reduction in TEER was enough to 
increase the cumulative flux of only the 4 kDa dextran over 60 min (Figure 3.1 
B).  
 
Overnight recovery after 60 min of apical exposure to different 
concentrations of PIP 640 peptide showed a dose-dependent outcome with 
monolayers treated with 10 mM and 5 mM showing incomplete TEER 
recovery, whereas cell monolayers treated with 1 mM achieved almost 
complete TEER recovery (Figure 3.1 A). Since the basolateral levels of the 






Figure 3.1: Dose-dependent effect of PIP 640 peptide on Caco-2 cell monolayer trans-
epithelial electrical resistance (TEER) and permeability properties. A) PIP 640 peptide 
was applied apically at the concentration shown for 60 min, at which time the apical 
media was replaced with fresh DMEM media lacking PIP 640 peptide (arrow). TEER 
values were continued to be monitored over the next 12 h to assess functional recovery 
of the epithelium. B) Cumulative apical to basal flux rate of fluorescent dextran (4 and 70 
kDa) across Caco-2 cell monolayers measured over 60 min of apical exposure at 
different concentrations of PIP 640 peptide. For both experiments, values represent 
means ± SEM of 3 independent experiments; n= 9 for control and 10 mM PIP 640 
peptide; n= 6 for PIP 640 peptide at both 5 and 1 mM (*p value< 0.05, **p value< 0.01, 
***p value<0.001 and ****p value<0.0001).    
of PIP 640 peptide could have remained in the Caco-2 monolayers treated 
with 5 mM and 10 mM after apical media replacement that remained above 
the concentration to reduce TEER values after an overnight ‘washout’ that 
occurred by the same MoA as the initial actions occurring after apical addition. 
These results supported the use of 1 mM in future in vitro studies using Caco-
2 cell monolayers to assess the reversible function of PIP 640 peptide and 
supported the use of changes in the permeability of 4 kDa dextran to 















3.2.3. Validation of PIP 640 peptide functional properties in vitro   
 
Studies examining the concentration-dependent effect of PIP 640 peptide 
suggested that 1 mM of this peptide was sufficient to induce reversible 
permeation-enhancing actions. The second question that was now asked 
involved variation of amino acids in the peptide to look for potential 
modifications to the peptide sequence that might optimize PIP 640 peptide 
function. To do this, different analogues of PIP 640 peptide were synthesised 
that replaced specific amino acids with the D-isomer of alanine (a). Sites for 
this amino acid exchange were selected to ask specific question regarding the 
cell penetration and CPI-17-mediated actions of the PIP 640 peptide (Table 
3.2). These PIP 640 peptide analogues were examined in vitro using Caco-2 
cell monolayers for their ability to increase MLC-pS19 levels, decrease TEER, 
and enhance the permeability of 4 and 70 kDa dextrans. Studies examined the 
actions of these PIP 640 peptide analogues after a 60 min exposure and 
functional recovery overnight after washout of the apical compartment.  
 
 
Table 3.2:	 Summary of PIP 640 peptide analogue sequences and the aspect being 
tested. Modifications to the original PIP 640 peptide sequence are shown in red. 
Peptide 
analogues 
Sequence  Tested aspect Analytical 
characterization  
PIP 640 peptide 
(original) 
rrdykvevrr-NH2 -------- Appendices 
 (Section 7.1 A) 
PIP 641 peptide rrdykvavrr-NH2 Phosphomimetic  Appendices 
 (Section 7.1 B) 
PIP 642 peptide rrdakvevrr-NH2 Tyr role  Appendices 
 (Section 7.1 C) 
PIP 643 peptide rraykvevrr-NH2 Asp role Appendices 
 (Section 7.1 D) 
PIP 644 peptide rrrykvevrr-NH2 Increase in +ve charge Appendices 









The parent PIP 640 peptide was designed rationally based upon published 
structural information regarding binding of CPI-17 to MLCP, an interface that 
include a threonine at position 38 that must be phosphorylated (pT38) for 
optimal CPI-17 inhibitory function (154, 156, 157). To test the phosphomimetic role 
of D-glutamic acid (e) residue to replace (pT38) in the PIP 640 peptide, the e 
residue was replaced with a D-alanine (a), resulting in a peptide termed PIP 
641 (Table 3.2). An apical exposure to 1 mM of PIP 641 peptide for 60 min 
showed no significant effect on TEER or dextran flux (Figure 3.2 A and B). 
These findings validated the role of glutamic acid as a phosphomimetic 
analogue for pT, and was consistent with the essential role of this structural 
feature in the PIP 640 peptide.  
 
 
A previous study showed that certain amino acid residues surrounding the 
pT38, primarily a tyrosine three residues away, are essential for pT38-CPI-17 
targeting to MLCP because replacement of this residue with alanine in the 
CPI-17 protein eliminated its inhibitory effect (155). Hence, the PIP 642 peptide 
where the tyrosine residue (y) was replaced with alanine (a) was synthesized 
to study the impact of this change on PIP 640 peptide function (Table 3.2). 
Consistent with the previous study performed on the full-length CPI-17 (155), 
this substitution eliminated peptide-mediated effects on TEER and dextran flux 
(Figure 3.2 A and B). 
 
 
 Since the PIP 640 peptide must cross the plasma membrane to reach its 
intracellular target of MLCP for its desired actions on epithelium to occur, we 
wished to examine the potential role of specific positive charges in the peptide 
that had been included to increase its CPP-like character. Exchange of 
negatively-charged aspartic acid (d) in the PIP 640 peptide with alanine (a) 
resulted in the PIP 643 peptide (Table 3.2). Apical exposure of Caco-2 
monolayers to 1 mM of PIP 643 peptide showed a significant reduction of 






compared to the PIP 640 peptide at the same concentration (Figure 3.2 A). 
The difference in TEER reduction was not statistically significant (Figure 3.2 
A). However, the effect of the PIP 643 peptide on the flux of 4 kDa dextran 
was only about 50 % of that induced by PIP 640 peptide (Figure 3.2 B). 
Despite the reduced flux rate observed with the PIP 643 peptide, these results 
indicated that PIP 640 peptide could function to some extent in the absence of 
the aspartic acid residue.  
 
 
After demonstrating that the aspartic acid residue of the PIP 640 peptide 
was not absolutely required for its actions on Caco-2 cell monolayers, the 
question of whether this residue in the peptide could be replaced with a 
positive charge was investigated. The goal here was to determine whether 
increasing the net positive charge of the PIP 640 peptide could improve its cell 
penetration properties and hence lower the concentration needed. The PIP 
644 peptide was therefore synthesized where the d residue of the PIP 640 
peptide was replaced with the D-isomer of arginine (r) (Table 3.2). Apical 
application of 1 mM PIP 644 peptide to Caco-2 monolayers showed a stronger 
effect on TEER reduction and a reduced overnight recovery compared to the 
PIP 640 peptide (Figure 3.2 A). PIP 644 peptide also produced an 
approximately 3-fold increase in 4 kDa flux rate compared to the PIP 640 
peptide, and a significant increase in the cumulative flux of 70 kDa dextran 
over 60 min, an action that was not observed with the rest of the PIP 640 






Figure 3.2:	Effect of selected amino acid replacement on PIP 640 peptide actions. A) 
Caco-2 cell monolayers TEER change induced by 1 mM of PIP 640 peptide were 
compared to that induced by a series of analogues. Apical media was replaced with 
fresh DMEM medium after 60 min to allow examination of TEER recovery (arrow). B) 
Cumulative apical to basal flux rate of fluorescent 4 and 70 kDa dextran across Caco-
2 cell monolayers after 60 min of apical exposure of the PIP 640 peptide and the 
analogues noted in (A). All peptides were tested in 3 independent experiments, with 
all analogues being tested in parallel with the PIP 640 peptide and control (untreated 
cells). Data are means ± SEM; n= 24 for control, n=18 for PIP 640 peptide; n= 8 for 
PIP 643 peptide; and n= 6 for PIP 641, PIP 642 and PIP 644 peptides. (*p value< 








     The data on in vitro examination of different PIP 640 peptide analogues 
presented above probed the role of selected amino acids on the PIP 640 
peptide sequence with respect to its presumed function in emulating the 
actions of the CPI-17 protein. The action of this peptide is based upon its 
potential to mimic the properties of pT38-CPI-17. If this were true, the decrease 
in TEER and increase in solute permeability induced by the PIP 640 peptide 
should correlate with increased MLC-pS19 levels that would lead to TJ barrier 
relaxation by inhibiting MLCP (160, 161). To address this hypothesis, a time 
course immunoblotting analysis was conducted to monitor the change in MLC-
pS19 levels induced by PIP 640 peptide analogues on Caco-2 monolayers. 
Apical addition of 1 mM PIP 640 peptide showed that the MLC-pS19 level 
relative to total MLC increased within 15 min and remained at an increased 
level at 45 min (Figure 3.3 A and B). This observation correlated well with the 
previously described effect of PIP 640 peptide on Caco-2 monolayers TEER 
(Figure 3.2 A).  
 
 
      Neither the PIP 641 peptide nor the PIP 642 peptide, when tested at 1 mM 
concentration showed any significant effect on MLC-pS19 relative to total MLC 
(Figure 3.3 A and B), consistent with their lack of effect on TEER (Figure 3.2 
A). Although, TEER changes observed for Caco-2 monolayers treated apically 
with 1 mM of either PIP 640 peptide or PIP 643 peptides were statistically 
similar (Figure 3.2 A), there was a slower onset of action in changing MLC-
pS19 relative to total MLC for the PIP 643 peptide compared to the PIP 640 
peptide (Figure 3.3 A and B). This delay in the change of the MLC-pS19 levels 
might explain the reduced dextran flux rate obtained with the PIP 643 peptide 
(Figure 3.2 B). Interestingly, both the PIP 644 and PIP 640 peptides showed a 
similar onset and intensity of the increase in MLC-pS19 compared to total MLC 
(Figure 3.3 A and B). Assuming that the actions of both peptides are 
comparable for mimicking CPI-17 function and there is a maximal response in 
this Caco-2 monolayers system for inducing MLC-pS19 relative to total MLC, 







properties that allows more peptide to enter the cells more rapidly and to be 
retained in the cell longer compared to the PIP 640 peptide. Thus, its effective 
activity may look more like 10 mM PIP 640 peptide. Alternately, the activity of 
the PIP 644 peptide could reflect effects on other cellular pathways that are 













Figure 3.3: Effect of the PIP 640 peptide and selected peptide analogues on MLC-
pS19 levels in Caco-2 monolayers 15 and 45 min after 1 mM apical addition. A) 
Immunoblot assessment of MLC-pS19 compared to total MLC levels. B) 
Quantitative analysis of MLC-pS19 and MLC levels for immunoblots shown in A). 
Data represent means ± SEM of independent experiments; PIP 640 peptide (n=4); 







3.2.4. Intracellular fate of PIP 640 peptide analogues 
 
PIP 640 peptide analogues induced reduction of Caco-2 monolayer TEER 
values and enhanced paracellular flux of dextran in a manner that correlated 
with increased MLC-pS19 levels. These actions are presumed to occur by 
inhibiting MLCP that, in turn, alters the function of the actomyosin 
microfilaments surrounding TJs. A critical aspect in the design of the PIP 640 
peptide was to integrate CPP-like elements that would allow it to pass across a 
cell membrane barrier to reach the cytoplasm and interact with MLCP involved 
in regulating TJ function. The data described above, showing enhanced levels 
of MLC-pS19 is consistent with this hypothesis. In order to explore this issue 
further, the PIP 640 peptide and the selected PIP peptide analogues 641, 642, 
643, and 644 were synthesized with a N-terminal biotin residue to allow 
microscopic investigation of these peptides’ ability to cross the cell membrane 
and distribute within the cell at perijunctional actomyosin microfilaments where 
the phosphorylation of MLC at this location is known to regulate TJ 
permeability (103). Localization of biotin-labelled peptides (analytical 
characterization in Appendices Section 7.1 F-J) was assessed by 
immunofluorescence microscopy using fluorophore-labelled streptavidin. 
Cellular distribution of these N-terminally biotinylated peptides was coordinated 
with immunofluorescent labelling of TJ protein occludin.  
 
 
Cell penetration and intracellular distribution of the biotinylated PIP 
peptides was examined 45 min after the apical addition to Caco-2 monolayers 
after repeated washing to remove surface-associated peptide, fixation and 
membrane permeabilization (Figure 3.4 and Figure 3.5).  The 45 min time 
point was a time for which  all functional PIP peptides (PIP 640, PIP 643 and 
PIP 644) showed significant alteration of the amount of MLC-pS19 relative to 
MLC (Figure 3.3 A and B). Biotinylated PIP 640 peptide was located 
intracellularly and often in close proximity to membrane demonstrated by 
occludin labelling (Figure 3. 4). This observation is consistent with the 






increase levels of MLC-pS19 that then act to modify TJ permeability properties 
(Figure 3.3 A and B). Similar to biotinylated PIP 640 peptide, both biotinylated 
PIP 641 and PIP 642 peptides were detected intracellularly, suggesting that 
the integrated positive residues were sufficient to impart CPP-like activity for 
these peptides (Figure 3.4). However, both peptides showed random 
distribution within the cytoplasm rather than localization to the plasma 
membrane, supporting the premise that the glutamic acid (to emulate a pT 
residue) and adjacent tyrosine residue are both important for PIP 640 peptide 
targeting to plasma membrane. It should be noted that in a few cells, the 
biotinylated PIP 642 peptide aligned along the plasma membrane without co-
localization with TJ structures as identified by occludin immunofluorescence.  
 
 
Biotinylated PIP 643 peptide showed some similarity in cellular distribution 
to the PIP 640 peptide, but there seemed to be qualitatively less of this peptide 
associated with the perijunctional areas compared to biotinylated PIP 640 
peptide (Figure 3.4). This observation correlated nicely with the slower onset of 
increased MLC-pS19 levels observed with PIP 643 peptide after 15 min of 
exposure (Figure 3.3 A and B). Moreover, the observed distribution of 
biotinylated PIP 643 peptide indicated that replacing the aspartic acid residue 
with an alanine might have reduced the ability of the biotinylated peptide to 
efficiently engage with MLCP localized to TJ structures. Importantly, removal of 
the negative charge associated with this amino acid did not dramatically alter 
its ability to access the cytoplasm but did reduce its ability to target and/or be 
retained at TJ structures relative to the biotinylated PIP 640 peptide.  
 
 
Enhancing the net positive charge of the PIP 640 peptide was achieved by 
substituting the aspartic acid with an arginine in the biotinylated PIP 644 
peptide. This peptide showed an intracellular distribution that was distinct from 
all of the other biotinylated peptide examined: there was an alignment to the 






defined TJ structures (Figure 3.4). Also, the biotinylated PIP 644 peptide was 
observed to localize at a distinct distance from the plasma membrane as 
occasionally observed for the biotinylated PIP 642 peptide. Uniquely, the 
biotinylated PIP 644 peptide was organized in what appeared to be aggregate 
clusters that were not observed for any of the other biotinylated peptides. This 
altered intracellular distribution may provide insights into the stronger action of 
the PIP 644 peptide on TEER reduction and enhanced 70 kDa dextran flux 
compared to the PIP 640 peptide (Figure 2 A and B). The results could 
suggest a more intense action on MLCP that results in disorganization of 
structures typically present at TJs, or that the PIP 644 peptide may engage 






















Figure 3.4: Confocal microscopy images of Caco-2 monolayers showing the intracellular 
distribution of N-terminally biotinylated PIP 640 peptide and analogues 45 min after apical 
exposure. The first column from the left represents the distribution of of the PIP 640 peptide 
analogues, as detected by Alexa 488-conjugated streptavidin (green). The second column 
shows cell distribution of the TJ-associated protein occludin stained with Alexa 546-
conjugated secondary antibody against a primary antibody (red). The third column 
represents merged images showing co-localization of the PIP 640 peptide and analogues 
with occludin. The last column to the right shows magnified images of the areas highlighted 
by the white boxes. The arrows show PIP peptide co-localization profile with TJs. Scale bar, 




























Figure 3.5: Z-stack scan images of Caco-2 monolayers obtained by confocal 
micorscopy, showing surface and subcellular localization of N-terminally biotinylated 
PIP 640 peptide analogues after 45 min of apical exposure. PIP 640 peptide or an 
analogue was detected using by Alexa 488-conjugated streptavidin (green). TJs were 
stained with Alexa 546-conjugated secondary antibody against occludin primary 
antibody (red). Nuclei were stained with DAPI (blue). Scale bar, 20 µm. Images are 
representative of 3 independent experments with n=3 for all peptides. 
A Z-stack analysis (XZ-plane) of Caco-2 cell monolayers treated with 
biotinylated PIP 640 peptide and its analogues confirmed their intracellular 




















A C-terminally biotinylated version of PIP 640 peptide was also prepared 
that contained a polyethylene glycol (PEG) spacer between the peptide and 
the biotin unit: PIP 640 peptide-PEG-biotin (analytical characterization in 
Appendices Section 7.1 K). Interestingly, PIP 640 peptide-PEG-biotin behaved 
differently from the N-terminally biotinylated version, and was associated 
predominantly with the cell membrane surface (appendices, Figure 7.2 A and 
B), unlike the N-terminally labelled 640 peptide (Figure 3.5). Moreover, PIP 
640-PEG-biotin produced no significant change in Caco-2 monolayers TEER 
(appendices, Figure 7.2 C). This behaviour supports the suggestion that PIP 
640 peptide-PEG-biotin was not able to access the cytoplasm. However, it was 
not clear whether the lack of cell permeability of PIP 640 peptide-PEG-biotin 
occurred as a result of changing the location of the biotin label from the N-
terminus to the C-terminus or because of changing the physiochemical 
properties of the peptide by adding a PEG spacer. 
 
 
3.2.5. PIP 640 peptide functions by blocking MLCP 
 
The studies described above validated the membrane permeability property 
of the PIP 640 peptide and showed its potential to selectively localize at TJ 
structures. Such outcomes are consistent with its proposed action on MLCP 
through a specific, physical association with regulatory subunits (PP1:MYPT1). 
We further examined this possible interaction using a pull-down protocol with 
the N-terminally biotinylated version of the PIP 640 peptide as bait under non-
denaturing conditions to capture protein binding partners from Caco-2 cell 
lysates using streptavidin beads. However, despite several attempts using 
slightly different conditions, neither PP1 nor MYPT1 could be shown to 












Native polyacrylamide gel electrophoresis (PAGE) was employed next to 
assess the effect of the PIP 640 peptide on the MLCP complex, MYPT1:PP1. 
This technique has been used extensively to study changes in protein 
association within protein complexes (162, 163). In this study, the PIP 640 peptide 
was incubated with Caco-2 cell lysates under non-denaturing conditions for 60 
min prior to analysing with native PAGE. The intensity of detected protein 
bands on the native PAGE reflects the amount of non-associated MYPT1 and 
PP1, since under native PAGE conditions individual proteins migrate faster 
than when they are assembled into a complexes. Under native PAGE 
conditions, MYPT1 was observed to migrate faster in the gel than PP1 even 
though MYPT1 has a larger molecular weight than PP1. MYPT1 was detected 
at ~45 kDa, while PP1 was detected at ~75 kDa relative to protein standard 
markers (Figure 3.6 B). These findings were consistent with the surface charge 
properties of these proteins that would have greatly affected their mobility in an 
electric field (91). Incubating Caco-2 cell lysates with PIP 640 peptide showed a 
concentration-dependent reduction of the non-associated PP1 and MYPT1 
(Figure 3.6 B). This result supports the contention that PIP 640 peptide 
function involves binding to both MYPT1 and PP1, similar to the emulated 
binding site of pT38-CPI-17 that binds to both regulatory subunits of MLCP and 


















Figure 3.6:	A) SDS-immunoblot of MLCP protein components, PP1 and MYPT1, from 
Caco-2 cell lysates analyzed in a pull-down using  biotinylated PIP 640 peptide. No 
association of these MLCP components with PIP 640 peptide was observed. Actin 
loading controls were used from supernatants to normalise the amount of lysate 
probed. Control lanes are streptavidin beads incubated in Caco-2 cell lysates in the 
absence of biotinylated PIP 640 peptide. Data are representative of 3 independent 
experiments, n=3. B) Immunoblot of MLCP components present in Caco-2 cell lysates 
treated with different concentrations of PIP 640 peptide for 60 min. Under these native 
polyacrylamide gel electrophorisis conditions PP1, which has MW of 34 kDa, was 
detected at ~ 75 kDa and MYPT1, which has a MW of 130 kDa, was detected at ~45 






















      As the anticipated function of the PIP 640 peptide appears to involve 
binding both regulatory subunits of MLCP, the same method involving native 
PAGE was applied to explore the impact of sequence modifications in the PIP 
640 peptide analoges on binding to MLCP subunits PP1 and MYPT1. Both PIP 
641 and 642 peptides failed to interact with either PP1 or MYPT1 under the 
conditions used (Figure 3.7 A and B), being consistant with their lack of effect 
on MLC-pS19 levels and random distribution in polarized Caco-2 cells. PIP 643 
peptide showed a slightly greater interaction with PP1, but a loss of interaction 
with MYPT1 compared to PIP 640 peptide (Figure 3.7 A and B). This shift in 
specificity for PP1 over MYPT1 was even greater in the case of PIP 644 
peptide (Figure 3.7 A and B). Data obtained with PIP 643 and PIP 644 
peptides demonstrated that the loss of negative charge presented by the 
aspartic acid residue was important for interaction with MYPT1 but supressed 
its interactions with PP1. Additionally, changing this residue in the peptide from 
a negative or neutral amino acid to a positively-charged amino acid further 
enhanced its activity towards PP1 without affecting the loss of MYPT1 
interactions. These observations were consistent with the changing in PIP 644 
peptide cellular localization from TJ structures to locations adjacent to the 
plasma membrane. Thus, while possibly improving the CPP-like 
characateristics for the PIP 643 and PIP 644 peptide, changes made to the 
PIP 640 peptide sequence to generate these analogues also resulted in loss of 
selectivity for MYPT1 and shifted it towards PP1, which would likely results in 
action not related to CPI-17-regulated processes. These studies demonstrated 
that only the PIP 640 peptide bound to both PP1 and MYPT1 (Figure 3.7 A 






Figure 3.7:	 Binding of PIP 640 peptide or PIP 640 peptide analogues with MLCP 
components. Peptides (0.8 mM) were incubated with Caco-2 cell lysates for 60 min 
prior to analysing using native PAGE. Quantitative determination of capture (depicted 
as removal from the lysate) for A) PP1 and B) MYPT1. Data are representative of 4 
independent experiments, n=4 for all data. Quantitative analysis of the immunoblots 
obtained in (A) induced by PIP 640 peptide analogues. Data are means ± SEM of 4 























3.2.6. PIP 640 peptide effects on epithelial cell viability 
 
All in-vitro data presented above suggested that the PIP 640 peptide could 
regulate TEER and paracellular permeability properties of Caco-2 monolayers 
by enhancing MLC-pS19 through a blockadge of MLCP function. These effects 
were either eliminated or altered by mutating specific amino acids in the PIP 
640 peptide sequence. Washout of these peptides after 60 min of apical 
exposure showed that all tested PIP peptides that demonstrate these 
properties did so through a reversible mechanism (Figure 3.2 A). Such studies 
however, failed to address the question of whether these peptides and/or the 
actions they induce interfered with cell viability. To test this possibility, Caco-2 
cell viability was investigated by measuring 3-(4,5-dimethylthiazol-2-yl)-          
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) dye 
conversion to formazan in viable cells. This so-called MTS assay reflects the 
integrity of the cells’ metabolic activity. The formazan that is formed has an 
intense purple colour, which is proportional to cell viability. All tested PIP 
peptides were incubated with Caco-2 cells for 12 h prior to adding the MTS 
reagent. Triton X-100 was used as a positive control to induce cell death, 
resulting in cell viability levels less than 10 % (Figure 3.8). PIP 640, PIP 641 
and PIP 642 peptides showed no significant interference with Caco-2 cell 
viability compared to untreated cells (Figure 3.8). This indicates that the 
permeability enhancement function of the PIP 640 peptide occurred without 
inducing cell toxicity. A lack of effect on cell viability also suggested that these 
PIP 640 peptide analogues, while retaining their ability to enter cells (Figure 
3.4 and Figure 3.5) but having lost their ability to affect Caco-2 cell monolayer 
TEER and permeability properties (Figure 3.2 A and B), are harmless to 
epithelial cells. In contrast, PIP 643 and PIP 644 peptides, which showed an 
ability to enhance permeability (Figure 3.2 A and B), reduced Caco-2 cell 
viability to approximately 50 % of control values (Figure 3.8). This might 
occurred in response to shifting the specificity of these two peptides toward 
PP1 (Figure 3.7 A and B), possibly resulting in the activation of signalling 






Figure 3.8: Colorimetric cell viability assessments of Caco-2 cells after 12 h exposure 
to 1 mM of each PIP 640 peptide or PIP 640 peptide analogues as evaluated by MTS 
dye conversion by cells. Here, Triton x-100 (0.01%) was used as a positive control. 
Data are means ± SEM of 3 independent experiments, n=9 for all data. (*p value< 
0.05, ****p value< 0.0001). 
Figure 3.8: Colorimetric cell viability assessments of Caco-2 cells after 12 h exposure 
to 1 mM of each PIP 640 peptide or PIP 640 peptide analogues as evaluated by MTS 
dye conversion by cells. Here, Triton x-100 (0.01%) was used as a positive control. 
Data are means ± SEM of 3 independent experiments, n=9 for all data. (*p value< 0.05, 




















Oral delivery of peptide therapeutics is typically limited by their sensitivity to 
intestinal digestive enzymes. Even when strategies are taken to limit this 
degradation, the physicochemical properties of these molecules restrict their 
ability to cross the intestinal epithelial barrier (164). Previous efforts to overcome 
these issues were mainly focused on the use of agents that alter the barrier 
function as a means to enhance intestinal permeability (5). Accordingly, several 
oral therapeutic peptide formulations have now reached clinical trial stages 
(117), however, most of these peptide therapeutic formulations failed to make it 
past the trial stages (117). In most of these permeability enhancers (PEs), this 
lack of clinical success is due to unacceptable safety concerns that can be 
linked to uncertainties regarding a lack of a selective and well-understood MoA 
(5). For example, sodium caprate, is a medium chain fatty acid that has been 
used as a PE in many therapeutic peptide formulations. Studies have 
proposed that sodium caprate enhances permeability through transcellular 
routes by general disruption of cell membranes (165). Other studies suggest that 
permeability enhancement associated with sodium caprate occurs through 
paracellular routes by activating MLCK (120), or by redistributing claudin-5 and 
tricellulin proteins (57).  The lack of clear MoA for sodium caprate could be the 
reason why its clinical use in a rectal ampicillin suppository was associated 
with non-specific damage to the rectal mucosa in humans (166).  
 
 
In the current approach, we have attempted to address the unmet need for 
the development of an efficient and safe strategy to enhance the permeability 
of therapeutic peptides across intestinal epithelium. This was done by utilizing 
rationally designed agents targeting an intracellular mechanism that is 
naturally involved in transiently regulating the TJ barrier function of the 
intestinal epithelium associated with enhancing nutrient uptake through 
paracellular routes (88, 167). This mechanism of enhancing paracellular 
permeability of nutrients is mediated by increasing MLC-pS19 levels that are 






established that manipulating MLC phosphorylation could regulate TJ barrier 
function. This was first observed with the application of a permeable inhibitor of 
MLCK (PIK) peptide that was reported to be effective in rectifying the defective 
TJ barrier function associated with chronic epithelial inflammations that are 
characterized by leaky epithelia generated by hyper-activation of MLCK (53, 103, 
129). Recently, we utilized an approach similar to that used to design the PIK 
peptide to design selective membrane permeant inhibitors for MLCP termed 




 Two PIP peptides, termed 250 and 640, were designed to target different 
protein-protein interfacial sites that regulate MLCP function. These two 
peptides were shown to enhance paracellular permeability of insulin in vivo 
(127). Their permeability enhancement effect was consistent with transient 
action induced by increasing MLC-pS19, as this effect was reversed within a 
few minutes (127). Because PIP 640 showed better onset and recovery of 
paracellular permeability enhancement compared to PIP 250 peptide (127), the 
work in this chapter was aimed at refining the understanding of the PIP 640 
peptide MoA in vitro and exploring the possibility of optimizing its permeability 
enhancement function.  
 
 
PIP 640 peptide was designed to mimic a phosphorylated binding site of 
CPI-17, R36V(pT)VKYDRR44, which is responsible for selective inhibition of 
MLCP (90, 148, 160). A D-retro inverso strategy was used to produce an 
enzymatically stable version of the PIP 640 peptide; the peptide was 
synthesised using D-amino acids in reverse order of sequence (158). Thus, 
orientation of the amino acid side chains of the D-sequences would be similar 
to the parent L-sequences, though the amide bonds are inverted. This strategy 
was validated previously for enhancing PIK peptide stability without affecting 






standard 9-fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis 
(SPPS) techniques (128). This technique involves repetitive coupling of amino 
acids to a growing polypeptide chain bound to a solid support. This solid 
support is typically composed of small polystyrene beads to which the peptide 
is attached during the repetitive washing and filtration steps of these 
processes. The first amino acid is generally bound to the resin through its α-
carboxylic acid function, via an ester or amide linkage, depending on the 
choice of the solid support and desired C-terminal functional group (128). For 
synthesis of PIP 640 peptide and its analogues, a Rink amide polystyrene 
resin was chosen in order to generate a C-terminal peptide amines upon 
removal of the final peptide from the solid support. In the Fmoc SPPS 
approach, the α-amino functions of the amino acids that are added 
successively to the N-terminus of the peptide are blocked by the base-sensitive 
Fmoc group, which is easily removed by a secondary amine (piperidine) (128). 
For synthesis of the PIP 640 peptide and analogues, any side chain amino 
acid functions were blocked by appropriate acid-labile protecting groups that 
are stable to the repetitive removal of Fmoc during each coupling cycle. Acid-
labile side chain protecting groups were used for lysine (Boc), arginine (Pbf), 
tyrosine (tBu), glutamic acid and aspartic acid (OtBu), which could all be 
removed under the same conditions as those required for cleaving the final 
peptide from the Rink Amide support with a strong acid (128). Introduction of a 
glutamic acid residue into the PIP 640 peptide was intended to serve as a 
stable phosphomimetic analogue of pT because the length of a glutamic acid 
side chain is similar to pT, allowing for a delocalized negative charge from the 
ionized carboxylic acid at about the same position as the phosphate group on 
the side chain of pT. Previous structural studies of pT38-CPI-17 have 
suggested that the flanking residues of pT38 within the R36V(pT)VKYDRR44 
sequence, except R36 and K40, of CPI-17 are involved in binding to MLCP (155-
157, 169). However, Y41 seemed to be critical for the inhibitory function of CPI-17, 
as single alanine substitution to Y41 was able to abolish pT38-CPI-17 inhibitory 
function. Therefore, a single arginine was introduced onto the N-terminus of 






because residues located N-terminally to R36 have been reported not to be 
involved in CPI-17 binding to MLCP (155).        
 
Previous in vivo studies of PIP 640 peptide functions were focused on 
proving the concept of the ability of the PIP 640 peptide to enhance 
paracellular permeability of therapeutic peptides by increasing MLC-pS19 levels 
(127). An essential consideration for successful in vivo application of the PIP 
640 peptide was the onset of peptide cell entry to rapidly increase MLC-pS19 
and enhance the permeability of a poorly absorbed therapeutic agent in the 
intestinal lumen. In order to potentially increase the rate of cell uptake of the 
PIP 640 peptide, a longer version with three additional basic amino acids on 
the C-terminus was used in vivo, sequence: rrdykvevrrkkr-NH2 (127). This longer 
version of the PIP 640 peptide induced rapid paracellular permeability of 
insulin across intestinal epithelia by enhancing MLC-pS19 that started a few 
minutes after direct intraluminal injection. Since work in this chapter was to 
investigate PIP 640 peptide MoA, studies were performed using the parent 
sequence of PIP 640 peptide, rrdykvevrr-NH2, which has only one additional 
arginine at the N-terminus that is not present in the original emulated sequence 
of CPI-17, R36V(pT)VKYDRR44. This can be used for a more precise 
assessment of PIP 640 peptide target binding and to potentially reduce the 




An initial step in exploring the MoA of PIP 640 peptide was to define the 
ideal concentration of the peptide that can induce a regulated TJ permeability 
to be used in the in vitro investigations. This eliminated the possibility that any 
activity observed with the PIP 640 peptide was due to exposure to high 
concentrations of the peptide. This was monitored by measuring TEER change 
and apical to basolateral transport of molecules across epithelial cell 
monolayers induced by different concentrations of the PIP 640 peptide. Varied 






(hydrodynamic radius ~ 60 Å), were used in the permeability assays to 
estimate the extent of TJ opening. In this regard, insulin has a hydrodynamic 
radius of ~11 Å, while leaky TJs associated with chronic intestinal inflammatory 
diseases have been shown to be permeable to macromolecules up to ~ 60 Å 
(53, 54). The data in (Figure 3.1 A and B) indicated that 1 mM of PIP 640 peptide 
seemed to be a realistic concentration for in vitro MoA investigations because 
the permeability of 70 kDa dextran that was observed with higher 
concentrations of PIP 640 peptide was eliminated at 1 mM. Moreover, a 
complete TEER recovery of Caco-2 monolayers was only obtained with an 
application of 1 mM of the PIP 640 peptide.  
 
 
Manipulating specific phosphatase complexes using small peptides has 
been a widely-used strategy to study the function of a variety of phosphatases, 
some of which can deliver therapeutic benefits (153, 170). It has been reported 
that pT38-CPI-17 can specifically inhibit MLCP and induce alteration of TJ 
function by enhancing MLC-pS19 (160, 161). Although the PIP 640 peptide at a low 
concentration induced a reversible reduction of TJ barrier in Caco-2 
monolayer, it was not clear whether the actions of this peptide were indeed 
achieved by mimicking pT38-CPI-17. The PIP 640 peptide was synthesised 
using a D-retro inverso strategy, which have shown limited success on some 
occasions at mimicking the functional properties of parent L-peptides (171). 
Therefore, a structure activity relationship (SAR) study was performed on the 
PIP 640 peptide sequence by substituting specific amino acids. The selection 
of the residues for these modifications was based on previous structural 
studies that identified critical residues within the emulated sequence of CPI-17, 
R36V(pT)VKYDRR44, which are essential for inhibiting MLCP. Accordingly, a 
limited set of PIP 640 peptide analogues were designed and examined in vitro 









PIP 641 peptide revealed the importance of a negative charge (provided by 
a glutamic acid) that could function as phosphomimetic analogue of pT. 
Similarly, the tyrosine residue in the PIP 640 peptide seems critical for 
permeability enhancement function of PIP 640 peptide, as demonstrated with 
the PIP 642 peptide. These findings are consistent with structural 
characterization of pT38-CPI-17 that showed the importance of these two 
positions for CPI-17 function (148, 155). Moreover, these outcomes indicated that 
the D-retro inverso version of the PIP 640 peptide was indeed able to emulate 
CPI-17 function. A key consideration in optimizing the PIP 640 peptide was to 
improve the cell penetration function of the peptide by enhancing its net 
positive charge; this was accomplished by maintaining basic acids and 
reducing non-essential acidic residues. In this context, in vitro permeability 
enhancement data for PIP 641, sequence: rrdykvavrr-NH2, and PIP 643, 
sequence: rraykvevrr-NH2, demonstrated that the role of the negatively charged 
glutamic acid residue in PIP 640 peptide is more critical than that of aspartic 
acid (Figure 3.2 A and B) (Figure 3.3 A and B). Exchange of the negative 
charge of the aspartic acid for a positive charge to possibly improve the cell 
permeability properties as in PIP 644 peptide increased the extent of MLC-
pS19 induction compared to the PIP 640 peptide, but it also dramatically altered 
the intracellular localization and altered its selectivity between PP1 and 
MYPT1. This may indicate the possible involvement of other cellular pathways 
being accessed by the PIP 644 peptide versus the PIP 640 peptide and refines 
our understanding of how to selectively inhibit MLCP to increase the intestinal 
paracellular permeability of therapeutic peptide drugs with these compounds.  
 
 
Since altering specific amino acids in the PIP 640 peptide sequence was 
associated with changes to permeability enhancement function, as 
represented by the tested PIP 640 peptide analogues, biotinylated versions of 
PIP 640 peptide analogues were used to explore the role of these specific 
mutations on PIP 640 peptide cell penetration properties and to see how the 






distribution. Initially, biotin labelling was performed using Fmoc-PEG-biotin 
resin that produces a C-terminally biotinylated peptide with PEG spacer 
between the peptide and biotin unit. The use of this labelling technique was 
expected to be advantageous for a variety of reasons: having a hydrophilic 
spacer, the PEG chain, should enhance the peptide’s water solubility, improve 
its efficiency in binding assays by separating the biotin functionality from 
peptide residues that are involved in target binding and, more practically, 
simplify the synthesis because the biotinylated peptide would be obtained 
immediately after the cleavage from the solid phase resin (130, 131). Although this 
method of biotin labelling has been validated by previously studies involved the 
intracellular localization of peptides (130), C-terminally biotinylated PIP 640 
peptide, PIP 640-PEG-biotin peptide, seemed to be associated with the cell 
membrane surface instead of entering Caco-2 cells, resulting in an elimination 
of the permeability enhancement function of the PIP 640 peptide itself 
(Appendices, Figure 3.2 A-C). It has been reported previously that changing 
the coupling site of the same cargo may have a significant effect on the cell 
penetration properties of CPP peptides (172). Interestingly, when the PIP 640 
peptide and its analogues were biotinylated at the N-terminus, using the p-
nitrophenyl ester derivative of biotin, all the peptides obtained were able to 
cross cell membrane (Figures 3.4 and 3.5). The precise reason for the different 
behaviour of C- and N- terminally labelled PIP 640 peptide is not clear, 
however, the nature of the spacer between the biotin labels and the peptides in 
the two cases are quite different, and this may also be significant as well as 
the point of attachment.  
 
 
Immunofluorescent images showed that the PIP 640 peptide was localized 
at the perijunctional areas, an observation consistent with its action of 
enhancing MLC-pS19. Similar to the outcomes obtained in the previous SAR 
study, removal of either Glu or Tyr in PIP 641 and PIP 642 peptides, 
respectively, changed their cellular distribution. In an attempt to improve PIP 






synthesized with less negatively charged residues, and this showed a 
substantial loss of the perijunctional distribution obtained with the PIP 640 
peptide. Increasing the net positive charge of the PIP 640 peptide by switching 
Asp to Arg in the PIP 644 peptide shifted the peptide distribution back toward 
the perijunctional areas in a cluster format that was less associated to TJ 
compared to the PIP 640 peptide. Overall, data from immunofluorescent 
images indicate that the probed residues within PIP 640 peptide including Glu, 
Tyr and Asp are essential for evoking PIP 640 peptide permeability 
enhancement function.  
 
 
MYPT1 binding to PP1 generates the MLCP holoenzyme that specifically 
functions to dephosphorylate MLC-pS19 (91, 153). Phosphorylation of CPI-17 at 
pT38 enables it to selectively form a complex with MLCP to block its 
phosphatase function (90). Studies characterizing the nature of pT38-CPI-17 
binding to MLCP have suggested that a minimal inhibitory domain within CP-
17 is essential for recognition of MLCP, which includes R36V(pT)VKYDRR44 
(155, 156, 169). Since PIP 640 was designed to mimic this sequence, we 
addressed the ability of PIP 640 peptide to bind MLCP. This was performed 
using native PAGE immunoblotting because it has been shown that native 
PAGE can be used to anticipate changes in protein complex bindings (162, 163). 
Unlike SDS-PAGE, protein migration in native PAGE depends on both 
hydrodynamic size and charge of the protein involved. This means that protein 
complexes would migrate slowly or not enter the native gel. Under the 
experimental conditions employed, the PIP 640 peptide showed a 
concentration-dependant association with both the MLCP components, 
MYPT1 and PP1 (Figure 3.6 B), which is consistent with the binding pattern of 
pT38-CPI-17 with MLCP. The intensity of the migrating bands of both MYPT1 
and PP1 did not change with either the PIP 641 or PIP 642 peptides indicating 
that these peptides did not bind to MLCP, an observation consistent with their 
inability to enhance MLC-pS19 (Figure 3.3 A and B). A previous study 






binds to the MYPT1 subunit of the MLCP complex via Arg44 (156). However, 
removal of the negatively charged Asp residue in PIP 643 peptide shifted its 
binding towards PP1, and the effect was further increased by introducing Arg 
in this position in the PIP 644 peptide (Figure 3.7 A and B). These findings 
show that Asp might be essential for PIP 640 peptide binding to the MYPT1 
subunit of MLCP complex; this probably applies to CPI-17. Although only the 
PIP 640 peptide seems to associate with both regulatory subunits of MLCP in 
native PAGE, it was not clear whether the data obtained from native gel 
experiments represent an absolute effect of the PIP 640 peptide on MLCP, as 
other cellular proteins present in the cell lysates still might contribute to PIP 




Native PAGE immunoblotting data indicated that the different permeability 
enhancement profiles between the PIP 640 peptide and several analogues of 
this peptide (Figure 3.2 A and B) could be correlated to differences in binding 
nature to MLCP components (Figure 3.7 A and B). Indeed, loss of the ability to 
enhance TJ permeability by PIP 641 and PIP 642 peptides correlated with their 
inability to induce MLC-pS19 (Figure 3.3 A and B). PIP 643 and PIP 644 
peptides, however, both retained the ability to decrease TEER and enhance 
paracellular permeability and this was correlated with a retained ability to 
induce MLC-pS19 (Figure 3.3 A and B). There was no strong correlation 
between the ability of these peptides to alter TJ permeability and their binding 
pattern with MLCP compared to the PIP 640 peptide (Figure 3.2 A and B) 
(Figure 3.7 A and B), as the PIP 643 and PIP 644 peptides showed similar or 
stronger TEER reduction, respectively, compared to the PIP 640 peptide but 
showed more association to PP1 instead of MYPT1.  This shift in PIP 643 and 
PIP 644 binding towards PP1 suggested that they acquired greater non-
specific PP1 inhibitory function that might have involved MLC-pS19 increases in 







In essence, PIP 643 and PIP 644 peptides may have acquired greater non-
specific protein phosphatase inhibitory function. Such actions may be similar to 
okadaic acid (OA), a toxin produced by dinoflagellates that can inhibit multiple 
protein phosphatases including protein phosphatase 2 A (PP2A) and PP1, 
which is known to cause cell toxicity at high concentrations (173). It has been 
reported that OA is responsible for causing diarrhetic shellfish poisoning 
characterized by a leaky TJ barrier, which has been suggested to be induced 
by sustaining phosphorylation of various proteins, including MLC-pS19 (173, 174). 
Cell viability data of the PIP peptides tested in these studies support the idea 
that non-specific functions of both PIP 643 and PIP 644 peptides could be the 
cause of their associated cytotoxicity (Figure 3.8). This might suggest that PIP 
643 and PIP 644 peptides caused general protein phosphatase inhibition that 
is responsible for increasing MLC-pS19 associated with reducing cell viability 
and changing permeability enhancement profiles; in particularly, the enhanced 
permeability of 70 kDa dextran induced by the PIP 644 peptide. 
 
 
In conclusion, the present studies have provided a greater understanding of 
the MoA for a novel agent, PIP 640 peptide, which was designed to increase 
the intestinal absorption of protein therapeutics. PIP 640 peptide was designed 
to be stable in the intestinal lumen and access the cytoplasm of enterocytes to 
alter the phosphorylation state of MLC in order to transiently alter epithelial TJ 
barrier function. These studies characterized the permeability properties, 
recovery of TEER properties, intracellular localization, protein target selectivity 
and potential cytotoxicity for the PIP 640 peptide, but importantly examined 
these same properties for a selected series of PIP 640 peptide analogues. In 
doing so, a greater understanding has been acquired for how the PIP 640 
peptide functions as a relatively safe and effective agent by enhancing MLC-
pS19 to manipulate an endogenous mechanism regulating TJ permeability. 
Although the next logical step in the development of the PIP 640 peptide 
technology will likely be a large animal safety and efficacy study to improve the 






characterized a series of peptides that could be used as tools by researchers 















Chapter 4 : Characterization of 
tight junction opening induced 



























Functional integrity of the body’s epithelia is essential for their ability to 
allow the body to maintain its homeostasis and protect it from the casual entry 
of unwanted and potentially dangerous materials (14). This barrier function 
requires polarized epithelia to generate, maintain and regulate a set of 
structures organized between adjacent epithelial cells that are collectively 
known as the apical junctional complex (AJC) (14, 15). The tight junction (TJ) is 
the most apical structural element of the AJC and it consists of protein 
complexes that establish a size- and charge-selective barrier that can 
selectively restrict the transport of ions and small molecules ~< 4 Å through the 
paracellular space located between adjacent epithelial cells (14, 175). TJ 
structures contain many transcellular proteins that include the claudin protein 
family (35), junctional adhesion molecule (JAM) proteins (64) and TJ-associated 
Marvel proteins (TAMPs) members: occludin, tricellulin and MarvelD3 (36). 
These transmembrane TJ proteins are connected to a network of peripheral 
scaffolding proteins, which function as adaptors connecting transmembrane TJ 
proteins to adjacent elements of the cell’s cytoskeleton; zonula occluden (ZO) 
proteins represent a prominent family of these adaptor proteins (74). 
 
 
 Claudin proteins exist in at least 27 different isoforms that are naturally 
expressed in various patterns and combinations in different organs’ epithelia, 
which determine the distinct properties of TJ barrier demonstrated by each 
epithelium of the body (176). Distinct isoforms are primarily known to either seal 
(sealing claudins) or to function in the charge selective ion properties (pore-
forming claudin) of the different TJs (38). While most of the functions of claudin 
proteins are associated with altered permeability of ions and low molecular 
weight solutes. Some studies have also suggested that claudin proteins may 
be involved in regulating the paracellular permeability of macromolecules. It 
has been shown that knockout or disruption of some claudin proteins result in 
the enhanced passage of large solutes (26, 39, 40). In contrast, TAMPs and ZO 






permeability through TJs (36, 53, 84, 118), while JAM proteins play a role in TJ 
stability and immune cell migration (65, 66).      
 
 
TJ proteins bind to each other through complicated interactions that have 
been studied using techniques such as fluorescence recovery after 
photobleaching (FRAP) and fluorescence loss in photobleaching (FLIP). FRAP 
and FLIP studies have revealed that TJ proteins are highly dynamic in the 
resting state, meaning that the TJ protein complex is subject to continuous 
remodelling. Moreover, different TJ proteins have distinct dynamic behaviours 
to provide a fence function that is essential for the separation of apical and 
basolateral domains of the plasma membrane. For example, claudin-1 was 
found to be less dynamic than occludin and zonula occluden-1 (ZO-1) (46, 95, 
177). The discovery that TJ proteins exist at AJC structures in a dynamic 
manner has led to the hypothesis that modulation of TJ protein components 
could be a mechanism by which TJ barrier function could be rapidly regulated 
in response to different stimuli.  
 
 
In intestinal epithelia, for example, it was found that TJ pore permeability is 
regulated by induction of the Na+-glucose co-transporter, which induces TJ 
permeability by activating myosin light chain kinase (MLCK) (88). These events 
were associated with increased ZO-1 mobility without altered expression at TJ 
structures through a mechanism that could be reversed by inhibiting MLCK (95). 
Casein kinase-2 (CK2)-mediated phosphorylation of occludin at the serine 408 
(occludin-pS408) increased TJ pore permeability of cations by changing TJ 
protein organization and dynamic behaviour of TJ elements (46). CK2-mediated 
increases in occludin-pS408 enhanced occludin mobility at TJs and occludin 
dimerization, resulting in dissociation from ZO-1, claudin-1, and claudin-2 
proteins (46). These events coincide with the formation of claudin-2 pore 
channels between adjacent epithelial cells, which enhances TJ cation 






Consistent with the role of altering TJ protein composition induced by 
different stimuli in determining barrier properties, proinflammatory cytokines 
such as tumour necrosis factor-α (TNF-α) and interferon-γ (INF-γ) are known 
to induce the loss of TJ barrier function and increase macromolecular solute 
permeability associated with intestinal inflammatory diseases, such as Crohn’s 
disease (53, 103, 137). Proinflammatory cytokine-induced TJ barrier loss is 
associated with occludin endocytosis induced by prolonged activation of MLCK 
(53, 103, 137). Sodium caprate has been shown to function as a TJ permeability-
enhancing (PE) agent, increasing paracellular permeability across the human 
intestinal cell line HT-29/B6 in vitro for dextran molecules up to 10 kDa (118). 
The action(s) of sodium caprate on epithelial TJ structure, similar to 
proinflammatory cytokines, also affected TAMP and claudin protein family 
members; in this case the redistribution of tricellulin and claudin-5 were 
observed without a striking alteration of their cellular expression (118).  
	
	
We have hypothesized that pharmacological activation of MLCK could 
increase TJ solute permeability to produce a transient state where paracellular 
permeability is sufficiently increased to provide an enhancement of therapeutic 
peptide absorption from the intestinal lumen. To achieve this, a membrane-
permeant peptide capable of regulating myosin light chain phosphatase 
(MLCP) activity to induce myosin light chain phosphorylation in the serine 19 
(MLC-pS19) was identified through a rational design process. The results 
presented in Chapter 1 showed that a membrane-permeant inhibitor of MLCP 
(PIP), termed the PIP 640 peptide, was able to enter Caco-2 cell monolayers, 
co-localize with TJ structures, increase cellular MLC-pS19 levels, and enhance 
the permeability of 4 kDa dextran through the TJ. The observed co-localization 
of PIP 640 peptide with the TJ structures, induction of MLC phosphorylation, 
and changes in paracellular solute permeability properties were all consistent 








The studies performed in this chapter were aimed at providing a preliminary 
characterization of biochemical changes associated with TJ proteins induced 
by the actions of the PIP 640 peptide. With this information, we hope to 
increase our understanding of how TJ components involved in controlling TJ 
barrier function are affected by the PIP 640 peptide. Also, this work 
investigates the potential impact of alteration of TJ proteins induced by PIP 






4.2. Results  
 
4.2.1. Effect of PIP 640 peptide on TJ proteins 
 
TJ protein structures function as gates regulating the paracellular 
permeability of an epithelium (38). Studies have shown that the paracellular 
permeability of solutes through intestinal TJs in both physiological and 
pathological conditions are associated with reorganization of TJ protein 
complexes (53, 94, 95). The data discussed in Chapter 1 showed that PIP 640 
peptide-enhanced TJ permeability of 4 kDa dextran (hydrodynamic radius ~ 14 
Å), which is unable to cross epithelial cell TJs under baseline physiological 
conditions (88), moved across Caco-2 cell monolayers in vitro in a manner 
consistent with increased levels of MLC-pS19. However, it is not yet known 
whether the permeability enhancement induced by PIP 640 peptide involves 
alteration of TJ proteins. To address this, immunoblotting analysis of total cell 
lysates as well as immunofluorescent imaging of Caco-2 cell monolayers were 
performed to assess possible changes in the protein levels and cellular 







Initially, this work focused on studying the effect of PIP 640 peptide on the 
TAMP protein family and the scaffolding protein ZO-1, as these proteins are 
the most commonly studied TJ proteins for regulating large solute permeability 
through intestinal epithelial TJs (36, 53, 84, 118). Therefore, the effect of apical 
exposure to 1 mM of PIP 640 peptide for 60 min on TAMPs and ZO-1 was 
investigated. The results of immunoblotting showed no significant changes in 
the cellular levels of occludin, tricellulin, MarvelD3 and ZO-1 in association with 
increase in MLC-pS19 induced by PIP 640 peptide (Figure 4.1 A and B). 
Further, apical PIP 640 peptide treatment of these confluent monolayers of 
Caco-2 cell line in vitro failed to demonstrate any striking changes to the 
cellular distribution of TAMPs and ZO-1 proteins as assessed by 






PIP 640 peptide enhances the permeability of epithelial cells impermeable 


























Figure 4.1: Evaluation of the changes in the cellular level and distribution of TAMPs 
(occludin, tricellulin, and MarvelD3) and the scaffolding protein ZO-1 induced by 1 
mM of PIP 640 peptide. A) Immunoblotting analysis showing the effect of MLC-pS19 
induction by an apical exposure to 1 mM of PIP 640 peptide for 60 min on the 
cellular level of TAMPs and ZO-1 in Caco-2 cell monolayers. B) Quantitative 
analysis of the immunoblots obtained in A). Data are means ± SEM of 3 
independent experiments, n=6 for control and treated monolayers. C) 
Immunofluorescent images of Caco-2 monolayers showing normal TJ localization of 
TAMPs and ZO-1 between monolayers treated with PIP 640 peptide and untreated 
monolayers. Images are representative of 3 independent experiments, n=3. Scale 
bar, 10 µm. n.s: not significant. 













Although claudins have been recognised as paracellular ion channels (38), it is 
been observed in many cases that macromolecule permeability across TJ was 
associated with changes in the expression or distribution of distinct claudin 
family members (26, 39, 40). Therefore, it is possible that the permeability 
enhancment function induced by PIP 640 peptide might be corelated with 
changes in a specific set of claudins either through changes in cellular levels 
and/or distribution at the TJ. To test this hypothesis, we examined polarized 
Caco-2 monolayers in vitro following a 60 min apical treatment of 1 mM PIP 
640 peptide for biochemical changes and cellular distribution of claudin 
proteins present in human intestinal epithelial cells (176). It is important to note 
that some of the tested claudins have been reported to regulate the 
permeability of TJ solute permeability (25, 26, 39, 118). Examination of the total 
cellular protein levels of claudin-1, -2, -3, -4, -5, -7, -8 and -15 via 
immunoblotting analysis showed that only claudin-2 cellular levels were altered 
in response to the PIP 640 peptide and consistent with the increased MLC-
pS19 levels (Figure 4.2 A and B). The observed increase in total claudin-2 cell 
levels observed by western blot analysis were consistent with increased levels 
of this protein at the plasma membrane, presumably where it had integrated 
into the functional TJ structure (Figure 4.3).  
 
 
       The immunofluorescence microscopy studies of TJ protein elements in 
reponse to PIP 640 peptide were performed using a similar fixation process 
reported in a previous study (87). Application of the -20 °C methanol cell fixation 
method, which has been reported to effectively preserve intracellular 
localization of TJ proteins (87), provided a more refined prespective and 
revealed that, in untreated Caco-2 monolayers, intracellular claudin-2 was 
concentrated in specific regions of the cell cytoplasm, while claudin-2 was 
widely distributed in the cytoplasm of monolayers treated with PIP 640 peptide 
(Figure 4.3), an effect was not observed with TAMPs or ZO-1 (Figure 4.1 C). 
No significant differences were observed in the intracellular or TJ distributions 






Figure 4.2: Effect of apical treatment of Caco-2 monolayers with 1 mM of PIP 640 
peptide for 60 min on different claudin proteins. A) Immunoblotting analysis showing 
the effect of MLC-pS19 induction by PIP 640 peptide on the cellular levels of claudin-
1, -2, -3, -4, -5, -7, -8 and -15. B) Quantitative analysis of the immunoblots obtained 
in A). Data are means ± SEM of 3 independent experiments, n=6 for the control and 
treated monolayers, (*p value< 0.05).  
monolayers with the same concentration of the PIP 640 peptide within the 
indicated time (Figure 4.3). This observation suggests that claudin-2 was 
redistributed from its intracellular locations to the plasma membrane and 














Figure 4.3: Immunofluorescent images of Caco-2 monolayers showing the cellular 
localization of claudin-1, -2, -4 and -7 before (top row) and after exposure to the PIP 
640 peptide (second row). PIP 640 peptide increased TJ localization of claudin-2. 
Areas highlighted as white boxes in the top and second rows are magnified areas 
shown in the third row. Intracellular locations of claudin-2 in untreated Caco-2 cell 
monolayers that changed after exposure to PIP 640 peptide is highlighted by red 
arrows (third row). Images are representative of 3 independent experiments, n=3. 


















4.2.2. PIP 640 peptide-induced enhancement of claudin-2 at the TJ 
correlates with the induction of MLC-pS19. 
 
Reduction of TJ barrier function that correlates with enhanced paracellular 
permeability is usually associated with the remodelling of TJ protein complexes 
(45). The mechanism of this remodelling can range from redistribution to 
changes in expression of TJ proteins (102, 118). Hence, changes in the cellular 
levels and distribution of different TJ proteins were examined after exposure to 
1 mM of PIP 640 peptide. The data presented above showed that only claudin-
2 of the TJ proteins examined was affected over a time-course that associated 
with changes in paracellular permeability and TEER of Caco-2 monolayers. 
Claudin-2 levels as determined by western blotting were significantly increased 
and the localization of claudin-2 at the TJ as determined by 
immunofluorescence microscopy was increased in response to exposure to 
PIP 640 peptide for 60 min (Figure 4.1 and Figure 4.2). Studies have shown 
that modulation of claudin-2 alone or in combination with other TJ proteins 
could result in changes to TJ permeability properties (39, 102, 178). Importantly, we 
observed that the PIP 640 peptide-enhanced TJ permeability also correlated 
with increased MLC-pS19 levels. Based on the current outcomes, it is unclear 
how increased claudin-2 levels are related to the increased MLC-pS19 in 
response to the PIP 640 peptide treatment.  
 
 
To examine a potential relationship between increased claudin-2 levels and 
the elevation of MLC-pS19 in response to the PIP 640 peptide, a time-course 
study that monitored these two parameters over time was performed. At 
different time points, the TEER of Caco-2 cell monolayers was measured after 
exposure to 1 mM of PIP 640 peptide to monitor changes in the TJ barrier 
function. Subsequently, immunoblotting and immunofluorescent analyses were 
used to evaluate changes in the total cellular level and distribution of claudin-2 
within cells. TEER reduction in response to apical exposure of the PIP 640 






2 that was detectable by 10 min after exposure to the PIP 640 peptide, but it 
was only observed significantly after 20 min of treatment when compared to 
control cell monolayers (Figure 4.4 A, B and C). This time course for the 
increase in claudin-2 was correlated with an increase in MLC-pS19 levels over 
time, but MLC-pS19 seems to increase faster than claudin-2, as the increase of 
MLC-pS19 levels induced by the PIP 640 peptide was observed significantly 
after 10 min (Figure 4.4 B and C). Thus, time course studies are consistent 
with the hypothesis that increased levels of claudin-2 occur secondarily to 
increased levels in cellular MLC-pS19.  
 
 
A time-course immunofluorescent assessment of cellular claudin-2 
distribution in Caco-2 monolayers after exposure to PIP 640 peptide was also 
performed to determine whether the increase in claudin-2 levels observed by 
immunoblotting data correlated with increased claudin-2 at the TJ. The data 
showed that the claudin-2 localization at the TJ increased over time (Figure 
4.5). In addition, these changes in the intracellular distribution of claudin-2 
were observed a few minutes after PIP 640 peptide exposure (Figure 4.5). 
This rapid onset of changes in the intracellular organization of claudin-2 and an 
increase in its level at the TJ suggested that redistribution of intracellular 
claudin-2 to the TJs occurred in response to the PIP 640 peptide treatment 
rather than the synthesis of new proteins because stimuli-inducing protein 
synthesis, particularly that of claudin-2, should take longer than 10 minutes 
(102). Removal of PIP 640 peptide from Caco-2 monolayers after 60 min of 
apical treatment followed by overnight incubation with fresh medium led to 











Figure 4.4: Time-course assessment of changes in claudin-2 levels relative to 
changes of MLC-pS19 levels associated with changes in permeability properties 
induced by PIP 640 peptide. A) TEER changes in Caco-2 cell monolayers induced 
by 1 mM of PIP 640 for 60 min. Removal of apical PIP 640 peptide to initiate 
recovery of actions is highlighted with an arrow. B) Representative immunoblots 
showing correlation of MLC-pS19 levels and claudin-2 levels over time following 
apical application of 1 mM of PIP 640 peptide. C) Quantitative analysis of 
immunoblots obtained for MLC-pS19 and claudin-2 induced by PIP 640 peptide in B). 
Data points represent means ± SEM of 3 independent experiments with n=6 for 
TEER data, n= 3 for both MLC-pS19 and claudin-2 immunoblotting data at all time 
points, immunoblot data obtained for MLC-pS19 for 40 min exposure n=1 (*p value< 
0.05, **p value< 0.01 and ***p value<0.001). 















Figure 4.5: Time-course assessments of cellular claudin-2 distribution as assessed 
by immunofluorescence microscopy following exposure to 1 mM of PIP 640 peptide. 
Images of Caco-2 monolayers suggest redistribution of claudin-2 to TJ structures in 
response to the PIP 640 peptide exposure for the indicated period of time. Images are 







							To verify that the increase in claudin-2 at the plasma membrane (possible 
at TJ structures) is a function of modulating MLCP activity by the PIP 640 
peptide, the action of a PIP peptide mutant was examined. PIP 644 peptide 
(sequence: rrrdykvevrr-NH2), as shown in Chapter 3, non-specifically induces 
an increase in MLC-pS19 via an association with PP1 instead of the MLCP 
complex (MYPT1:PP1) to produce a more pronounced reduction of TJ barrier 
function compared to the PIP 640 peptide. Caco-2 monolayers were treated 
with 1 mM of both the PIP 640 and the PIP 644 peptides for 10 and 60 
minutes. Consistent with the data discussed in Chapter 3, both peptides 
induced MLC-pS19 over time, but, only the PIP 640 peptide increased claudin-2 
levels (Figure 4.6 A and B). Additionally, the distribution of claudin-2 in Caco-2 
cell monolayers treated with the PIP 644 peptide was similar to that in the 
untreated cell monolayers, while the level of claudin-2 increased at TJs after 
exposure to the PIP 640 peptide (Figure 4. 5 C). Together, these data are 
consistent with the hypothesis that changes in claudin-2 associated with the 
inhibitory action of the PIP 640 peptide possibly involve the redistribution of 




















Figure 4.6:	PIP 640 but not PIP 644 peptides alters claudin-2 following induction of 
increased MLC-pS19 levels in Caco-2 cell monolayers. A) Immunoblots showing 
cellular levels of MLC-pS19 and claudin-2 levels over time following apical application 
of 1 mM of PIP 640 or PIP 644 peptides. B) Quantitative analysis of the 
immunoblots obtained for MLC-pS19 and claudin-2 induced by PIP 640 peptide in A). 
Data are means ± SEM of 3 independent experiments with n=3 for both MLC-pS19 
and claudin-2 immunoblotting data at all time points (**p value< 0.01). C) 
Immunofluorescent staining of claudin-2 in Caco-2 cell monolayers treated with PIP 
640 or PIP 644 peptide for 60 min. Images are representative of 3 independent 




















4.2.3. Effect of PIP 640 peptide on the phosphorylation of serine 
residues of claudin-2   
    
 Growing evidence suggests that the molecular organization of epithelial TJ 
proteins is subject to continuous remodelling that regulates TJ barrier and 
permeability functions in the resting state and in response to changes in the 
environment experienced by the epithelial cells (95, 175, 177). It has been reported 
that this dynamic function of TJ proteins could be modified by either altering 
expression or post-translational modifications, such as phosphorylation, of TJ 
proteins. For example, induction of interleukin-13 (IL-13) release by the 
intestinal mucosa is associated with intestinal inflammatory diseases and this 
event has been correlated with increased claudin-2 expression and enhanced 
TJ permeability (39, 102, 179). Additionally, TJ barrier function can be regulated by 
phosphorylation of serine residue at position 208 of claudin-2 (claudin-2-pS208), 
and this post-translational process has been suggested to reduce claudin-2 
trafficking to lysosomal degradation and increase its TJ localization (180, 181).  
 
Since PIP 640 peptide induced rapid redistribution of claudin-2 to TJs and 
phosphorylation of TJ proteins is often responsible for alteration of TJ barrier 
function (46, 180), we investigated the potential effect of PIP 640 peptide on the 
phosphorylation of serine residues of claudin-2. Immunoprecipitation of 
claudin-2 isolated from confluent Caco-2 cells grown in 75 cm2 flasks were 
assessed for the phosphorylation state of serine residues using an anti-
phosphoserine antibody following treatment with 1 mM of PIP 640 peptide for 
10 or 60 min. Under control conditions, claudin-2 was phosphorylated at the 
serine residues, but this level of phosphorylation was increased following the 
application of the PIP 640 peptide (Figure 4. 6). This observation was 
consistent with recent reports showing that increasing claudin-2-pS208 is 
associated with increased TJ localization of claudin-2 (180, 181). These results 
indicate that the PIP 640 peptide enhances claudin-2 recruitment to TJs by 
increasing its phosphorylation at serine residues, potentially the serine residue 






Figure 4.7: Effect of the PIP 640 peptide on phosphorylation of claudin-2 serine 
residues. A) Confluent Caco-2 cells seeded in 75 cm2 were treated with 1 mM of the 
PIP 640 peptide for the indicated period of time. Cell lysates were immunoprecipitated 
(IP) with anti-claudin-2 IgG or a control IgG and immunoblotted (IB) with anti-claudin-2 
IgG or anti-phosphoserine IgG. Arrows indicate the heavy chain (50 kDa) and the light 
chain (25 kDa) of the IgGs used. Claudin-2 and phosphoserine-claudin-2 bands are 
indicated by the star symbol (22 kDa). B) Levels of claudin-2 phosphorylation at 
serine residues in response to PIP 640 peptide over time were quantitated. Change in 
phosphorylation is expressed as a ratio of band intensity for phosphoserine-claudin-




























4.2.4. PIP 640 peptide induced a perm-selective TJ permeability 
 
Studies have shown that enhancement of intestinal TJ permeability is 
induced by different intestinal inflammatory disorders, such as inflammatory 
bowel diseases (IBD), and these changes have been demonstrated to involve 
MLC-pS19 induction by prolonged activation of MLCK. This process, in turn, 
results in rearrangement of TJ proteins, such as induction of occludin 
endocytosis and/or claudin-2 upregulation, which results in increased 
paracellular solute permeability (53, 102, 179, 182). The data presented above 
indicate that cellular changes induced by PIP 640 peptide were associated 
with increased levels of claudin-2 at the TJs that was correlated with increased 
levels of MLC-pS19 levels, similar to mechanisms demonstrated for TJ barrier 
dysfunction associated with IBD. Thus, it was important to compare the extent 
to which permeability was enhanced by the PIP 640 peptide in comparison to 
effects induced by pro-inflammatory cytokines that have been demonstrated to 
drive this increased permeability associated with IBD-like conditions. To do so, 
apical to basal permeability of different size fluorescent molecules, 4 kDa, 10 
kDa and 70 kDa dextran, across Caco-2 monolayers was assessed after 
exposure to either PIP 640 peptide or a mixture of pro-inflammatory cytokines, 
tumour necrosis factor-α and interferon-γ (TNF-α/INFγ), which have been 
identified as essential mediators of IBD (138, 183).  
 
 
Monolayers TEER changes and the cumulative flux of fluorescent dextrans 
were monitored for 60 min after apical PIP 640 peptide application to Caco-2 
monolayers and these parameters were compared to the action of basal 
treatment with TNF-α/INFγ after 4h to ensure induction of an inflammatory 
process (54). Exposure to PIP 640 peptide for 60 min reduced the TEER values 
of Caco-2 monolayers to ~ 70 % of the initial TEER values, whereas treating 
the monolayers with TNF-α/INFγ for the indicated time induced a decrease in 
TEER to ~ 55 % of the initial TEER values (Figure 4.8 A). Both PIP 640 
peptide and TNF-α/INFγ treatments induced MLC-pS19, but occludin down-






This is consistent with studies showing occludin down-regulation is required for 
pro-inflammatory cytokine-induced TJ barrier dysfunction (54, 137). In response 
to TEER reduction induced by both PIP 640 peptide and TNF-α/INFγ, apical to 
basal flux of 4 kDa dextran was significantly increased compared to controls 
(Figure 4.9). However, TNF-α/INFγ allowed more 4 kDa dextran to cross the 
monolayers compared to PIP 640 peptide (Figure 4.9). Apical to basal flux of 
10 kDa and 70 kDa dextran across Caco-2 monolayers was enhanced in 
monolayers treated with TNF-α/INFγ but, not following PIP 640 peptide 























Figure 4.8: Effect of TNF-α/INFγ or PIP 640 peptide on the barrier properties of 
Caco-2 cell monolayers. A) Change in the TEER of Caco-2 monolayers after 60 min 
of apical exposure to 1 mM of PIP 640 peptide and after 4 h of basal exposure to 
TNF-α (5 ng/mL)/ INF-γ (10 ng/mL). Data are means ± SEM of 3 independent 
experiments, with n=9 (**p value< 0.01 and ***p value< 0.001). B) Immunoblotting 
assessment of changes in MLC-pS19 and occludin levels induced by both PIP 640 
peptide and TNF-α/INF-γ treatment after time indicated in A). Data are 
representative of 4 independent experiments, n=4. Data are means ± SEM of 3 























Figure 4.9: Cumulative apical to basolateral flux of fluorescent dextran (4 kDa, 10 
kDa and 70 kDa) across Caco-2 cell monolayers induced by basal TNF-α/INF-γ or 
apical PIP 640 peptide treatment. The extent of fluorescent dextran across 
monolayers was monitored for 60 min after induction of barrier dysfunction by pre-
treatment TNF-α/INF-γ while these values were similarly determined for PIP 640 
peptide added apically at the time of dextran application. Data are means ± SEM of 




























4.2.5. Perm-selectivity of PIP 640 peptide solute transport   
 
Claudin proteins are known to regulate ion flux through TJs between the 
apical and basolateral sides of epithelial cells (38, 45). At TJs, claudin-2 establish 
an ion channel that is selectively permeable to small cations and water (27, 184). 
Claudin-2 ion channels are involved in generating essential gradients that also 
mediate the paracellular permeability of molecules (38, 45). Studies have shown 
that claudin-2 regulation is involved in the induction of physiological gradient-
dependent paracellular flux of nutrient molecules (178). Increased levels of 
claudin-2 at TJ structure, however, have also been linked with many intestinal 
disorders characterized by a leaky epithelium (102, 179, 182). The data presented 
above showed that treatment of both the PIP 640 peptide and TNF-α/INF-γ 
increased MLC-pS19 levels and led to changes in the TJ permeability 
properties of Caco-2 cell monolayers. However, the PIP 640 peptide increased 
Caco-2 monolayers permeability to 4 kDa dextran but not 10 kDa dextran, 
while TNF-α/INF-γ enhanced the permeability of dextrans as large as 70 kDa 
(Figure 4.9). In addition, TNF-α/INF-γ-induced permeability changes to Caco-2 
monolayers were associated with occludin down-regulation (53), whereas TJ 
permeability induced by the PIP 640 peptide did not appear to alter occludin 
protein levels (Figure 4.8 B).  
 
 
PIP 640 peptide increased claudin-2 levels at TJ structures and also 
caused an increase in the permeability of a macromolecular solute, in this case 
4 kDa dextran. We next asked whether these PIP 640 peptide-mediated 
changes to TJ function also affected the charge selectivity of macromolecular 
solutes through the paracellular route in a manner consistent with the nature of 
claudin-2 perm-selectivity. To study this, TEER changes of Caco-2 cell 
monolayers and apical to basal transport of fluorescent dextrans with either an 
overall positive or negative charge were compared to that of neutral dextran in 
vitro. In separate monolayers, 4 kDa size forms of positively-charged 
diethylaminoethyl-dextran (DEAE-dextran; structure shown in Figure 4.10 A) or 






Figure 4.10 B) were mixed with neutral 4 kDa dextran and applied apically to 
Caco-2 monolayers treated with 1 mM of the PIP 640 peptide. After 60 min the 
extent of apical to basal compartment transfer for the dextrans being tested 
were determined and the apical media was replaced with fresh media and 
TEER values for the Caco-2 cell monolayers were monitored over the next 5 h 
to ensure recovery of TJ function (Figure 4.10 C and D). These studies 
showed that Caco-2 monolayers treated with PIP 640 peptide were more 
permeable to 4 kDa positively-charged DEAE-dextran than neutral 4 kDa 
dextran, but that the permeability changes induced by PIP 640 peptide were 
similar for 4 kDa negatively-charged CM-dextran and 4 kDa neutral dextran 
(Figure 4.10 D). These findings might indicate that the positively charged 
molecule selectivity of claudin-2 might contribute to PIP 640 peptide 
permeability enhancement function to some extent, as Caco-2 monolayer were 



















Figure 4.10: PIP 640 peptide enhances the permeability of positively-charged solutes 
relative to neutral or negatively-charged solutes. Chemical structures of the charged 
dextran derivatives used, A) Diethylaminoethyl-dextran (DEAE-dextran) and B) 
Carboxymethyl-dextran (CM-dextran). C) Change in TEER of Caco-2 cells 
monolayers induced by 640 peptide. Apical media containing PIP 640 peptide and 
dextrans was replaced with fresh DMEM medium after 60 min to allow examination of 
TEER recovery over a subsequent 5 h period. D) Cumulative apical to basal transport 
across Caco-2 monolayers treated with fluorescent DEAE-dextran or CM-dextran with 
neutral dextran (all 4 kDa in size) over 60 min. Data are means ± SEM (*P < 0.05 and 



















4.3. Discussion  
 
The intestinal epithelial barrier performs a critical task of protecting the 
human body from the invasion of harmful agents or pathogens that might 
induce systemic disorders and/or local inflammation to the intestine (45, 101). 
However, the barrier characteristics that grant this protection also hinder the 
absorption of therapeutic peptides (5). Accordingly, most of the available 
therapeutic peptides are limited to parenteral applications, which are 
considered inconvenient for patients that require long-term treatment. 
Therefore, various approaches have been investigated to enhance the oral 
delivery of such drugs across the intestinal epithelial barrier (5, 117). For 
example, many permeability enhancers (PEs) have shown to effectively 
enhance drug permeability across epithelial cells (5, 117), with most of them 
acting non-selectively on the epithelial barrier by disorganizing TJ proteins or 
generally disrupting the epithelial cell membrane (13, 119).        
 
 
The TJ barrier is comprised of complex protein structures that consist of 
many cell membrane integral proteins, organized as a network of membrane 
peripheral proteins linking to the TJ-associated actomyosin cytoskeleton (14). 
TJ proteins possess a distinct dynamic behaviour by which association of TJ 
integral membrane proteins and their organization within the TJ can be 
modulated (175, 177). The restricted transport of solutes across the TJ barrier is 
regulated by a wide array of intracellular signalling molecules that modulate TJ 
protein components (45). Application of agents to enhance the paracellular 
permeability of therapeutic peptides across the TJs of intestinal epithelial cells 
has gained wide acceptance as a drug delivery strategy (5, 117), as TJ routes 
are more suitable for hydrophilic medication that are unable to cross the lipid 
bilayers of epithelial cell membranes, being the mechanism used in the oral 
absorption of small molecule drugs (5). However, opening the TJs non-
specifically for drug delivery may lead to epithelial damage and/or inflammation 







It is well established that induction of MLC-pS19 in the intestinal epithelium 
can trigger dynamic modulation of TJ protein structures that reversibly regulate 
the TJ barrier properties (88, 95, 103), an endogenous mechanism involved in the 
regulation of physiological uptake of molecules, such as nutrients, through 
paracellular routes (88, 167).  The main goal of the current project was to 
examine a strategy to improve oral delivery of therapeutic peptides by 
enhancing their ability to cross the intestinal epithelial barrier. Accordingly, we 
designed a small cell permeant peptide, PIP 640 peptide, to regulate MLCP 
activity, inducing MLC-pS19 levels that would result in the induction of a 
transient TJ opening to allow for enhanced therapeutic peptide absorption. The 
data presented in Chapter 1 showed that the PIP 640 peptide was able to 
reversibly reduce the TEER of Caco-2 cell monolayers and enhance the 
permeability of 4 kDa dextran through the TJ in vitro by the proposed MoA. 
However, it was not clear whether the permeability enhancement function of 
PIP 640 peptide was associated with changes in TJ protein elements. In 
addition, the studies presented in Chapter 1 that investigated intracellular 
distribution of PIP 640 peptide in Caco-2 cell monolayers showed that the 
peptide was closely associated with the TJ protein structure, as it was co-
localized with the integral membrane protein occludin. These observations led 
us to the hypothesis that PIP 640 peptide might induce TJ permeability by 
altering the structure of TJ proteins. Therefore, the studies performed in the 
current chapter were aimed to investigate biochemical changes in TJ proteins 
associated with the permeability enhancement function of the PIP 640 peptide.     
 
 
Major determinants of TJ barrier properties in different epithelial barriers 
are regulated by the composition of specific TJ proteins and their expression 
levels (21, 45). Hence, based upon such differences, TJ barrier of epithelial cells 
lining organs such as the intestine and kidney tubules are relatively more 
permeable than those covering the urinary bladder lumen (21, 45). Studies have 
determined that TJs are naturally permeable to ions and small solutes < 4 Å 






enhanced the permeability of 4 kDa dextran (~ 14 Å radius) across Caco-2 
monolayers in vitro. It has been suggested that the permeability of 
macromolecules of this size through TJ routes is associated with the 
displacement of TJ proteins, especially TAMPs and ZO-1. For example, 
occludin endocytosis that is associated with TNF-induced MLCK hyperactivity 
in IBD that induces macromolecules permeability across epithelial TJs (53, 185). 
Similarly, disruption of tricellulin has been recognized as a pathway to enhance 
TJ permeability in cultured monolayers to molecules such as 10 kDa dextran 
(118). Knockdown of the third member of TAMP, MarvelD3, in Caco-2 cells was 
also associated with changing TJ barrier properties (59). The scaffolding protein 
ZO-1 has a major role in the assembly of TJ proteins, and it has been shown 
that ZO-1 down-regulation was associated with enhancement of the flux of 
large solutes across epithelial cells in vitro (186, 187). In addition, TAMPs and ZO-
1 were shown to be highly dynamic at the TJs compared to other TJ proteins 
such as claudin-1 that seems to be more stable at TJ (36, 177). Therefore, our 
initial thought was that the permeability enhancement induced by the PIP 640 
peptide might be regulated by modulating these TJ proteins. Accordingly, we 
investigated the potential effect of the PIP 640 peptide on TAMP family and 
ZO-1 proteins. Immunoblot analysis of total cell lysates of Caco-2 monolayers 
before and after treatment with PIP 640 peptide showed no significant 
difference on TAMPs and ZO-1 levels (Figure 4.1 A and B). Similarly, 
immunostaining of these proteins in Caco-2 monolayers treated with PIP 640 
peptide showed normal TJ localization and no marked difference compared to 
the control (Figure 4.1 C).   
 
 
Since data investigating the effect of the PIP 640 peptide on TJ proteins 
revealed that the peptide does not seem to interfere with TAMPs and ZO-1 
functions, we explored the status of other membrane integrated TJ proteins 
such as members of the claudin family, as disruption or reorganization of some 
claudin proteins have been shown to enhance the paracellular permeability of 






claudins, we focused on different claudin isoforms that are expressed in 
intestinal epithelium and contribute differently to TJ barrier function with the 
assumption that changes in these proteins might explain TJ permeability 
property changes induced by the PIP 640 peptide. These include claudins-1, -
3 and -5, which have been shown to act as sealing proteins to the paracellular 
routes to reduce paracellular permeability (25, 40). In addition, we explored the 
alterations to claudin-4, -7 and -8 that have been shown to contribute to the 
regulation of TJ permeability to negatively charged ions (29, 188). Also, we 
investigated changes to claudin-2 and -15 that promote the passage of 
positively charged ions (28, 115). Immunoblotting data showed that PIP 640 
peptide-induced MLC-pS19 was associated with an apparent increase in 
claudin-2 in Caco-2 monolayers and no effect was observed on the other 
tested claudins (Figure 4.2 A and B). This increase in claudin-2 was consistent 
with TJ localization (Figure 4.3). Moreover, claudin-2 was widely distributed 
intracellularly, which might suggest that the PIP 640 peptide induced claudin-2 
recruitment to TJ structures (Figure 4.3). 
 
 
 It is been shown that the pore size of claudin-2 permits the permeability to 
small cations but not larger molecules such as 4 kDa dextran (115). This might 
suggest that the permeability enhancement of 4 kDa dextran associated with 
PIP 640 peptide might be primarily mediated by other untested TJ proteins and 
claudin-2 likely contributes to charge selectivity of the permeability 
enhancement function of the PIP 640 peptide. In addition, imaging of fixed 
tissues and cell monolayers might not reveal some of the changes in the 
organization of TJ proteins that are associated with paracellular permeability. 
For example, paracellular permeability induced by activation of MLCK 
associated with Na+-glucose co-transport showed normal distribution of ZO-1 
protein at the TJs (94). However, application of FRAP techniques in living cells 
revealed that the dynamic behaviour of ZO-1 changes during Na+-glucose-
induced MLCK. This appeared as less ZO-1 protein was associated with the 






necessary in future for precise assessment of the action of the PIP 640 peptide 
on the organization of TJ proteins that mediate macromolecule permeability, 
such as occludin.  
PIP 640 peptide was designed to mimic the inhibitory function of CPI-17 
towards MLCP by emulating the binding properties of CPI-17 to MLCP 
components (MYPT1:PP1). This was done to increase MLC-pS19 levels, an 
intracellular mechanism that is known to regulate TJ barrier properties (88, 160, 
161), in order to enhance the paracellular permeability of peptide therapeutics. 
The data presented in chapter 1 suggest that PIP 640 peptide regulates MLCP 
activity by increasing MLC-pS19 levels. This induced reversible TJ permeability 
of molecules with a radius of ~ 14 Å. We then attempted to characterize 
changes to the TJ proteins associated with PIP 640 peptide-induced TJ 
permeability. The data showed that of the many TJ integral membrane proteins 
examined, only claudin-2 was significantly increased at the TJ. Analysis of the 
cellular levels and distribution of claudin-2 over time in response to exposure 
to the PIP 640 peptide revealed a time-dependent increase of claudin-2, 
reduction of TEER and increase in MLC-pS19 levels (Figure 4.3, and Figure 
4.4). However, the PIP 644 peptide, an analogue of PIP 640 peptide described 
in chapter 1 that increases MLC-pS19 levels by acting as a general 
phosphatase inhibitor instead of acting specifically on MLCP, had no 
significant effect on claudin-2 (Figure 4.6). These findings might indicate that 
the increase in claudin-2 induced by the PIP 640 peptide was due to regulation 
of MLCP activity and not by enhancing MLC-pS19 levels, as PIP 644 peptide 
did not change claudin-2 levels. Moreover, the delayed onset of claudin-2 
increases compared to MLC-pS19 increases observed in (Figure 4.3) might 
suggest that PIP 640 peptide-induced claudin-2 increase at the TJ is regulated 
by a secondary mechanism triggered by regulating MLCP activity. 
 
 
Various studies have defined mechanisms mediating TJ protein trafficking 
that are essential for modulating TJ barrier function. For example, TNF-






mediated by caveolin-1, a lipid raft protein that plays a role in protein 
endocytosis (189). Moreover, it was found that phosphorylation of occludin at 
threonine residues at positons 403 and 404 increases occludin recruitment to 
the TJs and accordingly enhances TJ barrier function (190). Our data showed 
that the PIP 640 peptide increased claudin-2 levels at the TJ significantly after 
20 min, an effect that seems to occur secondarily to the increase observed in 
MLC-pS19 levels (Figure 4.3, and Figure 4.4). Studies have shown that claudin-
2 expression increases in response to cytokines (39, 102, 179). This cytokine-
induced claudin-2 up-regulation appears to be a slower onset and more 
durable process compared to the more dynamic actions of the PIP 640 peptide 
on Caco-2 cell monolayers in vitro. Therefore, we excluded the possibility that 
the effect of PIP 640 peptide on claudin-2 levels was related to expression 
level. Instead PIP 640 peptide seems to redistribute claudin-2 to TJs.   
 
 
It is been established that the TJ proteins, including claudin-2, are found in 
a cholesterol-enriched glycolipids raft (lipid raft) of plasma membranes, which 
forms a tightly packed detergent-insoluble region (196). Studies have suggested 
that claudin-2 disassembled from TJ is rapidly targeted to lysosomal 
degradation (181, 191). Cellular trafficking of claudin-2 has been shown to be 
regulated by different signalling pathways. For example, Rab-14, a small 
guanosine triphosphatase (GTPase), has been shown to play a regulatory role 
in the delivery of claudin-2 to TJs and the internalization of claudin-2 (191). In 
addition, claudin-2-pS208 was found to be essential for the recruitment of 
claudin-2 to TJ structures (181). Also, phosphorylation of claudin-2 at this 
position was shown to enhance claudin-2 detergent solubility (181). These 
mechanisms were also found involved in regulating claudin-2 targeting to 
lysosomes (181, 191). Expression of mutated claudin-2 in the serine residue at 
position 208 in MDCK I cells caused claudin-2 down-regulation by lysosomal 
degradation (181). Similarly, knockdown of Rab-14 in MDCK II cells was 
associated with a reduction in claudin-2 and increase in the TJ barrier function, 






14 in regulating claudin-2 levels was linked to directing claudin-2 to lysosomes, 
as inhibiting lysosomal degradation in Rab-14 knock-down MDCK II cells 
resulted in maintenance of claudin-2 levels (191). In our investigation of the 
effect of PIP 640 peptide treatment of Caco-2 monolayers on TJ proteins, we 
observed a rapid time-dependent increase of claudin-2 localization at the TJ, 
an effect that was also detected in the immunoblot data using total cell lysates. 
This increase in claudin-2 was associated with a rapid enhancement of 
claudin-2-pS208 (Figure 4.7). Since the half-life of claudin proteins has been 
suggested to be ~ 6 h (181), such a rapid alteration in claudin-2 levels that was 
observed in the immunoblot data is unlikely to occur by reducing claudin-2 
degradation, a process that is regulated by claudin-2-pS208 as discussed earlier 
(180, 181). However, this increase in claudin-2 levels that was induced by the PIP 
640 peptide might resulted from enhancing claudin-2 detergent solubility from 
lipid raft, a function of enhanced claudin-2-pS208 (181). This can be confirmed by 
performing differential detergent extraction and sucrose density centrifugation.  
 
 
Increased intestinal TJ permeability is commonly associated with cytokine-
induced inflammatory disorders, such as IBD (53, 102, 179, 182).  Elevation of TNF-α 
in intestinal mucosa enhances MLCK activation and has been shown to be the 
major cause of leaky TJs, which are permeable to macromolecules in patients 
with Crohn’s disease (53, 103). Other cytokines, such as INF-γ, were found to 
have a boosting effect to the barrier dysfunction induced by TNF-α (138, 183). 
Short exposure to TNF-α/INF-γ was shown in the current studies to induce 
barrier dysfunction characterized by activation of MLCK-induced MLC-pS19 
levels and occludin endocytosis (53, 54, 103, 138, 183). Chronic exposure to these 
pro-inflammatory cytokines was shown to cause more changes to the TJ 
structure, such as increasing claudin-2 expression, and consequent epithelial 
cell damage (138, 192). The data presented above showed that PIP 640 peptide 
induced TJ permeability of 4 kDa dextran by enhancing MLC-pS19 levels, an 
effect that was associated with claudin-2 increase, although it is currently 






transport. Thus, additional TJ modifications may be induced by PIP 640 
peptide. Since TNF-α/INF-γ-induced TJ permeability is activated by increasing 
MLC-pS19, the same endogenous mechanism that regulates TJ permeability 
induced by the PIP 640 peptide, it is particularly interesting to note that 
changes of TJ barrier properties induced by PIP 640 peptide were distinct from 
those induced by TNF-α/INF-γ. 
 
 
Our data showed that Caco-2 cell monolayers treated with either PIP 640 
peptide or TNF-α/INF-γ decreased TEER associated with elevated MLC-pS19 
levels (Figure 4.8 A and B). However, the pattern of TEER reduction is 
different for each treatment. TNF-α/INF-γ induced further TEER reduction than 
did the PIP 640 peptide. This might have occurred in response to occludin 
down-regulation that was only observed in Caco-2 monolayers treated with 
TNF-α/INF-γ (Figure 4.8 B). Data concerning the permeability of solutes of 
different sizes across Caco-2 monolayers revealed that the PIP 640 peptide 
induced perm-selective permeability of TJs that allowed the passage of 
molecules with ~ < 14 Å radius size (Figure 4.9). However, Caco-2 monolayers 
treated with TNF-α/INF-γ were also permeable to 70 kDa dextran (~60 Å 
radius) (Figure 4.9). This outcome was consistent with previous reports 
concerning TJ permeability associated with TNF-α/INF-γ (54). Another well-
defined characteristic of TJ barrier dysfunction associated with TNF-induced 
MLCK activation is the irregular, undulating distribution of the scaffolding 
protein ZO-1 at the TJ (53, 183). This was not observed for PIP 640 peptide 
treated Caco-2 monolayers (Figure 4.1 C). These data imply that PIP 640 
peptide and TNF-α/INF-γ enhance TJ permeability by distinct mechanisms, 
although they are both able to increase MLC-pS19.   
 
 
Claudin-2 is a tetraspan pore-forming TJ protein that is size- and charge-
selective (27, 32, 115). Similar to most claudin proteins, the charge-selectivity of 






1 (ECL-1), which is stabilized by two cysteine residues (32). The charge-
selective property of paracellular routes in tissue epithelial barriers, which is 
dependent upon the type of claudin proteins expressed in that epithelium, is 
typically determined by studying the flow of ions across the epithelial cells (29, 
115, 188). In our in vitro investigations, we have determined that PIP 640 peptide 
induced a modification of TJs that resulted in an enhanced transport of small 
macromolecules in a perm-selective manner. Such changes are distinct from 
that observed for TJ changes induced by pro-inflammatory cytokines (Figure 
4.9). This means that the PIP 640 peptide changed the pore size-selectivity of 
TJ from being permeable to molecules with < 4 Å radius, such as mannitol (175, 
193), to molecules with < 14 Å radius, 4 kDa dextran.  
 
 
The TJs of Caco-2 cell monolayers are generally more permeable to 
positively charged and neutral molecules than negatively charged ones, all 
with < 5 Å radius (194). This preference was maintained for the same solutes 
after changing TJ pore size to ~ 15 Å by treating the monolayers with 
palmitoylcarnitine (194), a PE that was shown to non-specifically enhance TJ 
permeability (5). In agreement with this report of the charge preference of Caco-
2 cells, TJ permeability induced by sodium caprate across Caco-2 monolayers 
was higher for neutral 4 kDa dextran than negatively charged Lucifer yellow 
(LY) dye (122), although that the latter has a smaller radius ~ 5 Å (195) compared 
to 4 kDa dextran ~14 Å. However, sodium caprate has been shown to induce 
changes to different TJ proteins (118, 196). A study has shown that one such 
change is displacement of claudin-4 (196), which has been shown to contribute 
to the regulation of passage of negatively charged molecules (29, 197), from TJs. 
Thus, claudin-4 displacement induced by sodium caprate might be the reason 
for the reduced permeability of LY across Caco-2 monolayers. Our results 
show that charge-preferential paracellular permeability changes induced by 
PIP 640 peptide were only significant for DEAE-dextran (Figure 4.9 D). These 
findings suggest that claudin-2 might contribute to PIP 640 peptide-induced TJ 






claudin-2 is the only protein responsible for enhancing the TJ permeability 
function of PIP 640 peptide.  
 
 
In conclusion, in this Chapter we have studied biochemical changes to TJ 
protein associated with the permeability enhancement function of the PIP 640 
peptide, which is mediated by enhancing MLC-pS19 levels through the 
modulation of MLCP activity. Our results showed that PIP 640 peptide induced 
a time-dependent increase of claudin-2 cellular level that was correlated with 
increase of MLC-pS19, whereas no changes were observed for a wide range of 
other integral membrane TJ proteins that were examined. The PIP 640 
peptide-induced increase in claudin-2 correlated with an enhancement of 
claudin-2 phosphorylation at serine residues, potentially claudin-2-pS208, which 
could result in increased detergent extractability and enhancement of its 
cellular distribution at TJs. In addition, the PIP 640 peptide was shown to 
induce a perm-selective permeability increase in TJ pore size in a manner that 
differed from that induced by proinflammatory cytokines. Finally, this increase 
in claudin-2 at TJ structures induced by the PIP 640 peptide seems to 
contribute to regulating paracellular permeability of charged molecules, 
preferentially to positively charged molecules with a radius of at least 14 Å but 















Chapter 5 : Application of PIP 
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Most of the currently-known therapeutic peptides have poor oral 
bioavailability. This is due to their undesired physiochemical characteristics of 
being too large and hydrophilic to cross the intestinal epithelial barrier in a 
manner similar to small molecule drugs (117). Many strategies have been 
explored to improve the oral delivery of such therapeutics; some of these 
strategies have shown promising outcomes in terms of overcoming the 
intestinal epithelial barrier (5). For example, application of permeability 
enhancer (PE) agents that have been used to transiently enhance the 
transport of a co-administered peptide therapeutic across the intestinal 
epithelium. Previously described strategies to enhance the oral delivery of 
peptide therapeutics usually define their effectiveness in enhancing the 
permeability by using in vitro cell culture models of the intestinal epithelium or 
an excised intestinal tissue (5, 13, 135). This is typically is done by examining the 
transport of various stable solutes that have physicochemical properties similar 
to peptide therapeutics as a way to predict whether the strategy can enhance 
the permeability of a desired peptide drug in vivo (5, 135). In addition, in vitro 
models have been widely used in efforts to define the mechanism of action 
(MoA) by which a delivery strategy enhances the permeability of molecules. 
This information is critical to explore potential toxicity events associated with a 
given delivery strategy (5, 13).  
 
 
A human colorectal adenocarcinoma cell line, Caco-2 cells, is one of the 
intestinal epithelial cell models most frequently used to study drug permeability 
across the intestine because it is simple to use and can provide reproducible 
results (135, 198). These advantages have lowered the reliance on animal models 
for the initial examination of delivery strategies across the intestinal epithelium 
(198). Fully differentiated Caco-2 cells are able to show many features of the 
small intestine epithelial barrier, a status that can be achieved when these 
cells are grown on semi-permeable filters to form a single layer of polarized 






these Caco-2 cell monolayers has been found to contain various membrane 
transporters and metabolic enzymes known to exist in human intestinal 
epithelium (135, 198). However, the Caco-2 cell model is not an optimum model to 
study drug permeability across the intestinal epithelial cells, as it does not 
exactly reflect how a drug permeability enhancement approach will behave in 
vivo (5). Importantly, Caco-2 cells lack some of the naturally existing elements 
in the intestine that have been suggested to affect the drug absorption 
process, such as the mucus layer, and these elements need to be considered 
when developing a strategy to enhance oral delivery of therapeutic peptides in 
vivo (199).  
 
 
The mucus layer consists of mucin glycoproteins that form a viscous gel-
like structure that covers intestinal epithelial cells, thereby providing a 
protective barrier against a spectrum of potential pathogens (199). While the 
mucus layer allows the transport of small molecules, such as nutrients, it has 
the potential to entrap poly-ionic macromolecules (199). Studies have shown 
that the intestinal mucus layer is a factor that could slow the diffusion of poly-
ionic macromolecules to the epithelial surface, thus reducing their absorption 
rate (10, 200). For example, chitosan, a PE agent that can improve the intestinal 
permeability of a poorly absorbed drug such as atenolol, was more effective 
when tested in vitro using Caco-2 cell monolayers that do not secrete a mucus 
layer versus HT-29 cell monolayers that do produce a mucus layer (200). This 
effect of the mucus layer has also been shown to influence the permeability of 
peptide therapeutics (5, 10, 199).  
 
 
The need to evaluate safety is one of the major concerns of using PE 
agents to enhance the intestinal permeability of a peptide therapeutic and this 
cannot be accomplished by only using in vitro models (13).These in vitro models 
can overestimate toxicity associated with PE agents as they lack elements and 
mechanisms that protect the intestine from damage such as the mucus layer, 






intestinal epithelium are usually unable to predict the effect of long-term 
(repeated) exposure to PE agents on the intestinal epithelium or the potential 
induction of co-permeability of harmful elements present in the intestinal lumen 
(13). Hence, it is important to address the limitations of in vitro models in a more 
complex animal model in vivo. 
 
 
In our work, we sought to develop a novel PE agent: a small membrane-
permeant peptide to regulate the activity of myosin light chain phosphatase 
(MCLP). This PE agent, known as the PIP 640 peptide, was designed to 
increase myosin light chain phosphorylation at the serine 19 (MLC-pS19) to 
alter TJ properties and enhance the intestinal epithelial TJs permeability of 
peptide therapeutics. PIP 640 peptide at a concentration of 1 mM, showed an 
ability to reversibly enhance TJ permeability properties of Caco-2 monolayers 
in vitro without affecting cell viability, as discussed in Chapters 1 and 2. The 
next logical step was to assess PIP 640 peptide efficacy and validate its MoA 
in an in vivo model in order to predict its possible actions in an ultimate clinical 
application. This is particularly important because, typically, both the 
performance and the effective concentration of a PE agent tend to vary 
between in vitro and in vivo models (118, 202). For example, the PE agent sodium 
caprate at a concentration of 10 mM was able to improve the permeability of 
dextran molecules with molecular weight of 4 kDa and 10 kDa in HT-29 cell 
monolayers in vitro (118), while a concentration of 100 mM was required to 
enhance in vivo bioavailability of 4 kDa dextran to ~2 % in a rat animal model 
after intra-jejunal loop injection (202).     
 
The current chapter examines different aspects of PIP 640 peptide-induced 
permeability enhancement in vivo by measuring the systemic bioavailability of 
different peptide therapeutics in a rat model following co-administration with 
the PIP 640 peptide by direct intraluminal intestine injection (ILI). Moreover, 
the experiments in this study examined whether the permeability enhancement 
induced by the PIP 640 peptide increases the permeability of other harmful 






lipopolysaccharide (LPS). This chapter also sought to validate the defined MoA 
of the PIP 640 peptide from in vitro studies in vivo. Such results could provide 
valuable information regarding the in vivo permeability enhancement 


































5.3. Results  
 
5.3.1. Co-administration of the PIP 640 peptide with insulin lowered 
blood glucose level in vivo 
 
Our initial investigation of the PIP 640 peptide action in vivo involved using 
a longer version of the peptide that has three additional basic amino acids at 
the C-terminus of the peptide sequence, rrdykvevrrkkr-NH2, as it was thought 
that these additional amino acids would be important to increase the rate of 
intracellular uptake of the PIP 640 peptide in order to compensate for intestinal 
transit that could not be modelled in vitro (127). This longer version of the PIP 
640 peptide was tested to determine its ability to enhance insulin absorption in 
rat intestine following intraluminal intestinal injection (ILI). This peptide at a 
concentration of 20 mM showed an ability to enhance insulin transport to blood 
circulation and accordingly lowered blood glucose levels (127). In an effort to 
decrease the number of synthetic steps and lower the cost of peptide, as a 
part of the PIP 640 peptide optimization process, we tested the ability of the 
original PIP 640 peptide sequence: rrdykvevrr-NH2, to enhance the absorption 
of therapeutic peptides in vivo after validating its effectiveness and MoA in 
vitro, which was shown in Chapter 1 and 2. 
 
 
To explore the actions of the PIP 640 peptide in vivo, we applied the same 
conditions that were used to examine the in vivo actions of the longer version 
of the PIP 640 peptide (127). Rats were used because the intracellular protein 
targets of the PIP 640 peptide, MLCP components (MYPT1:PP1), are highly 
conserved between humans and rats (156, 203). Human insulin alone (control), or 
in combination with the PIP 640 peptide, was administered to non-diabetic rats 
by ILI with blood glucose level being monitored for the next 80 min. Citric acid 
at a concentration of 10 mM was used in the tested formulations to reduce 
intestinal proteolysis (204). A subcutaneous (SC) injection of insulin served as a 
positive control for changes in blood glucose levels. In our previous in vivo 






pharmacodynamics (PD) outcomes in rats at a concentration of 3 IU/kg after 
SC injection and 30 IU/kg when co-administered with 20 mM of the longer 
version of the PIP 640 peptide via ILI (127). Thus, we used the same 




SC injection of 3 IU/kg of human insulin reduced the blood glucose level in 
these non-diabetic rats to ~50% of their initial value after 30 min (Figure 5.1 A). 
This hypoglycaemic effect started to recover after ~50 min and it reached 70 % 
of the initial values after ~80 min, the time of study termination. ILI co-
administration of 30 IU/kg of human insulin with 20 mM of the PIP 640 peptide 
showed slower action in reducing blood glucose levels in comparison to the 
SC injection of 3 IU/kg of insulin. The blood glucose levels started to decrease 
significantly after 20 min, and reached ~55 % of the initial value after 40 min 
(Figure 5.1 B). However, the recovery profile that was observed with the ILI co-
administration of insulin and the PIP 640 peptide was faster in comparison to 
the SC injection of insulin (Figure 5.1 B). As expected, insulin alone 
administered by ILI at a concentration of 30 IU/kg, had no effect on blood 
glucose levels (Figure 5.1 B).  
 
 
In vitro data presented in Chapter 1 and 2 demonstrated that the PIP 640 
peptide can enhance the TJ permeability of intestinal epithelial cells over a 
time course consistent with increased MLC-pS19 levels. Therefore, we 
performed a similar biochemical analysis with rat intestinal tissues exposed to 
PIP 640 in vivo. Toward that end, we measured MLC-pS19 levels in rat 
intestinal tissue at the site of ILI 40 min after insulin alone or insulin co-
administrated with the PIP 640 peptide. Immunoblotting data showed that the 
MLC-pS19 level was only increased in rat intestine exposed to the PIP 640 
peptide (Figure 5.1 C and D). Together, these in vivo data are consistent with 






Figure 5.1: Effect of co-administration the PIP 640 peptide and insulin on blood 
glucose levels and MLC-pS19 levels in rats in vivo. Blood samples from the tail vein 
were used to monitor glucose levels. A) Effect of subcutaneous (SC) injection of 3 
IU/kg insulin alone on blood glucose levels. B) Effect of co-administration of 30 IU/kg 
of insulin and 20 mM of the PIP 640 peptide by intraluminal intestinal injection (ILI) on 
blood glucose levels. C) Immunoblot of MLC-pS19 compared to total MLC levels 40 
min after ILI of insulin with or without PIP 640 peptide. D) Quantitative assessment of 
MLC-pS19 levels immunoblots shown in A). Data represent means ± SEM of 3 
independent experiments; n=3 (*p value< 0.05, **p value< 0.01, ***p value< 0.001). 
insulin absorption across intestinal epithelial TJs with a simultaneous increase 











5.3.2. PIP 640 peptide enhanced claudin-2 localization at TJs in vivo 
 
Claudin-2 expression at TJ structures is associated with reduced barrier 
properties and enhanced epithelial permeability of small molecules with a 
radius < ~4 Å (27, 115). In the intestine, claudin-2 is highly expressed and was 
found to play an essential role in regulating intestinal physiological functions 
that include the regulation of Na+ transport from the submucosa to the lumen 
that seemed to be essential for nutrient absorption (178). In addition, increased 
claudin-2 levels are associated with many intestinal inflammatory disorders, 
such as Crohn’s disease (39, 102, 182). Data presented in Chapter 2 demonstrated 
that the PIP 640 peptide-mediated enhancement of the permeability across 
Caco-2 cell monolayers in vitro correlated with increased MLC-pS19 levels as 
well as an increase in total claudin-2 levels and increased levels of claudin-2 at 
TJ structures. Consistent with this possible MoA identified in vitro, the data 
presented above (Figure 5.1) suggests that the PIP 640 peptide also 
enhanced insulin permeability in vivo by enhancing MLC-pS19 levels. In order 
to fully compare the proposed MoA identified in vitro with in vivo outcomes, we 
sought to validate the PIP 640 peptide action on claudin-2 in rat intestine. 
 
 
Rat intestinal epithelial tissues were exposed to 20 mM of the PIP 640 
peptide by ILI for 40 min when the tissues were collected and analysed by 
immunoblotting and immunofluorescence microscopy to monitor the amount 
and cellular distribution of claudin-2. In agreement with our in vitro data, 
immunoblotting analysis detected an increase in claudin-2 that was correlated 
with an enhancement to MLC-pS19 level in vivo (Figure 5.2). We then 
examined the expression levels and distribution of claudin-2 using 
immunofluorescence staining. In un-treated (control) rat intestinal tissue, 
claudin-2 expression was observed to decrease in a crypt to villus tip direction 
(Figure 5.3 A); consistent with previous studies describing claudin-2 
expression in vivo (205-207). Claudin-2 expression was distributed at the TJs and 
the basolateral membranes of epithelial cells located in the middle of the villus 






located at the villus tips (Figure 5.3 A, arrowheads, control image). Claudin-2 
expression in rat intestinal tissues following exposure to the PIP 640 peptide 
for 40 min seemed similar to the control, with no striking change observed in 
the signal intensity. However, claudin-2 distribution at the TJ structures 
seemed to increase in cells located at the villus tips (Figure 5.3 A, arrowheads, 
PIP 640 peptide image). Epithelial cells located in the middle of the villus of 
control tissue showed that caludin-2 was distributed in both TJs and 
basolateral membranes, forming connected lines along some paracellular 
spaces. After exposure to the PIP 640 peptide, claudin-2 within these 
enterocytes was concentrated more at TJs than at the basolateral membrane 
(Figure 5.3 B). These results suggest that more claudin-2 was recruited to TJ 
structures in response to PIP 640 peptide exposure. No striking effect was 
observed on claudin-1 or occludin following exposure to the PIP 640 peptide 














Figure 5.2: Changes in MLC-pS19 and claudin-2 levels following ILI exposure to 20 mM 
of the PIP 640 peptide in non-diabetic rats in vivo. A) Immunoblots of rat intestine 
exposed to 20 mM of the PIP 640 peptide for 40 min showed an increase in both MLC-
pS19 and claudin-2 levels. B) Quantitative representation of the immunoblots obtained in 








Figure 5.3: Immunofluorescence microscopy of rat jejunum epithelium showing the effect 
of the PIP 640 peptide on TJ proteins in vivo. A) Claudin-2 distribution in villi before and 
after exposure to 20 mM of the PIP 640 peptide for 40 min. Changes in claudin-2 
distribution in the villi tips are highlighted with arrowheads. B) Claudin-2 is predominantly 
located at the TJs of rat intestinal epithelium after exposure to the PIP 640 peptide, while it 
is located in both TJs and lateral membranes in the control tissues. Images show no 
significant effect on claudin-1 and occludin. Images are representative of 3 independent 







5.3.3. Validation of the charge-preferential paracellular permeability 
induced by the PIP 640 peptide in vivo 
 
TJs are organized to restrict macromolecular flux but selectively permit the 
permeability of small and hydrophilic molecules between adjacent epithelial 
cells, known as the paracellular route (5). Transient alteration of TJ function by 
PE agents can increase the permeability of the paracellular route to peptide 
therapeutics (93). The permeability of peptide therapeutics through TJs is 
limited by molecular size and surface charge (208, 209). In our in vitro data 
presented in Chapter 2, we showed that the PIP 640 peptide induced a perm-
selective TJ permeability that was preferentially permeable to positively 
charged dextran with a molecular weight of 4 kDa (~14 Å radius). This was 
associated with an increase in claudin-2 at TJ structures of Caco-2 cell 
monolayers used for these in vitro studies. Since claudin-2 at TJ structures is 
known to correlate with increased flux of positively charged ions, we 
hypothesized that PIP 640 might affect a charge-preferential TJ permeability 
change that favoured positively charged molecules.  
 
 
To examine the possibility that PIP 640 produced a charge-preferential TJ 
permeability change in vivo, we measured the potential for enhanced uptake of 
either calcitonin (salmon) or exenatide. Both of these therapeutic peptides 
have a similar hydrodynamic size of ~11 Å radius, but they differ in their 
isoelectric point (pI) values. Since calcitonin has a pI value of 8.8 and 
exenatide has a pI values of 4.9, the net charge of these peptides at the 
physiological pH of the small intestine (i.e. jejunum; 5.7- 7.4) where they will be 
administered by ILI will be net positive and net negative, respectively (3, 210, 211). 
Unlike the previous study investigating insulin permeability enhancement that 
was discussed above (Figure 5.1), soybean trypsin inhibitor (SBTI) (1.5 
mg/mL) was used with both calcitonin and exenatide (0.5 mg) instead of citric 
acid to reduce local luminal proteolysis because it was shown that this 






inducing significant permeability enhancement (126). Additionally, the presence 
of 10 mM citric acid could significantly alter the local pH at the site of ILI, 
potentially negating the goal of this study. Additionally, uptake of exenatide or 
calcitonin following ILI was assessed in serum obtained from portal vein blood 
collections, and not tail vein as with the insulin studies, in order to eliminate the 
potential for unequal hepatic extraction.  
 
 
Injecting similar amounts exenatide or calcitonin with 20 mM of the PIP 640 
peptide into rat jejunum by ILI resulted in an enhancement of portal vein 
plasma concentrations in comparison to control animals that received an ILI of 
exenatide or calcitonin without PIP 640 (Figure 5.4 A and B). Examination of 
the portal vein concentration-time profiles suggested that calcitonin 
concentration after 30 min of exposure were slightly higher than exenatide, but 
the difference was not statistically significant (Figure 5.4 A and B). Both 
therapeutic peptides showed a similar maximum plasma concentration (Cmax) 
at 40 min of co-administration with PIP 640 (Figure 5.4 A and B) (Table 5.1). 
However, the data indicated that the area under the curve (AUC) value of 
calcitonin when co-administered with PIP 640 was elevated ~10-fold relative to 
control, while PIP 640 peptide enhancement of exenatide uptake had an 
increase in AUC value of ~5-fold in comparison to exenatide alone (Table 5.1). 
Although the complete pharmacokinetic (PK) parameters required to properly 
calculate bioavailability were not available, the AUC values presented here 
suggest that the PIP 640 peptide enhanced the bioavailability of positively-
charged calcitonin slightly more than negatively-charged exenatide. This 
finding is consistent with the observed charge-preferential TJ permeability 
function induced by the PIP 640 peptide in Caco-2 cell monolayer model in 









Figure 5.4: Permeability enhancement of calcitonin or exenatide as measured in 
blood collected from the portal vein of rats after co-administeration with 20 mM of 
PIP 640 peptide by ILI. All injected formulations (including calcitonin or exenatide 
only; control) contained 1.5 mg/mL soybean trypsin inhibitor (SBTI). A) Portal vein 
concentration-time profiles of exenatide alone or in combination with PIP 640. B) 
Time-course measurements of the plasma concentration of calcitonin alone or in 
combination with the PIP 640 peptide. Data are means ± SEM of 3 independent 
experiments; n= 3. One-way ANOVA indicated a significant difference between the 










Table 5.1: Physicochemical properties and portal vein pharmacokinetics (PK) 
parameters following intraluminal injection of calcitonin and exenatide with and without 
PIP 640. 
 
MW = molecular weight, calculated hydrodynamic radius and pharmacokinetic (PK) 
parameters obtained from data in Figure 5.4. The hydrodynamic radius was estimated 
as described in Section 2.13.6. The area under the curve between 0-60 min (AUC t 0-




































5.3.4. TJ permeability enhancement of therapeutic peptides induced 
by the PIP 640 peptide did not permit co-absorption of endotoxins 
 
Intestinal epithelium is normally exposed to different enteric bacteria that 
produce endotoxins, in particular lipopolysaccharide (LPS) (213, 214). LPS are 
small fragments of the gram-negative bacteria cell wall released by dead 
bacteria (214). Transport of LPS into systemic circulation is normally hindered by 
the epithelial cell barrier (13). Studies have shown that high LPS levels in blood 
is usually associated with both local and/or systemic inflammation (13). Thus, 
researchers have increased their focus on evaluating potential co-absorption 
of LPS when altering intestinal epithelial permeability for enhancing therapeutic 
peptides absorption when using PE agents (13, 215). The PIP 640 peptide was 
shown to enhance the uptake of therapeutic peptides following ILI into rat 
jejunum. We asked whether the PIP 640 peptide could also enhance intestinal 
permeability of endotoxins along with increasing the uptake of therapeutic 
peptides. To address this, we used a Limulus amebocyte lysate (LAL) assay to 
semi-quantitatively detect endotoxin levels in blood plasma samples collected 
from the portal vein of rats following administration of the PIP 640 peptide with 
a therapeutic peptide by ILI, as described above in Section 2.13.   
 
 
LAL reagent, which was obtained commercially, is prepared from a lysate 
of amebocytes of the horseshoe crab, Limulus polyphemus (140). When LAL is 
exposed to a sample containing Lipopolysaccharide (LPS) endotoxins for 1 h 
at 37 °C, the LAL reaction with endotoxin results in the formation of a gel-like 
clot (140). Depending on the endotoxin concentration in the sample, LAL 
reagent results could range from increasing the viscosity to formation of a hard 
gel; samples are only considered positive for endotoxin when the formed gel 
does not collapse after the sample tube is inverted 180° (140). Inverted test 
tubes are thus used to determine the endotoxin level are shown in Figure 5. 
Gel formation was not observed in any of the blood plasma samples collected 






Figure 5.5: Semi-quantitative Limulus amebocyte lysate (LAL) assay measuring the 
endotoxin levels in the blood plasma samples collected from the portal veins of rats 
following administration of the PIP 640 peptide by ILI. Images show inverted test tubes 
of different endotoxin standard dilutions and tested blood plasma samples. The 
surface of the generated gels in the standard tubes (except 0.01 EU/mL) is highlighted 
with a black arrow. Images are representative of 2 independent experiments, n=2.  
endotoxin standard tube with a concentration of 0.01 EU/mL formed a softer 
gel-like clot that collapsed as soon as the tube was inverted, which is 
considered to be a negative result. This indicates that endotoxin levels in the 






















5.4. Discussion  
 
The complexity of in vivo models used to study oral absorption has 
increased the reliance on in vitro models mainly because the latter provides an 
easier and faster way to predict the ability of a PE agent to effectively enhance 
oral bioavailability of poorly absorbed drugs (5, 135, 198). However, even if a PE 
agent enhanced the intestinal permeability of a poorly absorbed drug in an in 
vitro model, this does not ensure similar outcomes in vivo. Various epithelial 
cell lines have been developed to mimic the intestinal epithelium with each cell 
line emulating certain features of the intestinal epithelial barrier in vivo but 
failing to emulate other aspects (216). For example, Caco-2 cell monolayers can 
develop functional TJ structures as well as express a variety of metabolic 
enzymes and membrane transporters present in the intestinal epithelium in 
vivo (198, 216). However, polarized Caco-2 monolayers develop a TEER range of 
~ 250-400 Ω.cm2 (135, 217); this is higher than the physiological TEER value of 
intestinal epithelium in vivo, which is less than 100 Ω.cm2 (45, 135). In addition, 
use of these cell line-based in vitro models to evaluate the performance of a 
PE agent usually involves an apical application that remains at the cell’s 
surface for a period of time (often > 60 min) that is much greater than what 
might be expected in the intestine in vivo due to the movement of luminal 
contents resulting from complex muscular contractions (5, 13). These 
contractions mean that the intestinal transit in vivo can decrease the exposure 
time to a PE agent, altering its potential efficacy to enhance permeability of a 
poorly absorbed drug. Therefore, in our previous in vivo work we designed a 
longer version of the PIP 640 peptide with three additional positively charged 
amino acids: rrdykvevrrkkr-NH2, in an attempt to improve its rate of cell 
penetration to reach its intended intracellular target (127).  In vitro studies 
presented in Chapter 1 and 2 assessed the performance and defined a 
potential MoA of the original PIP 640 peptide: rrdykvevrr-NH2. Those studies 
demonstrated that the original PIP 640 peptide can enhance TJ permeability in 
Caco-2 cell monolayer in vitro. Therefore, the main aim of the current chapter 







First, we studied the ability of the original PIP 640 peptide, which does not 
have three additional basic amino acid residues, to overcome intestinal transit 
time and enhance the paracellular permeability of intestinal epithelial cells to 
therapeutic peptides following a direct ILI. This step was performed before 
tackling the formulation-related challenges associated with the oral delivery of 
therapeutic peptides, such as bypassing the stomach acidic environment and 
limiting the actions of pancreatic proteolytic enzymes, an issue that can be 
solved with existing pharmaceutical technologies such as use of an enteric 
coating (5). To do this, we studied the efficacy of the PIP 640 peptide to 
enhance human insulin permeability in rat intestine in vivo. Human insulin was 
used because it has rapid and easily measured pharmacodynamics (PD) once 
it is absorbed by simply monitoring the blood glucose levels (127). Moreover, 
insulin was chosen to compare the efficacy of the original PIP 640 peptide to 
the long version of the PIP 640 peptide because we already have defined the 
PK/PD profiles of insulin in vivo when co-administered with the longer version 
of the PIP 640 peptide (127). In addition, insulin has a hydrodynamic radius of 
~11 Å (218), which is consistent with the extent of TJ opening induced by the 
PIP 640 peptide; in Chapter 2 TJs were shown to be more permeable to 4 kDa 
dextran (~ 14 Å radius) but not larger dextrans. Citric acid was used as an 
acidifying agent in the injected formulation of insulin and PIP 640 peptide by 
ILI, as it has been shown to benefit therapeutic peptides by enhancing the 
stability of a peptide therapeutic against luminal proteolytic enzymes by 
lowering the luminal pH to < 6.5, which is below the optimal pH for the activity 
of these enzymes (204). In addition, application of an acidifying agent is 
beneficial particularly when studying the intestinal permeability of insulin, 
because insulin tends to have low solubility in a pH environment equal to or 
higher that its pI value of ~5.3, such as in the intestinal environment of pH 5.7-









Success in enhancing the intestinal epithelial TJ permeability of a 
therapeutic peptide using a PE agent in vivo requires their simultaneous arrival 
at the site of absorption with effective concentrations (5, 13). The ability to meet 
this requirement can be limited by the intestinal transit time and large surface 
of the intestinal epithelium: there could be different spreading and/or dilution of 
a PE agent and therapeutic peptide after oral gavage (5). Therefore, we 
attempted to translate in vitro information to in vivo outcomes by co-
administration in an ILI format, such an approach might be most readily 
achieved by an oral dosage form. This approach, however, does not 
completely correlate in vitro to in vivo outcomes since the issues of movement 
and dilution within the intestinal lumen cannot be emulated in vitro. For 
example, sodium caprate can effectively function as a PE in vitro with a 
concentration ~10 mM (118), while it was used at a high concentration, up to 
100 mM, to enhance permeability in vivo (202). Hence, in the current study we 
used a higher concentration of the original PIP 640 peptide (20 mM) relative to 
the concentration tested in our in vitro studies (1 mM) in Chapters 1 and 2. The 
data presented above suggests that co-administration of the PIP 640 peptide 
with insulin enhanced the TJ permeability of the latter by increasing MLC-pS19 
levels. This action induced a hypoglycaemic effect similar to the one induced 
by SC administration of insulin (Figure 5.1 A and B). Since the PD profile of 
insulin achieved by the original PIP 640 peptide (Figure 5. 1 B) is similar to the 
one obtained in our previous results using the longer version of the PIP 640 
peptide (127), we assumed that the original PIP 640 peptide achieved 
enhancement of insulin bioavailability that was similar to the longer version of 
the peptide, which enhanced the bioavailability to ~1.5 % (127). Consequently, 
we concluded that the original PIP 640 peptide was as effective as the longer 
version of the PIP 640 peptide.  
 
 
One of the aims of the current work was to validate the role of the PIP 640 
peptide in enhancing clauidn-2 at TJ structures, which was observed in the in 






which is highly expressed in tissues with leaky epithelia such as the intestine 
(115, 206, 207). Consistent with our in vitro studies, immunoblotting data presented 
above showed that treating rat intestinal epithelium in vivo with the PIP 640 
peptide can increase claudin-2 levels over a time frame that correlated with 
increased MLC-pS19 levels (Figure 5. 2). This presumably occurred, as 
suggested in Chapter 2, by decreasing claudin-2 trafficking to lysosomes. 
Studies have shown that claudin-2 distribution pattern varies between the 
small intestine and colon in different species (178, 205-207). In both foetal and adult 
human small intestines, claudin-2 is expressed in epithelial cells located in 
both the villus and crypt of the intestinal mucosa, while claudin-2 in the colon is 
limited to crypt base (206). In contrast, claudin-2 expression in the small 
intestine in rats and mice was found to decrease from the crypt to the villus (178, 
207), while claudin-2 expression and distribution have been found to be similar 
in the colons of rodents and humans, where it occurs in the crypt (178, 207). 
Consistent with the findings reported in these studies, our immunofluorescence 
microscopy data suggest a crypt to villus decrease of claudin-2 expression in 
rat intestine as previously described (Figure 5.3 A). Treating rat intestine with 
the PIP 640 peptide seemed to induce recruitment of more claudin-2 to the TJs 
(Figure 5. 3 A and B). These data support our in vitro findings that suggested a 
potential contribution of claudin-2 in PIP 640 function.  
 
 
 Previous studies have suggested that diffusion of therapeutic peptides 
through aqueous pores, such as TJs, can be affected by their surface charge, 
which is determined by their pI values and the pH of the surrounding 
environment (5, 208, 209). One study has shown that the paracellular permeability 
of a positively charged hexapeptide across Caco-2 monolayers was higher 
than a negatively charged peptide with the same size (208). In Chapter 2, we 
showed that PIP 640 peptide-induced claudin-2 at TJs in Caco-2 cell 
monolayers was associated with greater TJ permeability to positively-charged 
4 kDa dextran relative to neutral or negatively-charge dextran of the same 






permeability induced by the PIP 640 peptide for therapeutic peptides. To test 
this hypothesis we measured the extent of permeability enhancement of both 
exenatide (pI=4.9) and calcitonin (pI=8.8) across rat intestinal epithelium 
following co-administration with the PIP 640 peptide by ILI. Based on pI values 
of these therapeutic peptides, exenatide and calcitonin should exhibit a net 
negative and positive charge, respectively, in the small intestine pH range (5.7- 
7.4) (3). To maintain the same pH of the intestine, we used SBTI to protect the 
therapeutic peptides used from luminal proteolysis instead of citric acid, which 
was used earlier to examine the permeability of insulin (Figure 5.1).  
 
 
Our data showed that the TJ opening induced by the PIP 640 peptide in 
vivo was more permeable to calcitonin than exenatide (Figure 5.4), based 
upon calculated PK parameters (Table.1) that suggested a 10-fold increase in 
the calculated calcitonin AUC compared to a 5-fold increase for the calculated 
AUC value of exenatide relative to controls (Figure 5.4). It is important to note 
that both control treatments, calcitonin and exenatide injected into rat intestine 
without the PIP 640 peptide, showed a slight increase in AUC values, which 
appeared to be higher with exenatide (Table.1). This is probably caused by 
SBTI because it was shown that application of SBTI at a concentration of 1.5 
mg/mL can enhance insulin absorption to small extent (126). These 
observations correlate well with our in vitro findings of the preferential TJ 
permeability of positively charged molecules induced by the PIP 640 peptide. 
Since the PIP 640 peptide enhanced claudin-2 localization at TJs, the data 
suggest that claudin-2 might play a role in the charge-preferential permeability 
obtained in vivo. This information could help define the appropriate 
physiochemical properties of a peptide drug that can benefit from our delivery 
strategy, such as being positively charged.  
 
 
An essential function of the intestinal epithelium is to prevent uncontrolled 






pharmaceutically-acceptable PE agents to enhance drug permeability across 
the intestinal epithelium should not cause toxicity. In studies reporting the 
permeability enhancement effect of PE agents, it is common to evaluate their 
actions on cell viability, which only assesses epithelial cell integrity (5). 
However, less attention is paid to whether PE agents might enhance the 
permeability of toxic substances, such as endotoxins, which are present in the 
intestinal lumen; this has become one of the major safety concerns associated 
with PE agents (5, 13). Studies have shown that systemic endotoxin levels 
commonly range from 0 to < 2 EU/mL in healthy individuals (219, 220), while in 
patients with intestinal epithelial inflammatory disorders characterized by leaky 
epithelial barrier, such as Crohn’s disease, systemic endotoxin levels can be 
as high as 20-100 EU/mL (220). Therefore, we aimed to evaluate the potential 
enhancement of the intestinal luminal endotoxin permeability associated with 
PIP 640 peptide-induced TJ permeability. The LAL assay results showed that 
endotoxin uptake into the blood circulation was not enhanced in rats following 
induction of TJ permeability by the PIP 640 peptide. 
 
In conclusion, studies described in the current chapter validated the in vitro 
efficacy and MoA of the PIP 640 peptide in enhancing the intestinal epithelial 
TJ permeability of therapeutic peptides in vivo. In agreement with the in vitro 
studies demonstrated in Chapter 1 and 2, the results presented above showed 
that the PIP 640 peptide can effectively enhance intestinal TJ permeability of 
therapeutic peptides in vivo. This enhancement was associated with increased 
MLC-pS19 levels and increased localization of claudin-2 at TJs. Moreover, the 
data suggest that the TJ opening induced by the PIP 640 peptide was 
preferentially permeable to peptide drugs that are positively charged at the 
intestinal pH range, as the PIP 640 peptide enhanced the permeability of 
calcitonin more than exenatide. Finally, the PIP 640 peptide does not seem to 





















Chapter 6 : General conclusion 























TJ proteins of epithelial cells are subject to continuous remodelling events 
that provide a mechanism for dynamically altering their permeability properties 
through the paracellular pathway (89, 177, 221). The structural remodelling of TJ 
proteins are regulated by a wide array of intracellular signalling processes (89, 
221). One of the key players within these intracellular events in altering TJ 
permeability involves the phosphorylation status of myosin light chain at serine 
19 (MLC-pS19). The phosphorylation status of S19 in MLC is regulated by the 
reciprocal actions of MLC kinase (MLCK) and MLC phosphatase (MLCP), with 
MLC affecting the function of perijunctional actomyosin filaments (53, 88, 89, 92). 
MLCK activation by various stimuli increases MLC-pS19 levels and opens TJs, 
an event that is reversed by MLCP activation (53, 88, 89, 92). Identification of this 
intracellular pathway has led to the discovery of MLCK hyperactivation having 
a role in reducing TJ barrier function associated with intestinal epithelial 
inflammatory disorders, such as Crohn’s disease (53, 103). One of the tools used 
to study this role of MLCK was the application of a membrane permeant 
peptide inhibitor for MLCK, called PIK peptide. This peptide was shown to 
correct TJ barrier dysfunction induced by MLCK hyperactivation and 
suggested that modulation of MLCK function could represent a potential 
therapeutic strategy for diseases characterised by TJ barrier dysfunction (53, 
103).  
 
While studies have defined a role for MLCP in regulating MLC-pS19 levels 
and altering TJ permeability (92, 160, 161), nevertheless, there are still many 
questions about the precise role that MLCP plays in regulating TJ permeability. 
In this regard, the current studies focused on extending our previous work of 
developing specific membrane permeant peptide inhibitors for MLCP, PIP 
peptides, that were designed to enhance TJ permeability transiently by 
increasing MLC-pS19 levels via modulating MLCP activity (127). The current 
work was focused on the best PIP peptide candidates, PIP 640 peptide 
(rrdykvevrr-NH2), to explore potential modifications of its sequence to optimize 
its activity and to validate its intracellular target and mechanism of action 
(MoA) in vitro. Moreover, this work explored changes to TJ protein structure 
associated with increasing MLC-pS19 levels achieved by regulation of MLCP 





regulate TJ permeability in vivo. The overall motivations behind this work were 
to develop a strategy to improve oral delivery of therapeutic peptides through 
intestinal epithelial TJs through a hypothesis-driven strategy of modulating TJ 
permeability properties, as opposed to previous approaches to identify 
permeation enhancer (PE) agents that have used an essentially stochastic 
process. In addition, this work would improve our knowledge of TJ biology and 
the role of MLCP in regulating TJ permeability.    
  
We designed the PIP 640 peptide to mimic the binding domain of CPI-17 
to MLCP, which contains a phosphorylated threonine residue (pT38), in the 
sequence R36V(pT)VKYDRR44. Several strategies were employed to identify a 
version of this peptide that allowed it to be more stable in the intestinal lumen 
and access the cytoplasm of intestinal epithelial cells; both of these properties 
were assumed essential for use of the peptide to alter MLCP activity and 
increase MLC-pS19 levels in order to transiently alter epithelial TJ permeability 
in vivo. Data presented in Chapter 3 showed that the peptide induced a 
reversible TJ permeability by increasing MLC-pS19 levels in Caco-2 cell 
monolayers without interfering with cell viability. In addition, both the 
intracellular distribution of the PIP 640 peptide and its binding profile to the 
regulatory subunits of MLCP, when compared to series mutants of the PIP 640 
peptide, suggested an intracellular action of the PIP 640 peptide that was 
specified by a few essential amino acids. Since the results in Chapter 3 
suggested the importance of the glutamic acid residue in the peptide sequence 
in mimicking the pT38 residue, we plan in the future to explore the potential 
optimization of PIP 640 peptide function by introducing a phosphatase stable-
phosphothreonine mimetic, such as the 2-amino-3-methyl-4-phosphonobutyric 












Figure 6.1: Comparison of the structure of phosphothreonine with potential stable 












Studies discussed in Chapter 4, explored biochemical changes of TJ 
proteins associated with PIP 640 peptide-induced TJ permeability changes 
associated with increased MLC-pS19. Our results showed that, of the many TJ 
proteins evaluated, only claudin-2 protein levels were altered (increased) in 
response to the PIP 640 peptide and that there was an increase in the amount 
of claudin-2 at TJ structures. These modifications to claudin-2 correlated with 
an increased phosphorylation status, presumably at the serine residue in 
position 208, which has been shown to enhance claudin-2 detergent 
extractability and enhance its localization at TJs (181). These changes in TJ 
structure induced by the PIP 640 peptide were associated with opening of the 
TJ in a way that was preferentially permeable to positively charged molecules, 
suggesting a potential contribution of claudin-2 to the TJ permeability function 
of the PIP 640 peptide (Figure 6.2). In the future, live imaging studies using 
fluorescence microscopy could be performed to examine the actions of the PIP 
640 peptide on a Caco-2 cell line that constitutively expresses fluorescent TJ 
proteins, such as claudin-2 and occludin. Such a study would provide critical 
information regarding TJ structural changes associated with altered 
paracellular permeability induced by the PIP 640 peptide. In addition, more 
efforts could be focused on defining the intracellular signalling pathways 
involved in inducing claudin-2 localization at TJs induced by the PIP 640 





 In Chapters 3 and 4, we showed that the PIP 640 peptide is able to 
induce TJ permeability by increasing MLC-pS19 levels that were associated 
with increased claudin-2 localization at TJs in Caco-2 cell monolayers in vitro. 
Thus, in Chapter 5, we aimed to test this presumed mechanism of action 
(MoA) in an in vivo model. In addition, we sought to ensure that the extent of 
TJ opening induced by the PIP 640 peptide observed in vitro, could effectively 
enhance permeability of a therapeutic peptide in vivo. The results obtained 
showed that the PIP 640 peptide can effectively enhance the intestinal TJ 
permeability of three therapeutic peptides in vivo: insulin, calcitonin, and 
exenatide. Increased uptake of these therapeutic peptides from the rat jejunum 
following intra-luminal injection was associated with enhancement of MLC-pS19 
levels and increased claudin-2 at TJ structures. Moreover, the PIP 640 peptide 
induced similar charge-preferential permeability changes to those observed in 
vitro. One next logical step would be to develop an appropriate oral dosage 
form of the PIP 640 peptide with a therapeutic peptide to evaluate its safety 
and efficacy in vivo after repeat exposure.  
 
Overall, we have evaluated a small cell-permeant peptide, PIP 640 peptide, 
for its ability to open TJs for the enhanced uptake of a therapeutic peptide. The 
hypothesis-driven strategy for this approach focused on altering permeability 
across the intestinal epithelial barrier by manipulating an endogenous 
mechanism controlled by the phosphorylation status of MLC. This approach 
represents an advantage over most of other permeation enhancement 
strategies, which can act non-selectively and without a defined MoA to 
enhance intestinal epithelial TJ permeability. Data presented in this thesis 
show that the PIP 640 peptide is capable of acting selectively on this 
endogenous mechanism and induces a perm-selective TJ permeability in vivo 
and in vitro. Accordingly, we believe that application of the PIP 640 peptide in 
combination with other pharmaceutical technologies could lead to the 













Figure 6.2: Cartoon image summarizing changes in cellular signalling events 
associated with the TJ permeability enhancement induced by the PIP 640 peptide. A) 
Limited permeability of TJs occurring at steady state. B) Perm-selective increase in TJ 









































7.1. PIP Peptides analytical characterization 
 
The following peptides were synthesized on a 0.15 mmol scale (0.25 g 
resin).  
A) PIP 640 peptide (157 mg, 44 % yield); HPLC: tR= 4.3 min; ESI-MS+ 
calculated for C58H102N24O15: m/z = 1375.80; found m/z = 1375.82 
[M+H]+. HPLC analysis (Figure 7.3) and MS analysis (Figure 7.14).   
 
B)  PIP 641 peptide (125 mg, 39 % yield); HPLC: tR = 4.1 min; ESI-MS+ 
calculated for C56H99N23O14: m/z = 1317.77; found m/z = 1317.77 
[M+H]+. HPLC analysis (Figure 7.4) and MS analysis (Figure 7.15).   
 
C) PIP 642 peptide (118 mg, 38 % yield); HPLC: tR = 3.8 min; ESI-MS+ 
calculated for C52H98N24O14: m/z = 1283.77; found m/z = 1283.78 
[M+H]+. HPLC analysis (Figure 7.5) and MS analysis (Figure 7.16).   
 
D) PIP 643 peptide (162 mg, 51 % yield); HPLC: tR = 4.1 min; ESI-MS+ 
calculated for C57H100N23O14: m/z = 1331.78; found m/z = 1331.80 
[M+H]+. HPLC analysis (Figure 7.6) and MS analysis (Figure 7.17).   
 
E) PIP 644 peptide (174 mg, 49 % yield); HPLC: tR = 4 min; ESI-MS+ 
calculated for C60H109N27O13: m/z = 1416.87; found m/z = 1416.89 
[M+H]+. HPLC analysis (Figure 7.7) and MS analysis (Figure 7.18).   
 
F) N-terminally biotinylated PIP 640 peptide (133 mg, 52 % yield); 
HPLC: tR = 4.4 min; ESI-MS+ calculated for C68H116N26O17S: m/z = 
1601.88; found m/z = 1601.88 [M+H]+.. HPLC analysis (Figure 7.8) and 
MS analysis (Figure 7.19).   
 
G) N-terminally biotinylated PIP 641 peptide (124 mg, 37 % yield); 
HPLC: tR = 4.4 min; ESI-MS+ calculated for C65H112N27O15S: m/z = 
1543.86; found m/z = 1543.87 [M+H]+. HPLC analysis (Figure 7.9) and 




H) N-terminally biotinylated PIP 642 peptide (129 mg, 39 % yield); 
HPLC: tR = 4.2 min; ESI-MS+ calculated for C62H110N25O17S: m/z = 
755.41; found m/z = 755.44 [M+2H]2+. HPLC analysis (Figure 7.10) and 
MS analysis (Figure 7.21).   
 
I) N-terminally biotinylated PIP 643 peptide (118 mg, 47 % yield); 
HPLC: tR = 4.5 min; ESI-MS+ calculated for C67H116N26O15S: m/z = 
1557.89; found m/z = 1557.86 [M+H]+. HPLC analysis (Figure 7.11) and 
MS analysis (Figure 7.22).   
 
J) N-terminally biotinylated PIP 644 peptide (135 mg, 37 % yield); 
HPLC: tR = 4.3 min; ESI-MS+ calculated for C70H121N28O15S: m/z = 
821.96; found m/z = 821.99 [M+2H]2+. HPLC analysis (Figure 7.12) and 
MS analysis (Figure 7.23).   
The following peptide was synthesized on a 0.085 mmol scale (0.25 g 
resin) 
K) C-terminally biotinylated PIP 640 peptide (PIP 640-PEG-biotin) (93 
mg, 43 % yield); HPLC: tR = 4.9 min; ESI-MS+ calculated for 
C78H137N27O20S: m/z = 903.02; found m/z = 903.02 [M+2H]2+. HPLC 















Figure 7.1: Chemical structures of A) C-terminally biotinylated PIP 640 PIP peptide 
(PIP 640-PEG-Biotin) with an additional PEG spacer between the peptide and biotin. 
B) N-terminally biotinylated PIP 640 peptide that coupled directly to the biotin unit.  













Figure 7.2: A) Confocal microscopy images of Caco-2 monolayers showing 
distribution of C-terminally biotinylated PIP 640 peptide (PIP 640-PEG-biotin) after 45 
min of apical exposure. PIP 640-PEG-biotin was detected by Alexa 488-conjugated 
streptavidin (green). TJs are stained with Alexa 546-conjugated secondary antibody 
against occludin primary antibody (red). Scale bar, 10 µm. B) Z-stack scan image of 
Caco-2 monolayers obtained by confocal micrscopy showing surface and subcellular 
localization of PIP 640-PEG-biotin peptide after 45 min of apical exposure. Nuclei 
were stained with DAPI (blue). Scale bar, 20 µm. Images are repesentative of 3 
independent experiments with n=3 for all peptide. C) TEER change of Caco-2 cell 
monolayers induced by 1 mM of PIP 640-PEG-biotin. This data shows that PIP 640-
PEG-biotin peptide has no effect on the cell TEER. Data are means ± SEM of 3 
























7.3. HPLC and mass spectrometry characterization 
	
7.3.1.  HPLC analysis 
	
	
Figure 7.3: HPLC chromatogram of purified PIP 640 peptide, rrdykvevrr-NH2, 
detected at 220 nm 
	
	
Figure 7.4: HPLC chromatogram of purified PIP 641 peptide, rrdykvavrr-NH2, 








Figure 7.5: HPLC chromatogram of purified PIP 642 peptide, rrdakvevrr-NH2, 
detected at 220 nm 
	
	
Figure 7.6: HPLC chromatogram of purified PIP 643 peptide, rraykvevrr-NH2, 











Figure 7.7: HPLC chromatogram of purified PIP 644 peptide, rrrykvevrr-NH2, detected 
at 220 nm 
	
	
Figure 7.8: HPLC chromatogram of purified N-terminally biotinylated PIP 640 peptide, 











Figure 7.9: HPLC chromatogram of purified N-terminally biotinylated PIP 641 peptide, 
biotin-rrdykvavrr-NH2, detected at 220 nm 
	
	
Figure 7.10: HPLC chromatogram of purified N-terminally biotinylated PIP 642 











Figure 7.11: HPLC chromatogram of purified N-terminally biotinylated PIP 643 
peptide, biotin-rraykvevrr-NH2, detected at 220 nm 
	
	
Figure 7.12: HPLC chromatogram of purified N-terminally biotinylated PIP 644 











Figure 7.13: HPLC chromatogram of purified C-terminally biotinylated PIP 640 























Figure 7.14: ESI-MS+ spectrum of the PIP 640 peptide. Inset, the experimental isotopic 
pattern (top) in comparison with the calculated isotopic pattern (bottom) for the [M+H]+ 
species. 











Figure 7.15: ESI-MS+ spectrum of the PIP 641 peptide. Inset, the experimental isotopic 






Figure 7.16: ESI-MS+ spectrum of the PIP 642 peptide. Inset, the experimental isotopic 













Figure 7.17: ESI-MS+ spectrum of the PIP 643 peptide. Inset, the experimental isotopic 












Figure 7.18:	ESI-MS+ spectrum of the PIP 644 peptide. Inset, the experimental isotopic 










Figure 7.19: ESI-MS+ spectrum of the N-terminally biotinylated PIP 640 peptide. Inset, 
the experimental isotopic pattern (top) in comparison with the calculated isotopic pattern 











Figure 7.20: ESI-MS+ spectrum of the N-terminally biotinylated PIP 641 peptide. Inset, 
the experimental isotopic pattern (top) in comparison with the calculated isotopic 











Figure 7.21:	 ESI-MS+ spectrum of the N-terminally biotinylated PIP 642 peptide. Inset, 
the experimental isotopic pattern (top) in comparison with the calculated isotopic pattern 












Figure 7.22:	ESI-MS+ spectrum of the N-terminally biotinylated PIP 643 peptide. Inset, the 
experimental isotopic pattern (top) in comparison with the calculated isotopic pattern 











Figure 7.23:	 ESI-MS+ spectrum of the N-terminally biotinylated PIP 644 peptide. Inset, 
the experimental isotopic pattern (top) in comparison with the calculated isotopic pattern 












Figure 7.24: ESI-MS+ spectrum of the C-terminally biotinylated PIP 640 peptide. Inset, 
the experimental isotopic pattern (top) in comparison with the calculated isotopic pattern 
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